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Epidemiology
Chronic pancreatitis is a disease involving progressive inflammatory changes in the 
pancreas, usually leading to impairment of endocrine and exocrine function.1 Taking the 
data for European countries together, the incidence is approximately 6.0 per 100.000 
inhabitants.2 Around 80% of patients with chronic pancreatitis are male and the peak 
incidence is between 45 to 54 years.2 Chronic pancreatitis is a poorly understood disease, 
a major source of morbidity – and costly.3,4 The most important reason for admission to 
the hospital is to manage acute flares of inflammation with severe pain, malnutrition and 
treatment of complications like pancreatic duct strictures and pseudocysts.5 Admission 
rate to the hospital has shown a steady increase in the last decade, and has an incidence of 
8.5 per 100.000 person-years.6 The overall 10 and 20-year survival rate is 70% and 45%, 
respectively, which rates are significantly lower compared to the standard population.4 
Most deaths are not directly related to chronic pancreatitis but to cardiovascular disease 
and lung cancer, the result of alcohol abuse and smoking.7 These addictions are frequent 
in chronic pancreatitis patients.
Etiology
Traditionally the etiology of chronic pancreatitis has been divided into three categories: 
alcohol, idiopathic and ‘other’. In Western countries alcohol abuse is the major cause of 
chronic pancreatitis accounting for up to 70 - 80% of all cases.8 Idiopathic pancreatitis 
accounts for 20% of cases and the remaining 10% is categorized as ‘other’ i.e. trauma, 
pancreas divisum, hyperparathyroidism and autoimmune pancreatitis. More recently a 
more extensive classification system has been described; TIGAR-O, which is an acronym 
for: toxic-metabolic (T), idiopathic (I), genetic (G), auto-immune (A), recurrent (severe) 
acute pancreatitis (R) and obstructive mechanisms (O).9 Other causes are tropical 
pancreatitis and systemic diseases such as systemic lupus erythematous. Another 
classification system often used, the M-ANNHEIM classification system, combines 
etiology, clinical stage and severity of the disease.10
Pain
Pain is the leading symptom in chronic pancreatitis. Almost every chronic pancreatitis 
patient experiences short or long periods of pain during the disease course. The pain 
is typically located in the epigastrium, radiating to the flanks and back and described 
as vague to intense and boring. Patients often relate food intake, physical activity and 
psychological stress to increase of pain. Different pain patterns have been described 
varying from pain attacks with pain free intervals to continuous severe pain. Exact numbers 
regarding analgesia use in chronic pancreatitis are lacking, however high dosage opioid 
use and opioid dependence are not uncommon in typical clinical practice.11
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Pathophysiological mechanisms
Three groups of pathophysiological mechanisms have been suggested to cause pain in 
chronic pancreatitis: 1) inflammation of the pancreas (e.g. upregulation of inflammatory 
mediators, neuropeptides and growth factors); 2) increased intrapancreatic pressure 
within the parenchyma and/or pancreatic duct, causing tissue ischemia (e.g. pancreatic 
duct strictures or stones); and 3) (late) pancreatic and extrapancreatic complications (e.g. 
pseudocysts, portal thrombosis, bile duct/duodenal strictures and peptic ulcers).12-17
Pain management
Pain management in chronic pancreatitis is conventionally aimed at dealing with the 
source of the pain. The initial step includes correction of pancreatic insufficiency and life-
style advice. If such measures are not successful, the next step is typically symptomatic 
treatment with analgesics based on the ‘pain relief ladder’ provided by the World Health 
Organization.1,18 In the absence of satisfactory pain relief, the following step in the 
treatment strategy involves endoscopic therapies, usually performed for pancreatic duct 
strictures and pancreatic duct stones. Eventually patients in whom opioid therapy and 
endoscopic treatment have failed and pain persists are referred for surgery. This usually 
aims to drain the pancreatic duct with or without resection of an inflamed part of the 
pancreas. The reported success rate in terms of pain reduction by endoscopy or surgery 
varies considerably, ranging from good to poor results, and is accompanied by much 
debate regarding optimal timing of these interventions.19
However, even when the reason for pain seems obvious in the sense of a clear source of 
nociception, and even though this source (e.g. an inflammatory mass, a chronic cyst or a 
dilated main duct) appears to have been effectively treated, chronic pancreatic pain may 
persist.20,21 It thus seems plausible that the pain in chronic pancreatitis is not (only) due to 
the pancreas as a nociceptive source, but also due to changes in transmission of painful 
inputs emanating from the pancreas, i.e. damage to nerves innervating the pancreas, 
and changes in pain processing by the central nervous system, as is also reported for 
other chronic visceral pain syndromes.22
Peripheral sensitization
Alterations indicative of nerve damage, e.g. increased number and diameter of pancreatic 
nerves, and inflammation of perineural sheathes have been described in chronic 
pancreatitis.17,23-25 Tissue damage accompanying chronic pancreatitis leads to an increase 
of inflammatory mediators (e.g. nerve growth factors, brain-derived neurotrophic factors 
and proinflammatory cytokines). These mediators together with neural alterations will 
lead to an increase of excitability of nerves innervating the pancreas.26,27 Ongoing 
inflammation of the pancreas with local complications will lead to an aggressive barrage 
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of nociceptive input to nociceptors which subsequently become more sensitive to further 
stimulation.28,29 This sensitization of nociceptors and nerve transmission (peripheral 
sensitization) has been shown to correlate with clinical pain scores and thus seems to 
play an important role in maintaining pain in chronic pancreatitis.30
Central sensitization
Further sensitization, now of central pain processing, starts in the spinal cord where 
increased synaptic efficiency in neurons of the dorsal horn of the spinal cord and later 
of supraspinal sites develops following ongoing noxious stimulation. Such central 
sensitization due to ongoing painful input manifests itself as an increase in pain 
experience (hyperalgesia). Ultimately even non-painful inputs may become painful 
(allodynia). Convergence between visceral and somatic afferents in the spinal cord 
may lead to segmental or spreading hyperalgesia outside the area of injury.31-35 From 
the spinal cord visceral pain transmits to the brain through the spinothalamic tract to 
the thalamus. From the thalamus projections to the insula, amygdala, hypothalamus 
as well to the secondary somatosensory cortex, prefrontal cortices and cingulate have 
been observed. Cortical reorganization and functional changes in these areas and the 
brainstem are observed in the presence of chronic pancreatitis pain, suggesting a central 
neurodegenerative response to pain.36 Such pain is particularly aggressive regarding 
induction of central sensitization and somatotopic alterations due to the interaction of 
ongoing nociceptive input with increased excitability of neurons and decreased efficacy 
of inhibitory mechanisms. Alternative routes to central sensitization are high humeral 
concentrations of inflammatory mediators sensitizing peripheral nerves and the central 
nervous system.37 Finally, an autonomous state can be induced where pain is no longer 
dependent on (or driven by) the presence or intensity of a noxious peripheral stimulus.
Descending pain modulation
Descending pain modulation can lead to either an increase in the spinal transmission 
of pain (facilitation) or a decrease in its transmission (inhibition). The balance between 
the two states determines the perception of pain and central sensitivity to pain. 
Multiple regions of the central nervous system are involved in this process such as the 
periaquaductal grey, the rostroventromedial medulla and the limbic system. An example 
of descending pain modulation (‘pain inhibits pain’, a response to a noxious stimulus is 
inhibited by another noxious stimulus) is conditioned pain modulation - CPM (formerly 
known as diffuse noxious inhibitory controls (DNIC)). When central sensitization is 
present descending mechanisms often fail, due to a decreased activity in the inhibitory 
pathway of the spinal cord and an increase in facilitatory pathways, resulting in a further 
increase in pain.31-33,38,39
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Implications
It is clear from the above that the problem of pain in chronic pancreatitis is often not 
restricted to consideration of local, peripheral pancreatic pathology. In the pain of 
chronic pancreatitis, downstream extrapancreatic alterations in peripheral – and most 
importantly – central pain processing play a key role. This role must not be neglected if 
we are to achieve adequate understanding of the phenomenon of chronic pancreatitis 
pain resistant to adequate therapeutic measures targeting or deafferenting only the 
nociceptive source – i.e. the pancreas. Hence, a fourth point should be added to the 
earlier mentioned three mechanisms underlying the pathophysiology of pain in chronic 
pancreatitis: 4) alterations in the transmission of pain inputs by pancreatic nerves and the 
subsequent processing of pain by the central nervous system.
In summary, altered central pain processing should be taken into account in the 
management of chronic pancreatitis pain. However, how chronic nociceptive input leads 
to altered pain processing, how this is influenced by current therapies and how this may 
impact treatment success is largely unknown. Visualizing and measuring changes in pain 
processing clearly has the potential to provide us with exciting new insights for diagnosis 
and treatment.
A mechanism-orientated approach to chronic pain
To optimize diagnostics and treatment in chronic pain disorders a few key questions need 
to be answered:40
1) What is the source of nociception?
2) Is nociceptive transmission altered?
3) Is central pain processing altered?
4) Is altered central pain processing still dependent on peripheral nociceptive drive?
Suitable tools to answer these questions are i.e. quantitative sensory testing (QST), 
electroencephalography (EEG) and (functional) magnetic resonance imaging ((f)MRI). 
These three techniques have been used to describe changes in structure and function of 
the central nervous system in chronic pain disorders:
1) QST quantifies a test stimulus (i.e. pressure, electric or heat) and the patient’s response 
to this stimulus (i.e. pain). The stimulus is applied to an anatomical site and increased until 
the subject reaches a predefined sensory threshold (i.e. sensation, pain or pain tolerance). 
Descending pain modulation can be measured using the conditioned pain modulation 
paradigm. In this paradigm a test stimulus is applied, followed by a conditioning stimulus 
and then again the test stimulus.34,41 The difference between both test stimuli signals the 
size of descending modulation. By using different stimuli at different sites the subjects’ 
state of pain processing can be characterized.
Chapter 1
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QST has been applied in all different kinds of chronic pain disorders showing similarities 
in pain mechanisms and physiology i.e. hypersensitivity to stimuli near and distant to the 
area of tissue damage as a sign of segmental and generalized hyperalgesia (changes in 
central pain processing).
2) Recording of electrical brain activity by EEG can also be used to study chronic pain 
disorders.42 Two modalities are used in EEG: resting state (static element) and brain activity 
due to external stimuli reflected by evoked potentials (dynamic element). Alterations 
in the brain resting state have been observed in various chronic pain disorders. These 
alterations can be related to pain experience, however a direct correlation between pain 
intensity and alterations in the brain resting state is absent. Pain evoked studies in chronic 
pain disorders demonstrated alterations in dynamic pain processing after stimulation. 
Both support the presence of alterations in central nervous system processing in chronic 
pain disorders.
3) (f)MRI can be used to describe structural changes in the brain and changes in brain 
activity.43,44 A variety of different techniques have been used in (f)MRI to analyze the 
central nervous system in chronic pain disorders and have shown changes in brain activity 
and structure in areas related to pain processing.
Reason foR THIs THesIs
Our research group has a wide experience in research on pain processing and chronic 
pancreatitis.34,35,45-48 Our research underlying the present thesis was mainly aimed at 
chronic pancreatitis patients who had chronic pain that is difficult to treat, even after 
successful invasive treatments targeting the source of nociception (i.e. pancreatic 
resections/drainage procedures, splanchnicectomy and endoscopic therapies).
One of our first studies was performed in chronic pancreatitis patients with intractable 
pain. We used bilateral thoracoscopic splanchnicectomy to denervate the pancreas 
and found early encouraging pain relief.46 Long-term results of these patients showed 
that pain recurred in 50% of chronic pancreatitis patients, after four years this was 
75%.45,47 QST measurements in chronic pancreatitis patients before and after bilateral 
thoracoscopic splanchnicectomy showed an increase in pain thresholds, suggesting that 
bilateral thoracoscopic splanchnicectomy may reduce visceral nociceptive input.35 
Overall QST, EEG and (f)MRI can be useful diagnostics to analyze central pain processing 
and optimize treatment in chronic pancreatitis. However, many questions need to be 
answered to achieve an optimal mechanism-orientated approach to chronic pain i.e. 
how does pain processing change during disease progression and how is this influenced 
by our therapies? Based on changes in pain processing can we provide new treatment 
strategies?
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The main goal of this thesis is to describe the central pain mechanisms underlying chronic 
pain in chronic pancreatitis and to provide new insights regarding pain treatment in 
chronic pancreatitis. 
aIMs of THIs THesIs
1. To document and thus diagnose changes in central pain processing  
(central sensitization) in chronic pancreatitis, based on:
a. The role of QST
b. The role of (f)MRI
c. The role of EEG 
2. To evaluate the relationship between prognostic factors and central pain processing:
a. The role of disease stage and progression 
b. The role of previous surgical interventions 
3. To evaluate pain management in chronic pancreatitis and its relation to  
altered central pain processing:
a. The effect of pancreatic surgery on pain processing
b. The effect of medication active in the central nervous system
c. The indication for medication active in the central nervous system 
4. To propose a new, holistic view on pain management in chronic pancreatitis  
based on specific alterations in central pain processing present in the individual 
patient (therapeutic tailoring).
ouTlIne of THe THesIs
The above-mentioned four aims have been elaborated in a clinical trial with several 
clinical and experimental endpoints, retrospective analyses, a clinical experiment and a 
review, which are presented in the subsequent chapters of this thesis.
Changes in central pain processing; central sensitization
chapter 2 addresses abnormal brain function in painful chronic pancreatitis patients. 
Analysis of brain morphology using a 3T magnetic resonance scanner is used to compare 
cortical thickness (as a sign of structural reorganization) of brain areas involved in pain 
processing between healthy controls and chronic pancreatitis patients as a reflection of 
pain system dysfunction. It was shown that chronic pancreatitis patients have reduced 
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cortical thickness of brain areas involved in pain processing.
In chapter 3 disease stage or progression is introduced, based on the M-ANNHEIM 
severity index of chronic pancreatitis, as a possible contributor to the extent of changes 
in central pain processing in chronic pancreatitis based on measurements by QST. Results 
suggested that changes in central sensitization may be influenced by disease stage. These 
findings suggest that altered central pain processing (i.e. degree of central sensitization) 
should be taken into account for pain management in chronic pancreatitis.
chapter 4 addresses the question whether chronic pancreatitis patients after pain-
relieving pancreatic surgery exhibit altered central pain processing compared to a healthy 
population measured by QST. Measurements showed that chronic pancreatitis patients 
exhibit altered central pain processing compared with healthy controls and that poor 
postoperative pain outcomes are associated with more central sensitization. These results 
suggest that in some painful chronic pancreatitis patients central sensitization is present, 
even when the nociceptive source (the pancreas) is adequately treated by pancreatic 
drainage and/or resection procedure (i.e. central autonomy of pain).
Altered pain processing that is independent of ongoing peripheral nociceptive input was 
further studied in chapter 5. This phenomenon was tested by performing QST in chronic 
pancreatitis patients who had undergone bilateral thoracoscopic splanchnicectomy for 
central sensitization and then studying its relation to pain relief. A subgroup of patients 
showed no postoperative pain reduction linked to no reduction in central sensitization 
suggesting an autonomous pain state independent of peripheral nociceptive input.
When central sensitization is present, can we treat it?
In chapter 6 we describe the effects of S-ketamine (NMDA receptor antagonist) and 
placebo infusion on pain relief and pain thresholds, as a sign of central sensitization, 
in chronic pancreatitis patients. It is shown that S-ketamine infusion is more effective 
in increasing pain thresholds then placebo, although the effect did not outlast infusion 
duration.
The results of a randomized controlled trial which compares pregabalin (gabapentinoid) 
and placebo and its effect on pain in chronic pancreatitis patients are described in 
chapter 7. Study results showed that pregabalin is an effective adjuvant in pain treatment 
for chronic pancreatitis patients.
The experimental endpoints of the randomized controlled trial comparing pregabalin and 
placebo in chronic pancreatitis are reported and discussed in chapter 8. QST was used to 
evaluate the effect of pregabalin on pain processing in chronic pancreatitis and showed 
that pregabalin has moderate inhibitory effects on central sensitization. Evidence for QST 
as a monitoring strategy for pain treatment was also provided.
Other experimental endpoints of the randomized controlled trial are analyzed in 
General introduction
1
17
chapter 9. QST was used to investigate differences in pain sensitivity and modulation 
in chronic pancreatitis among responders and non-responders to placebo or pregabalin 
treatment. The results showed that there is a potent placebo effect in chronic pancreatitis 
patients. Antihyperalgesic effects are seen in chronic pancreatitis patients responding to 
pregabalin, but not in those responding to placebo. The observed antihyperalgesic effect 
affected both ascending and descending pathways.
A new holistic view on pain management in chronic pancreatitis
A systematic mechanism-orientated approach to pain in chronic pancreatitis is presented 
in chapter 10 as a general discussion of this thesis together with future perspectives. 
This approach is based on the finding that chronic pancreatitis shows similarities with 
other chronic pain disorders and should be managed in a similar fashion. In some patients 
ongoing pain may induce altered central pain processing. Suitable tools to visualize 
altered central pain processing are QST, EEG and (f)MRI and should be used to optimize 
treatment strategies in chronic pancreatitis receiving, e.g. central active medication.
Most studies in this thesis focus on changes in pain processing in chronic pancreatitis 
after interventions e.g. denervation procedures and resections or drainage procedures, 
and during disease progression. The other studies describe the clinical effect of centrally 
active medication on chronic pain and how medication changes central pain processing. 
All these studies taken together, together with the present literature on chronic pain 
management in visceral pain syndromes, formed the basis for the review in our last 
chapter (general discussion and future perspectives).
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absTRacT
Background & aims
Patients with painful chronic pancreatitis might have abnormal brain function. We 
assessed cortical thickness in brain areas involved in visceral pain processing.
Methods
We analyzed brain morphologies of nineteen patients with painful chronic pancreatitis 
and compared them with fifteen healthy individuals by using a 3T magnetic resonance 
scanner. By using an automated method with surface-based cortical segmentation, we 
assessed cortical thickness of the primary (SI) and secondary (SII) somatosensory cortex; 
prefrontal cortex (PFC); frontal cortex (FC); anterior (ACC), mid (MCC), and posterior 
(PCC) cingulate cortex; and insula. The occipital middle sulcus was used as a control 
area. The pain score was determined on the basis of the average daily amount of pain 
during one week.
Results
Compared with controls, patients with chronic pancreatitis had reduced overall cortical 
thickness (P = 0.0012), without effects of modification for diabetes, alcoholic etiology, 
or opioid treatment (all P values > 0.05). In patients with chronic pancreatitis, the cortical 
thickness was decreased when compared with controls in SII (P = 0.002), PFC (P = 0.046), 
FC (P = 0.0003), MCC (P = 0.001), and insula (P = 0.002). There were no differences in 
cortical thickness between chronic pancreatitis patients and controls in the control area 
(P = 0.20), SI (P = 0.06), ACC (P = 0.95), or PCC (P = 0.42). Cortical thickness in the 
affected areas correlated with pain score (r = 0.47, P = 0.003).
Conclusions
In patients with chronic pancreatitis, brain areas involved in pain processing have reduced 
cortical thickness. As a result of long-term, ongoing pain input to the neuromatrix, 
cortical thickness might serve as a measure for overall pain system dysfunction, as also 
seen in other diseases characterized by chronic pain.
cortical thickness in chronic pancreatitis
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InTRoDucTIon
In a majority of patients with chronic pancreatitis, abdominal pain represents a significant 
clinical problem and its management a major challenge. The pain is typically ongoing 
with recurrent pain attacks and is associated with malnutrition, physical and emotional 
disability, and reduced quality of life.1 The treatment of chronic pancreatitis pain is often 
ineffective and disappointing, which leads to a search for optimized treatment based on 
a better understanding of underlying pain mechanisms.
Traditionally, the pain in chronic pancreatitis has been ascribed to the diseased pancreas 
itself, i.e. ongoing inflammation, pseudocyst formation and ductal abnormalities with 
increased ductal and parenchymal pressure.2 However, in many of these patients, there is 
histological evidence of nerve damage.3,4 Previous studies have also reported sensitization 
of the central nervous system and reorganization of brain areas involved in visceral pain 
processing.5-11 Furthermore, microstructural changes in pain related brain areas assessed 
by magnetic resonance diffusion tensor imaging have been described. These findings 
support accompanying structural reorganization of the neuromatrix as also seen in other 
diseases characterized by chronic pain.10 However, the exact mechanisms behind both 
functional and structural changes are still not completely understood.
Recently, advanced cortical thickness analysis based on magnetic resonance imaging (MRI) 
of the brain has been applied in the study of pain mechanisms, with demonstration of 
pain related cortical changes in diseases such as irritable bowel syndrome and trigeminal 
neuropathic pain.12-14 Improved methods for automated extraction of the cortical 
boundaries allow accurate, robust and rapid analysis of cortical thickness15-17, which 
positions cortical thickness analysis as an effective and easy applicable tool for assessing 
changes in the central pain system. To our knowledge, cortical thickness analysis has not 
been reported in chronic pancreatitis patients.
We hypothesized that chronic pancreatitis patients with sustained abdominal pain have 
changes of cortical thickness in areas involved in visceral pain processing. The aims of the 
study were 1) to compare cortical thickness in areas involved in visceral pain processing 
in healthy controls and chronic pancreatitis patients; and 2) to correlate the findings in 
patients with the clinical pain data.
MeTHoDs
Subjects
Nineteen patients with chronic pancreatitis from the department of Gastroenterology 
and Hepatology, Aalborg Hospital were included. The diagnosis of chronic pancreatitis 
was based on the Mayo Clinic diagnostic criteria.18 The inclusion criteria were abdominal 
pain typical for pancreatitis (i.e. dull epigastric pain, eventually radiating to the back) and 
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chronic pain (i.e. pain ≥ three days per week for at least three months). Both patients on 
stable opioid medication and patients on non-opioid analgesics were included. Patients 
with other acute or chronic pain syndromes (e.g. irritable bowel syndrome and lower 
back pain) were excluded. The intensity of pain was graded by using the diary pain scores 
(on the basis of a 0 - 10 visual analogue scale) with assessment of daily average pain for 
one week prior to investigation. The pain was reported without any pause in medication.
Fifteen healthy volunteers were recruited as controls from hospital and university staff. 
They received no medication and did not have any gastrointestinal symptoms or pain-
related diseases. Subjects had no contraindications to MRI. The local Ethical Committee 
approved the study protocol (N-20080028MCH).
Cortical thickness analysis
The method for cortical thickness analysis, Fast Accurate Cortical Extraction (FACE), is 
described in detail by Eskildsen et al.16,17 In brief, the analysis allows measurements of 
the cortical thickness distribution throughout the entire cortical surface based on high-
resolution 3D MRI (Figure 1), including average data for the entire hemispheres and 
individual anatomical regions of interest (ROIs) according to the Montreal Neurological 
Institute system.19 The method is described in supplementary material.
The ROIs included in the present study were hypothesis-driven on the basis of previous 
studies and the knowledge of the processing of visceral pain10,12,13,20: 1) primary 
somatosensory cortex (SI) defined as the postcentral gyrus; 2) secondary somatosensory 
cortex (SII) defined as the Rolandic operculum; 3) dorsolateral prefrontal cortex (PFC) 
defined as the middle frontal gyrus; 4) laterofrontal cortex (FC) defined as the orbital 
parts of the superior and inferior frontal gyrus; 5) cingulate cortex defined as the anterior 
(ACC), mid (MCC), posterior (PCC) divisions of the cingulate cortex; 6) insula defined as 
the entire insula, and as control area; and 7) occipital middle sulcus.
Statistics
All results are expressed as means with standard deviations. Differences in age, gender 
distribution, and structural MRI findings were analyzed using Student’s t-test or 
Fisher’s exact test as appropriate. The differences in cortical thickness between chronic 
pancreatitis patients and controls were compared by a three-step procedure. First, the 
overall differences in cortical thickness were compared by Student’s t-test. The retrieved 
differences were further adjusted in a sub-analysis (two-way analysis of variance 
(ANOVA)), with stratification for opioid treatment, diabetes mellitus, alcohol etiology, 
and pain pattern (continuous vs. attack-wise) of chronic pancreatitis. Third, for each ROI 
a mixed ANOVA model was used to analyze differences in cortical thickness, with side 
(right vs. left) as a within subject factor and group (chronic pancreatitis vs. controls) as a 
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between subject factor. For each ROI the mixed ANOVA model accounted for multiple 
significances in the computations. This approach was used as it limits the likelihood 
of type II errors, which would result in truly important differences being deemed non-
significant.21 Normality was checked by Q-Q plots and the assumption of variance 
homogeneity by Levene’s test. Correlations between cortical thickness values and clinical 
parameters (Table 1) and between the dose of analgesics (morphine equivalents per day) 
and pain intensity were analyzed using the Pearson correlation coefficient. P < 0.05 were 
considered significant. The software package Stata version 11.2 (StataCorp LP, College 
Station, TX, USA) was used for the statistical analysis.
Figure 1
Steps in the cortical thickness analysis with extraction of the cortical boundaries. A) Spatially aligned MRI 
data with initiating extraction contours superimposed. B) Brain tissue classified as white and gray matter 
and cerebrospinal fluid. C) White and D) gray matter surfaces superimposed on the MRI data. E) The 
cortical thickness distribution of a healthy subject is shown.
ResulTs
The study was completed by all subjects. The demographic and clinical characteristics 
are given in Table 1. Age and gender were comparable between groups (all P > 0.05). 
Two patients had previous surgery with partial pancreatic resections. All control subjects 
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had a normal structural MRI of the brain, whereas three patients had evidence of diffuse 
cortical atrophy (two minor and one moderate), and six patients had minor white matter 
lesions (both P > 0.05 compared with controls). No other pathological findings were 
seen. None of the lesions were located in or near the ROIs.
Table 1
Demographic and clinical characteristics of patients and healthy volunteers
 
chronic pancreatitis 
(n = 19)
Healthy volunteers 
(n = 15)
Age – years (range) 52 (25 – 68) 47 (30 – 64)
Males – no. (%) 15 (79) 9 (60)
Etiology – no. (%)a  
 Toxic-metabolic (alcoholic) 11 (58)  
 Idiopathic 5 (26)  
 Genetic 2 (11)  
 Autoimmune 0 (0)  
 Recurrent and severe acute pancreatitis 1 (5)  
 Obstructive 0 (0)  
Diary Pain Score (VAS, 0 – 10)  
 Average pain 3.6 ± 2.0  
Morphine equivalents/day – mg (range) 53 (0 – 210)  
Duration of chronic pancreatitis – months 95 ± 45  
Diabetes mellitus – no. (%) 6 (32) 0 (0)
 
Data are means with standard deviations when not mentioned otherwise. ‘VAS’ means visual analogue 
scale. aAccording to the TIGAR-O classification system.39
 
Overall cortical thickness
In chronic pancreatitis patients the overall cortical thickness including the entire brain 
hemispheres was 1.98 ± 0.11 mm, compared with 2.11 ± 0.10 mm in the control group 
(P = 0.0012). No effect modification on the overall cortical thickness was seen from 
alcoholic etiology of chronic pancreatitis (F = 0.01, P = 0.92), the presence of diabetes 
mellitus (F = 1.61, P = 0.21), opioid treatment (F = 0.97, P = 0.33), or pain pattern 
(continuous vs. attack-wise) (F = 0.18, P = 0.67).
Cortical thickness in predefined pain-related regions of interest
Compared with controls, chronic pancreatitis patients had decreased cortical thickness 
in 1) SII (F = 11, P = 0.002), with right side thicker than the left (F = 18, P = 0.0002); 2) 
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PFC (F = 4.3, P = 0.046), with no side difference (F = 0.11, P = 0.74); 3) FC (F = 16, P = 
0.0003), with no side difference (F = 0.06, P = 0.80); 4) MCC (F = 13, P = 0.001), with 
no side difference (F = 0.49, P = 0.49); and 5) insula (F = 12, P = 0.002), with right side 
thicker than the left (F = 20, P = 0.0001) (Figure 2).
Figure 2
Mean cortical thickness (average of left and right sides) of the control area and pain-related areas in 
patients with painful chronic pancreatitis and in healthy subjects.
Values are means with standard deviations. Error bars are standard deviation. ‘SI’ is primary, ‘SII’ secondary 
somatosensory cortex, ‘ACC’ anterior cingulate cortex, ‘MCC’ is mid cingulate cortex and ‘PCC’ posterior 
cingulate cortex. *: P < 0.05.
No difference in cortical thickness between chronic pancreatitis patients and controls 
was seen in 1) SI (F = 3.8, P = 0.06), with no side difference (F = 3.3, P = 0.57); 2) ACC 
(F < 0.01, P = 0.95), with left side thicker than the right (F = 7.5, P = 0.01); and 3) PCC 
(F = 0.68, P = 0.42), with left side thicker than the right (F = 15, P = 0.0004).
In the control area (occipital middle sulcus) no difference in mean cortical thickness was 
seen between chronic pancreatitis patients and controls (F = 1.69, P = 0.20), but right 
side was thicker than left (F = 68, P < 0.0001). 
Correlation with clinical scores
The mean cortical thickness of all five ROIs showing a difference between chronic 
pancreatitis and controls (SII, PFC, FC, MCC and insula) was considered for correlation 
analysis. A positive correlation was seen between cortical thickness and diary pain score 
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(r = 0.47, P = 0.003) (Figure 3). A borderline significant negative correlation was seen 
between cortical thickness and the duration of chronic pancreatitis (r = -0.31, P = 0.06). 
No correlation was seen between cortical thickness and age (r = -0.16, P = 0.35) or dose 
of analgesics (r = 0.06, P = 0.64). A positive correlation was seen between the dose of 
analgesics and diary pain score (r = 0.48, P = 0.03).
Figure 3 
 
Correlation between the average daily pain score assessed on a 0 – 10 visual analogue scale (VAS) and 
the cortical thickness (including the mean of the: secondary somatosensory, prefrontal, frontal and mid 
cingulate cortex, and insula for left and right sides separately).
DIscussIon
In patients with painful chronic pancreatitis we found reduced cortical thickness in brain 
areas known to be involved in the processing of visceral pain. In contrast, no difference 
in cortical thickness was seen in the occipital control area. The cortical thinning found in 
these areas was correlated to the patients’ clinical pain score. Together with the absent 
effect modifications from comorbidities or previous alcohol abuse, this supports the 
meaningfulness of the results and suggests that the findings are related to the patients’ 
pain, with ongoing pain resulting in structural reorganization of the neuromatrix 
expressed as regional differences in cortical thickness.
Methodological considerations
Cortical thickness analysis is fundamentally different from voxel-based morphometry, 
which assesses gray matter density, and which has already been used to study chronic 
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pain.22 The method for cortical thickness analysis used in the present study (FACE) has 
proved to be fast, accurate and robust for segmenting the cortical boundaries, especially 
taking the problems with opposite banks of tight sulci into account.15 In terms of 
accuracy, the FACE method is comparable or better (more than 25 times faster) than the 
FreeSurfer method16, which has been used in studies of irritable bowel syndrome and 
trigeminal neuropathic pain.12-14
The selection of ROIs was hypothesis-driven on the basis of previous studies and the 
knowledge of the processing of visceral pain, i.e. the so-called pain matrix.10,12,13,20 The 
PFC and ACC are central in the processing of visceral pain, and the PFC is involved in 
the cognitive aspects of the pain experience. The FC receives sensory inputs from SI, SII 
and insula, and is involved in the processing of reward including decision making23, but 
also pain24. SII activation has been suggested to be involved in attention and rating of 
strength and quality of pain, insula is involved in integration of visceral sensory and motor 
function, and the cingulate gyrus is mainly involved in the emotional, affective/cognitive 
response to pain.25-31 In addition, the MCC is proposed to connect with hypothalamus 
and periaqueductal gray as a part of the descending pain modulation system.32 The 
selection of ROIs is comparable to that in studies of irritable bowel syndrome and 
trigeminal neuropathic pain, including the identical occipital control area where there is 
little or no evidence of any significant role in neuropathic pain.12-14
Chronic pain depends on multiple factors of which many are difficult to quantify and 
control. The diary pain score used in the present study is validated in chronic pain studies 
and represents a robust measure of pain intensity.33,34 It has previously been used in 
assessment of pain in chronic pancreatitis.10,35 The pain scores were based on one-
week reports and thus cannot represent the total pain intensity during several years. 
Unfortunately, no behavioral or psychological data of the pain experience were recorded, 
even though these parameters also are of great importance. However, most patients 
had a relative stable pain pattern and we therefore consider the one-week report 
representative for pain intensity over time. Furthermore, patients diagnosed with chronic 
pancreatitis often present with abdominal pain as their leading symptom. Consequently, 
the duration of pain corresponds roughly to the duration of chronic pancreatitis.
Pain processing in chronic pancreatitis
Previous neurophysiological studies of patients with painful chronic pancreatitis have 
found widespread visceral hypersensitivity with evidence for sensitization and cerebral 
reorganization.6,7,11 Hence, the underlying electrical brain activity to gut stimulation 
in chronic pancreatitis patients showed that the insular and cingulate sources were 
abnormally localized, and this shift in source localization correlated with clinical pain 
scores.5,35 The electrophysiological indication of functional reorganization of the cortex 
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was further supported in a recent study using magnetic resonance diffusion tensor 
imaging, where microstructural changes of white and gray matter in pain-related brain 
areas were found.10
The changes in cortical thickness seen in the present study further extend the evidence 
of changes in the pain matrix in painful chronic pancreatitis and are comparable with 
findings seen in irritable bowel syndrome and trigeminal neuropathic pain.12-14 Although 
establishment of an exact correlation between functional, microstructural and cortical 
changes is difficult, the observed cortical changes correspond in a meaningful way to the 
neurophysiological and microstructural changes described above.
The MCC cortical thinning in the present study is consistent with findings in patients with 
irritable bowel syndrome.12,36 The MCC functions together with the hypothalamus and 
periaqueductal gray as a part of the ‘top-down’ descending pain modulation system, 
where several supraspinal areas can directly or indirectly modulate the nociceptive 
processing in the spinal dorsal horn.32 The finding of cortical thinning in the MCC may 
therefore represent a neuroanatomical correlate of an impaired function of endogenous 
pain inhibition, in agreement with a previous study from our group.11
The cortical thinning in PFC and FC in chronic pancreatitis corresponds to previous findings 
in trigeminal neuropathic pain and might reflect that these brain regions are involved in 
cognitive aspects of pain.13 Apkarian et al found reduction in the volume of gray matter 
in the PFC and thalamus of patients with chronic back pain, with strong relation to pain 
characteristics (neuropathic vs. non-neuropathic).37 The reduced frontal cortical thickness 
in chronic pancreatitis may reflect a neglect of pain input. Although speculative, the 
positive correlation between cortical thickness (including both PFC and FC) and chronic 
pancreatitis pain may relate to such compensatory pain inhibitory mechanisms.
The insular cortical thinning corresponds to the cortical thinning in patients with 
short-term irritable bowel syndrome.12 The cortical changes in insula and SII, which 
are intensively functionally and anatomically connected, might thus correspond to the 
central position of these areas in the processing of chronic pancreatitis pain.5,35
The positive correlation between cortical thickness (including both SII and insula) and 
diary pain score parallels the positive correlation between anterior insula thickness and 
pain duration in irritable bowel syndrome and trigeminal neuropathic pain.12,13 In contrast, 
most cortical thickness studies (typical chronic somatic pain, such as chronic back pain, 
post-herpes neuralgia and osteoarthritis) have revealed a negative correlation between 
cortical thickness and pain.22 Even though data on the long-term use of analgesics were 
not available, the present dose of analgesics (morphine equivalents per day) did not 
correlate to cortical thickness indicating that previous use of analgesics per se cannot 
explain the positive correlation. This is further strengthened by the positive correlation 
between the dose of analgesics and pain intensity. However, the neuroplastic response 
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to prolonged pain input is likely complex, and the changes in neural architecture may 
result in a variety of microstructural and cortical thickness changes seen on MRI. Other 
factors such as behavioral and autonomic responses that can be negatively related to 
pain intensity were not controlled for. These may also influence brain activity and hence 
cortex thickness. In line with our findings, Fregni et al38 reported an over-activated SII in 
chronic visceral pain with pain relief after application of transcranial magnetic stimulation 
to this area and increased level of SII glutamate in chronic pancreatitis patients using 
magnetic resonance spectroscopy. Even though the pain pattern is known to influence 
the brain microstructure in chronic pancreatitis10, no effect modification from the pain 
pattern was seen in the present study.
The demonstrated cortical changes in painful chronic pancreatitis could be a result of 
neuroplasticity induced by sustained chronic pain and of increased synaptic activity in the 
brains pain matrix related to the greater inhibitory activity generated to counterbalance 
the nociceptive input. However, it cannot be excluded that secondary structural brain 
alterations induced by comorbidities influence cortical thickness. This cannot be 
definitively answered as the study lacked a matched control group of chronic pancreatitis 
patients without abdominal pain. Such patients are very difficult to find as they typically 
have less severe disease. On the other hand, there was no influence from comorbidities 
(excessive alcohol consumption, diabetes or opioid therapy), and there was a trend 
towards correlation between cortical thickness of pain-specific areas and the duration 
of chronic pancreatitis. Findings from other chronic pain conditions parallel our findings. 
We therefore consider chronic abdominal pain likely to be the most important drive of 
the demonstrated cortical abnormalities.
Conclusion
Patients with painful chronic pancreatitis have decreased cortical thickness of brain 
areas involved in visceral pain processing. These alterations seem to have functional 
significance and support the existing body of knowledge from neurophysiologic and 
microstructural studies. As the end result of longstanding ongoing pain input to the 
neuromatrix, cortical thickness might serve as a valid measure of the overall damage and 
dysfunction of the pain system. These findings might contribute to our understanding of 
the pathophysiology underlying pain in chronic pancreatitis.
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suPPleMenTaRy MaTeRIal
Cortical thickness analysis
All subjects were investigated at Aalborg Hospital on a 3T MRI scanner (Signa HDxt; 
General Electric, Milwaukee, WI) equipped with an 8-channel standard head coil. Axial 
T2-weighted fluid attenuated inversion recovery (FLAIR)-sequence images (field of view, 
25 x 25 cm; matrix 352 x 224; 5 mm slice thickness; whole brain coverage; repetition 
time 8802 ms; echo time 127 ms; inversion time 2200 ms) were evaluated for atrophy, 
white matter lesions and other pathology. Axial T1-weighted 3D brain volume imaging 
(BRAVO)-sequence images (field of view, 25x25 cm; 320x320 matrix; 1.0 mm slice 
thickness; full head coverage; flip angle 14°; repetition time 9.0 ms; echo time 3.6 ms) 
were obtained for the cortical thickness analysis. All images were checked for obvious 
motion and susceptibility artifacts that could affect the image processing and subsequent 
quantification.
The method consisted of the following completely automated steps. The 3D MRI data 
were registered to the ICBM152 model by using an automatic iterative multiresolution 
approach.1,2 Intensity non-uniformities were corrected by the N3 algorithm,3 and a brain 
mask was created using an algorithm similar to the brain extraction tool by Smith.4 
The voxels inside the brain mask were classified into white matter, grey matter and 
cerebrospinal fluid using a fuzzy clustering algorithm. Topologically correct surfaces of 
the white matter were generated from the white matter classification. These surfaces 
were iteratively deformed to respectively the white/gray matter and gray matter/
cerebrospinal fluid boundary of the cortex. The cortical thickness was calculated as the 
distance between the white/gray matter boundary and the gray matter/cerebrospinal 
fluid boundary perpendicular to the cortical surface. Thickness calculations were 
performed in scanner space to avoid a bias toward the model. Each cortical surface 
was geometrically smoothed and mapped to a reference surface in standard space by 
using a feature-driven surface mapping algorithm.5,6 The reference surface is divided into 
anatomical regions by using the definition by Tzourio-Mazoyer et al.7 Cortical thickness 
measurements were averaged within these regions.
cortical thickness in chronic pancreatitis
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absTRacT
Background
The most dominant feature in chronic pancreatitis is intense abdominal pain. Changes 
in spinal and/or supraspinal central nervous system pain processing due to visceral 
nociceptive input play an important role in this pain. How altered pain processing is 
related to disease stage still needs study.
Methodology / principal findings
Sixty chronic pancreatitis patients were compared to fifteen healthy controls. Two 
subgroups of pancreatitis patients were defined based on the M-ANNHEIM severity index 
of chronic pancreatitis; i.e. moderate and severe. Pain detection and tolerance thresholds 
for pressure and electric stimuli were measured in six selected dermatomes (C5, T4, T10, 
L1, L4 and T10 BACK (dorsal)). In addition, the conditioned pain modulation response 
to cold pressor task was determined. These measures were compared between the 
healthy controls and chronic pancreatitis patients. Severe pancreatitis patients showed 
lower pain thresholds than moderate pancreatitis patients or healthy volunteers. Healthy 
controls showed a significantly larger conditioned pain modulation response compared 
to all chronic pancreatitis patients taken together.
Conclusions / significance
The present study confirms that chronic pancreatitis patients show signs of altered central 
processing of nociception compared to healthy controls. The study further suggests 
that these changes, i.e. central sensitization, may be influenced by disease stage. These 
findings underline the need to take altered central pain processing into account when 
managing the pain of chronic pancreatitis.
Pain Processing and disease stage in chronic Pancreatitis
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InTRoDucTIon
Intense upper abdominal pain is common in chronic pancreatitis patients and is the most 
important predictor of health-related quality of life.1,2 The etiology of pain remains to be 
elucidated and no generally accepted guidelines exist for its treatment. Initial treatment 
typically consists of a low fat diet and non-narcotic analgesics.2 Alternatives to medical 
treatment, for example pancreatic surgery, thoracoscopic splanchnicectomy and lithotripsy, 
may have an effect on pain in selected patients.3-5 If no acceptable pain relief is obtained, 
opioids remain the mainstay for the management of pain. However, opioids have many 
adverse effects such as negative influence on gastrointestinal motility, central nervous 
system toxicity, addiction and abuse potential, and sometimes opioid-induced hyper-
algesia.6 Thus, new treatment regimes for the debilitating pain of chronic pancreatitis are 
still needed. Adjuvant therapy with, e.g. pregabalin has recently been proven to be effective 
in chronic pancreatitis.7,8 However, centrally acting agents i.e. gabapentinoids or tricyclic 
antidepressants are not yet an accepted part of pain treatment in chronic pancreatitis.
Answering questions like “How do chronic pancreatitis patients process pain and how does 
altered pain processing relate to their pain experience?” is fundamental for the design of 
new therapeutic strategies. In human experimental pain models basic pain mechanisms 
can be explored by quantitative sensory testing (QST), electroencephalography (EEG) 
or magnetic resonance imaging (MRI).9-12 These techniques provide insight into various 
aspects of pain processing during progression of a painful disease, as well as before and 
after a therapeutic intervention.13
QST is increasingly used to study pain mechanisms in painful conditions.13-16 A key 
described alteration in chronic pancreatitis patients is segmental and generalized 
hyperalgesia, often present despite (or because of) opioid usage.9,17 These changes are 
similar to those seen in neuropathic pain syndromes.11 Their presence suggests that 
increased sensitivity in the central nervous system at spinal and/or supraspinal sites 
(central sensitization) plays an important role in chronic pancreatitis pain, and that 
this is not effectively modulated by current opioid-based therapies.11 Conditioned pain 
modulation (CPM) is a dynamic QST paradigm designed to activate and measure pain 
modulating mechanisms, e.g. via descending inhibitory control where brain stem centers 
act on nociceptive neurons in the dorsal horn of the spinal cord.18 An impaired CPM 
response has been reported in chronic pancreatitis as well as in other gastrointestinal 
diseases and neuropathic conditions exhibiting hyperalgesia.19-21
At present, comprehensive comparisons between chronic pancreatitis patients at different 
disease stages and compared with a healthy population regarding pain processing are 
not available. Such observations related to disease progression may also be of clinical 
value for other chronic painful disorders e.g. ulcerative colitis and Crohn’s disease.22
The objective of this study is to investigate the difference in pain sensitivity and 
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modulation between healthy subjects and chronic pancreatitis patients using QST to 
determine: 1) pressure pain thresholds; 2) electric pain thresholds; and 3) CPM response. 
Our hypothesis is that pain in chronic pancreatitis is accompanied by alterations in pain 
processing, and that this is influenced by disease stage.
MeTHoDs
Study patients
The study was approved by the responsible Ethical Committees in both countries (CMO 
region Arnhem-Nijmegen, Nijmegen, the Netherlands and The local Ethics Committee North 
Region, Aalborg, Denmark) and all patients provided written informed consent. Patients 
were recruited for an investigator initiated double-blind, placebo-controlled, parallel-
group study of increasing doses of pregabalin conducted in the Netherlands (department 
of Surgery, Radboud university nijmegen medical center) and Denmark (department of 
Gastroenterology, Aalborg Hospital, Aarhus University Hospital). The study was powered 
on a clinical primary outcome measure which is presented in another manuscript and not 
on the QST measurements that are described in this manuscript. The present study only 
presents the baseline QST results of all the 64 patients that were included in this trial.7
To be included in this study, patients needed to have chronic abdominal pain typical for 
pancreatitis (i.e. dull epigastric pain more than three days per week for at least three 
months) and a diagnosis of chronic pancreatitis based on the Mayo Clinic diagnostic 
criteria.23 Patients were excluded from the study if they had a painful condition other 
than chronic pancreatitis, an active (or history of) major depression, severe renal 
impairment, an abnormal electrocardiogram at screening, allergy to pregabalin or any of 
it components and were pregnant or lactating.
Healthy controls
A healthy control group was recruited in Denmark for comparison with our chronic 
pancreatitis group. The controls did not have any active disease and no history of a 
medical condition that could interfere with our pain measurements. Measurements were 
performed in females in the same phase of the menstrual cycle. Informed consent was 
provided by all healthy controls.
Quantitative sensory testing
QST took place using a standard temporal test sequence.9 Testing in females with 
pancreatitis was not standardized with regard to phase of the menstrual cycle because 
all female pancreatitis patients had amenorrhoea or were postmenopausal. After initial 
QST training, pressure pain thresholds were obtained for muscles overlying bone using 
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a pressure algometer with a 1.0 cm2 probe (Somedic Sales AB, Horby, Sweden), at each 
of the following sites on the dominant body side: lower neck (C5 dermatome), sternum 
(T4 dermatome), pancreatic site (T10 BACK (dorsal) dermatome) and ventral (T10 
dermatome), hip region (L1 dermatome) and knee (L4 dermatome).
The pancreatic and more distant dermatomes were chosen to permit observation of 
segmental and spreading hyperalgesia respectively. The upper abdominal area (T10 
ventral and dorsal) was chosen to detect segmental hyperalgesia because dorsal horn 
neurons receiving painful stimuli from this skin area also receive nociceptive stimuli from 
the pancreas (i.e. pancreatic area). To examine spreading and generalized hyperalgesia 
we chose two dermatomes (proximal and dorsal) near the pancreatic area (dermatomes 
T4 and L1) and two dermatomes more distant (proximal and dorsal) from the pancreatic 
area (dermatomes C5 and L4). The more distant areas were chosen to act as a control 
area likely unaffected by pancreatic nociceptive input because the nociceptive pathways 
from these areas are well separated from those coming from the pancreas at both 
peripheral and spinal levels.
Two thresholds were measured: pressure pain detection threshold (pPDT) and pressure 
pain tolerance threshold (pPTT).
Thresholds to electric constant current skin stimulation (Digistim; Biometer A/S, 
Copenhagen, Denmark; tetanic stimulation at 100 Hz, 0.2 ms square waves, self-adhesive 
electrodes 3 cm apart) were measured on the same sites as for pressure stimulation. Two 
thresholds were measured: electric pain detection threshold (ePDT) and electric pain 
tolerance threshold (ePTT).
The conditioned pain modulation (CPM, previously known as diffuse noxious inhibitory 
control (DNIC)) paradigm was carried out to test the ability of the patient to generate 
descending inhibitory modulation.24,25 Thus pressure pain tolerance thresholds (pPTT, the 
test stimulus) were determined before and after the cold pressor task (the conditioning 
stimulus), and the CPM effect was determined as the relative change (%) in pPTT. For 
the cold pressor task the dominant hand was immersed in ice-chilled water (1.0 °C ± 
0.3 °C) continuously stirred by a pump. The patient was told to remove the hand from 
the water after two minutes of immersion - or sooner if the pain was considered to be 
intolerable – and the immersion time noted. Immediately after the cold pressor task, the 
subjects rated the pain experienced during the test by use of a visual analogue scale for 
quality control purposes. pPTT were obtained in the non-dominant L4 dermatome (knee) 
immediately before and after ice water immersion.
Disease stage
We formed two groups of patients based on ‘the M-ANNHEIM severity index of 
chronic pancreatitis’ which is a validated clinical disease stage classification for chronic 
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pancreatitis.26 The M-ANNHEIM classification system incorporates etiology, different 
stages of the disease, and various degrees of clinical severity. The M-ANNHEIM scoring 
system for a clinical severity index is a simple, accurate and noninvasive tool in clinical 
practice and may be helpful in investigating the impact and interaction of various risk 
factors on the course of the disease. Clinical severity is based on pain control, surgical 
interventions, pancreatic endocrine and exocrine insufficiency, morphological status and 
severe organ complications.
We divided the patients in two groups based on their score, namely: ≤ ten points, moderate 
chronic pancreatitis group (including: minor and increased severity level) and > ten points, 
severe chronic pancreatitis group (including: advanced and marked severity level).
Statistical analysis
The study was powered to detect a difference in average daily pain scores of 25% 
between groups during the three weeks of study treatment. We determined that a study 
with 30 patients per group was needed to provide a power of 90% with the use of a 
two-sided significance level of 0.05. Hence, the sample size was set at 64 patients to 
allow for possible dropouts.
We performed statistical analysis using the Statistica for Windows Software Package 
(Release 6.0, Statsoft Inc., Tulsa, OK, USA). All results are given as means with standard 
deviations or 95% confidence intervals as appropriate. We analyzed QST results using a 
mixed model two-way ANOVA with one between subjects factor (GROUP; i.e. a healthy 
control group and two chronic pancreatitis groups according to disease stage) and 
one within subjects factor (SITE; consisting of the six dermatomes mentioned under 
quantitative sensory testing). We analyzed CPM results using a one-way ANOVA with 
one between subjects factors (GROUP; as above). Post hoc analysis was performed using 
Fisher’s exact test.
ResulTs
Study population
From October 2008 to May 2010 a total of 236 patients diagnosed with chronic 
pancreatitis in the last five years in one of both hospitals were screened and 64 patients 
were randomized; the study was completed without any incident. The majority of 
patients not meeting inclusion criteria were pain free, had passed away or were no 
longer being treated in either of the hospitals. From those 64 patients, four patients were 
excluded due to a new pain condition (e.g. complication of chronic pancreatitis requiring 
surgery, tooth abscess, emergency vascular surgery and diagnosis of inflammatory bowel 
disease) that would interfere with their QST measurements (Figure 1). All patients in this 
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per-protocol analysis (24 women, 36 men; mean age 54 ± 11) had pain due to chronic 
pancreatitis and were on a stable analgesic therapy. The healthy control group consisted 
of fifteen volunteers. The moderate chronic pancreatitis group consisted of 34 patients 
and the severe group of 26 patients (Table 1). Pancreatitis groups were statistically 
comparable except – as expected – for previous interventions. More demographic data 
on the study population and control group are listed in Table 2.
Figure 1
study enrollment and randomization
The majority of patients ‘not meeting inclusion criteria’ had either died, was pain free or was no longer 
being treated in either of the hospitals.
Table 1
M-annHeIM severity index of chronic pancreatitis and distribution of patients
severity level Point range frequency 
no. (%)
M-ANNHEIM A
M-ANNHEIM B
M-ANNHEIM C
M-ANNHEIM D
M-ANNHEIM E
Minor
Increased
Advanced
Marked
Exacerbated
0 – 5
6 – 10
11 – 15
16 – 20
> 20
4 (7)
30 (50)
21 (35)
4 (7)
1 (2)
 
M-ANNHEIM scoring system points are added together, and the sum is used to categorize a patient’s 
disease according to the M-ANNHEIM severity index.
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Table 2 
Demographic and clinical characteristics of patients and healthy controls
Healthy
controls
 
(n = 15)
Moderate chronic 
pancreatitis
group 
(n = 34)
severe chronic 
pancreatitis
group  
(n = 26)
Age (years) 40 ± 9* 53 ± 11 53 ± 11
Males - no. (%)
Etiology - no. (%)
 Toxic-metabolic
 Idiopathic
 Genetic
 Autoimmune
 Recurrent and severe acute pancreatitis 
 Obstructive
Diary pain score (numeric rating score, 0 - 10)
 Average pain
 Maximal pain
Concomitant analgesics - no. (%)†
 None
 Weak analgesics 
 Strong analgesics 
MEQ/day (mg)
Antidepressants - no. (%)
Duration of chronic pancreatitis (months)
Diabetes mellitus - no. (%)
Previous interventions for chronic pancreatitis - 
no. (%)
 Pancreas resection / drainage procedures
 Thoracoscopic splanchnic denervation
 Celiac blockade
Patients treated with enzymes for pancreatic 
exocrine insufficiency - no. (%)
8 (53)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24 (71)
17 (50)
13 (38)
1 (3)
0
2 (6)
1 (3)
4 ± 2
5 ± 2
4 (12)
7 (21)
23 (68)
112 ± 132
6 (18) 
113 ± 85
4 (12)
2 (6)
2 (6)
1 (3)
0
11 (32)
12 (46)
13 (50)
8 (31)
1 (4)
1 (4)
1 (4)
2 (8)
4 ± 2
6 ± 2
1 (4)
10 (39)
15 (58)
72 ± 71
6 (23) 
100 ± 75
14 (54)*
13 (50)*
8 (31)*
7 (27)*
2 (8)*
17 (65)
 
All values are means with standard deviations unless mentioned otherwise. Percentages may not total 
100 due to rounding. †Weak analgesics were defined as NSAIDS, paracetamol, codeine and tramadol. 
Strong analgesics were defined as opioid-based therapies. ‘MEQ’ is morphine equivalents per day. Values 
marked with an asterisk were significantly different from each other.
Thresholds to pressure stimulation
For pPDT, there were significant differences between groups overall (GROUP; F = 8.88, 
P < 0.001). Post hoc analysis showed overall significantly lower thresholds for the severe 
chronic pancreatitis group compared to healthy controls (P = 0.001) and moderate 
pancreatitis group (P < 0.001). As expected, thresholds were significantly different 
according to dermatome of measurement (SITE; F = 45.28, P < 0.0001). A significant 
interaction was found for SITE and GROUP (F = 3.75, P < 0.0001) (Figure 2). Post hoc 
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analysis showed significantly lower thresholds for dermatome L1 (P = 0.04), L4 (P = 
0.04) and T10BACK (P = 0.05) in the severe chronic pancreatitis group compared to the 
moderate chronic pancreatitis group.
figure 2
Pressure pain detection thresholds
The horizontal axis shows all six dermatomes, the vertical axis shows pressure pain detection thresholds 
(pPDT) in kPa. 
Results are means with 95% confidence intervals. ‘Controls’ is healthy control group, ‘moderate’ is 
moderate chronic pancreatitis group and ‘severe’ is severe chronic pancreatitis group. The difference 
between study groups and all six dermatomes for pPDT is significant (F = 3.75, P < 0.0001). 
For pPTT there were no significant thresholds differences between groups overall, but 
only a trend (GROUP; F = 2.99, P = 0.06). Thresholds in the different dermatomes again 
significantly differed (SITE; F = 80.72, P < 0.0001). A significant interaction between SITE 
and GROUP (F = 3.27 and P < 0.001) was seen (Figure 3). However post hoc analysis was 
not significant, with only a trend to lower thresholds between the severe pancreatitis 
group and healthy controls for the pancreatic dermatome (P = 0.07).
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Figure 3
Pressure pain tolerance thresholds
 
The horizontal axis shows all six dermatomes, the vertical axis shows pressure pain tolerance thresholds 
(pPTT) mentioned in kPa. 
Results are means with 95% confidence intervals. Controls’ is healthy control group, ‘moderate’ is 
moderate chronic pancreatitis group and ‘severe’ is severe chronic pancreatitis group. The difference 
between study groups and all six dermatomes for pPTT is significant (F = 3.27, P < 0.001).
 
Thresholds to electrical stimulation
ePDT thresholds differed significantly according to dermatome (SITE; F = 17.48, P < 
0.0001) and groups overall (GROUP; F = 4.34, P = 0.02). Post hoc analysis for GROUP 
showed overall significantly lower thresholds for the severe chronic pancreatitis group 
compared to healthy controls (P = 0.007) and for the severe chronic pancreatitis group 
compared to the moderate chronic pancreatitis group (P = 0.03). There was also a 
significant interaction between SITE and GROUP (F = 3.72, P < 0.0001) (Figure 4). Post 
hoc analysis was not significant, with only a trend to lower thresholds for the severe 
pancreatitis patients in L1 compared to healthy controls (P = 0.053), but without obvious 
difference between other dermatomes.
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Figure 4
electric pain detection thresholds
 
The horizontal axis shows all six dermatomes, the vertical axis shows electric pain detection thresholds 
(ePDT) in mA. 
Results are means with 95% confidence intervals. ‘Controls’ is healthy control group, ‘moderate’ is 
moderate chronic pancreatitis group and ‘severe’ is severe chronic pancreatitis group. The difference 
between study groups and all six dermatomes for ePDT is significant (F = 3.72, P < 0.0001). 
For ePTT thresholds differed significantly for GROUP (F = 3.9, P = 0.03), with again a 
significant post hoc analysis for overall lower thresholds for the severe chronic pancreatitis 
group compared to healthy controls (P = 0.02) and for the severe chronic pancreatitis 
group compared to the moderate chronic pancreatitis group (P = 0.02). Thresholds 
differed significantly for SITE (F = 12.98, P < 0.0001). The interaction between SITE and 
GROUP was not significant (F = 0.91, P = 0.53) (Figure 5).
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Figure 5
electric pain tolerance thresholds
The horizontal axis shows all six dermatomes, the vertical axis shows electric pain tolerance thresholds 
(ePTT) in mA. 
Results are means with 95% confidence intervals. ‘Controls’ is healthy control group, ‘moderate’ is 
moderate chronic pancreatitis group and ‘severe’ is severe chronic pancreatitis group. The difference 
between study groups and all six dermatomes for ePTT is non-significant (F = 0.91, P = 0.53).
 
Conditioned pain modulation
The baseline pressure pain tolerance thresholds for dermatome L4 were not significantly 
different between groups (pPTT L4; F = 0.8, P = 0.45). Chronic pancreatitis patients and 
healthy controls showed an increase in thresholds after the cold pressor task. The moderate 
chronic pancreatitis patients tolerated the cold pressor task for 66 ± 59 sec and the severe 
chronic pancreatitis patients for 36 ± 27 sec versus healthy controls with 180 ± 1 sec – 
which was significantly different overall (F = 52.2, P < 0.0001). Post hoc analysis was only 
significant for the healthy controls versus the two pancreatitis groups (P < 0.0001).
The effect of CPM was smaller in the patient groups compared to the controls, but the 
difference between groups was not significant (GROUP; F = 2.2, P = 0.13; controls: mean 
32.8% ± 8.9% vs. moderate: 13.5% ± 21.4% vs. severe: 10.3% ± 39.9%). When all 
pancreatitis patients were taken together and compared to healthy controls, there was 
a significant difference (P = 0.04; controls: mean 32.8% ± 8.9% vs. pancreatitis: 12.0% 
± 4.8%).
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DIscussIon
Our study confirms that patients with chronic pancreatitis show signs of central sensiti-
zation, manifest as lower pain thresholds compared to healthy controls. Our results 
suggest that patients with more severe disease exhibit more central sensitization. We 
were unable to demonstrate a relation between disease stage and effectiveness of 
inhibitory pain modulation.
Altered pain processing
Peripheral nociception at the site of the pancreas spreads via ascending pathways of 
the spinal cord to supraspinal structures including the cortex.27,28 If neurons at the 
spinal cord undergo neuroplastic changes, these changes will typically manifest as 
segmental hyperalgesia in the corresponding segments.11,29 Increased nociceptive drive 
on secondary neurons leading to hyperexcitability and firing of supraspinal neurons at 
lower thresholds can then be expected to ultimately result in spreading and generalized 
hyperalgesia.11 Our findings are compatible with the above described changes and EEG 
studies in chronic pancreatitis pain patients showing alterations in the organization of 
the pain matrix.10,30 The main interest of our study is its provision of first evidence that 
patterns of altered pain processing may also reflect disease stage and progression.
The effect of endogenous feedback systems on nociceptive input can be measured 
using the CPM paradigm, which reflects effects of descending control from the brain on 
second-order neurons in the spinal cord.31 Recent evidence suggests that patients with 
chronic painful diseases like chronic pancreatitis may exhibit less effective descending 
inhibitory control.21,32 Our study confirms this result.
Both peripheral and central pain signaling are potentially sensitized in chronic pancreatitis. 
Several studies provide evidence for peripheral visceral nerve damage in chronic 
pancreatitis.11 The presence of central sensitization demonstrated in chronic pancreatitis 
patients in the present study (and others) means that pain signaling is exaggerated in 
the central nervous system too. This central sensitization can be due to either a direct 
increase of sensitivity of neural structures, or due to a loss of inhibitory modulation 
of neural structures. The latter is tested by the CPM paradigm and was unaffected by 
disease stage but greater in chronic pancreatitis patients versus healthy controls. The 
lacking effect of disease stage on CPM could be real or due to lacking study power in 
the face of greater variability in CPM measures as compared to pain thresholds.33 Clearly 
this topic needs further investigation in a larger patient collective.
Clinical implications
The findings concerning variations in supraspinal central sensitization in relation to disease 
stage suggest implications regarding treatment approaches in chronic pancreatitis. Firstly, 
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it has been demonstrated that degree of hyperalgesia in neuropathic pain patients is 
inversely related to analgesic efficacy of opioids.34 If this applies in chronic pancreatitis, 
then increasing hyperalgesia will be linked to decreasing analgesic efficacy of opioids – 
and probably also increased risk of opioid-induced hyperalgesia.35 Secondly, therapeutic 
measures aimed at nociceptive deafferentation alone (e.g. splanchnic denervation, 
surgery aimed at specific anatomical causes, peripheral analgesia) are unlikely to be 
effective unless combined with specific treatments targeting central sensitization (e.g. 
gabapentinoids, tricyclic antidepressants and ketamine).2,7,11,36,37 This is again more likely 
to be the case in patients with more hyperalgesia, which in turn appears related to 
disease stage. Finally, there are indications that long-term, ongoing nociceptive input 
may result in supraspinal alterations to pain processing becoming independent of 
peripheral nociceptive input (autonomy).6 This likely renders therapeutic measures aimed 
at depressing peripheral nociceptive input ineffective, making treatment of altered 
central pain processing the foundation of pain treatment in these patients.2,11 Such a 
course of events leading to autonomy would appear more likely in patients with more 
hyperalgesia and a longer history of their disease – and may again be related to disease 
stage. The diagnostic and therapeutic implications of these observations deserve further 
study.
Other chronic pain disorders
Our results support the hypothesis that patients with more severe disease exhibit more 
central sensitization. This hypothesis is further supported by other studies regarding 
relationships between disease severity, degree of central sensitization and therapeutic 
effect. For complex regional pain syndrome, a clear relationship between degree of 
central sensitization and disease progression has been demonstrated.38 In inflammatory 
bowel disease and endometriosis a relation has been found between segmental 
or generalized hyperalgesia as a sign of central sensitization and clinical difficulty in 
controlling pain.16,22,39 Similar results have been described in the past in Crohn’s disease 
and ulcerative colitis, where the degree of central sensitization was related to extent 
of bowel inflammation.40-43 Clearly more research is needed in chronic pain patients to 
establish the relation between disease severity, changes in the central nervous system 
processing and therapeutic success. As a result of this, recently we started a longitudinal 
observational study with serial QSTs in chronic pancreatitis patients who are early in their 
disease to describe changes in pain processing during disease progression.
Methodological considerations
A limitation of this study is the relatively small size of the two chronic pancreatitis disease 
stage subgroups. Nevertheless, even the present explorative study provides evidence 
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of significant differences between healthy controls and a validated classification of 
pancreatitis disease stages. A better powered study might have provided more robust and 
significant evidence across all the modalities and individual dermatomes we measured 
in our study.
Sensitization of neurons and the extent of sensitization could be different between 
different tissues (skin vs. deeper tissues) and dermatomes. This might explain the 
differences between electric pain thresholds (a more superficial stimulus) and pressure 
pain thresholds (a stimulus of deeper tissues) in different dermatomes.
The healthy control group is slightly younger than the pancreatitis group. However, the 
impact of aging on pain processing remains controversial, some studies described an 
increase of pain thresholds during aging44, others showed no effect45 and some showed 
a decrease in thresholds during aging.46
A further important limitation of this study is that it is only cross-sectional. For definitive 
answers, a larger and longitudinal study will need to be performed. In this study only QST 
measurements were performed. Combining QST with EEG measurements or brain imaging 
would provide more detailed data on changes in the central nervous system in relation to 
pain processing on which to base more effective therapeutic strategies in the future. The 
M-ANNHEIM classification is at the moment the most comprehensive classification system 
for different stages of chronic pancreatitis and various degrees of clinical severity. In our 
study the classification proved simple, objective and accurate to apply.26
Conclusion and summary
The present study confirms that chronic pancreatitis patients show signs of altered central 
processing of nociception compared to healthy controls. The study further suggests that 
these changes may be influenced by disease stage. These findings underline the need 
to take altered central pain processing into account when managing the pain of chronic 
pancreatitis and may have important implications for its treatment. More research is 
needed to further characterize the link between disease severity and progression and its 
relationship to altered pain processing and treatment in chronic pancreatitis and other 
chronic pain disorders.
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absTRacT
Background
Chronic abdominal pain is common in chronic pancreatitis and may involve altered 
central pain processing. This study evaluated the relationship between pain processing 
and pain outcome after pancreatic duct decompression and/or pancreatic resection in 
patients with chronic pancreatitis.
Methods
Patients with chronic pancreatitis underwent quantitative sensory testing. Pain processing 
was measured via electrical pain detection (ePDT) and electrical pain tolerance (ePTT) 
thresholds in dermatomes C5 and L4. Inhibitory descending pain control mechanisms 
were assessed using the conditioned pain modulation (CPM) paradigm. Healthy controls 
and patients with chronic pancreatitis were compared, and patients with chronic 
pancreatitis and a poor pain outcome (visual analogue scale (VAS) score greater than 30) 
were compared with those with a good pain outcome (VAS score 30 or less).
Results
Forty-eight patients with chronic pancreatitis had lower ePDT, ePTT and CPM responses 
compared with values in fifteen healthy controls (P < 0.030). The sum of ePDT values was 
lower in patients with a poor pain outcome than in those with a good outcome (median 
7.1 chronic pancreatitis vs. 11.2 mA; P = 0.008). There was a correlation with the VAS 
score and the sum of ePDT values (rs = −0.45, P = 0.016) and ePTT values (rs = −0.46, P 
= 0.011), and CPM response (rs = −0.43, P = 0.006) in patients with chronic pancreatitis.
Conclusion
After pain-relieving pancreatic surgery, patients with chronic pancreatitis exhibit altered 
central pain processing compared with that in healthy controls. Poor pain outcomes 
are associated with more central sensitization and more pronociceptive descending pain 
modulation, and this should be considered when managing persistent pain after pain-
relieving surgery for chronic pancreatitis.
central pain processing after surgery for chronic pancreatitis
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InTRoDucTIon
Pain control in chronic pancreatitis can be a challenge.1,2 As pain progresses during the 
course of chronic pancreatitis, a substantial group of patients have multiple endoscopic 
and/or surgical interventions in an attempt to alleviate the pain.3-7 Even when these 
invasive procedures are technically successful, some patients continue to suffer pain. This 
group of patients tends to be refractory to further classical pain management, exhibiting 
opioid dependence, failure of nerve blockade, recurrent hospitalization and impaired 
quality of life.1,8,9
A possible explanation for this type of intense chronic pain involves changes in the central 
nervous system due to chronic nociceptive input.10 Ongoing nociceptive input, caused by 
nerve damage and local inflammation, is increasingly recognized to result in altered pain 
processing at spinal and supraspinal levels of the central nervous system.11,12 Together 
with the loss of descending inhibitory control mechanisms and activation of descending 
facilitation, this central sensitization is manifest as generalized hyperalgesia.13 Ultimately, 
these changes may become independent of nociceptive input, thus maintaining the 
chronic pain state.14
Accumulating evidence supports this view of chronic pain in chronic pancreatitis.9,10,15,16 
Insight into various aspects of pain processing in patients with chronic pancreatitis has 
been gained using experimental pain models and explored by quantitative sensory 
testing (QST), electroencephalography or (functional) magnetic resonance imaging ((f)
MRI).9,10,17-19 These approaches are further supported by recent findings demonstrating 
that treatment with S-ketamine infusion, pregabalin and thoracoscopic splanchnicectomy 
is accompanied by a reduction in generalized hyperalgesia.15,16,18
Based on the hypothesis that poor clinical pain outcomes after pancreatic surgery are 
associated with more central sensitization and less effective inhibitory modulation, the 
aim of this study was to explore the relationship between pain outcomes based on pain 
experience and altered central pain processing in patients with chronic pancreatitis who 
had undergone pancreatic surgery for pain relief, in the hope of being able to target and 
design more effective therapies for this group.
MeTHoDs
Consecutive patients with chronic pancreatitis who underwent pancreatic surgery for 
pain were identified from electronic registries for surgical procedures at three Dutch 
university hospitals with special interest in the treatment of chronic pancreatitis (Radboud 
university nijmegen medical center, University Medical Centre Utrecht and Erasmus MC). 
The period of inclusion varied from eight to fifteen years between centers. Inclusion 
criteria were confirmed diagnosis of chronic pancreatitis and that the primary indication 
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for surgery was pain. All patients were aged eighteen years or more.
Patients included in the study underwent either a drainage procedure (pancreatico-
jejunostomy), a duodenum-preserving pancreatic head resection (Beger or Frey procedure), 
a pancreaticoduodenectomy or a left-sided pancreatic resection (tail resection).20-22 The 
indication for the type of surgery was based on the location of pathological changes 
in the pancreas on preoperative computed tomography or MRI. All procedures were 
considered a technical success by the operating surgeon. Patients with other indications 
for pancreatic surgery, previous pancreatic surgery and known malignancy at time 
of operation were excluded. None of the patients had a new endoscopic or surgical 
intervention after the pancreatic drainage or resection procedure.
For inclusion in the study, patients needed to have a history of chronic abdominal 
pain typical of pancreatitis (dull epigastric pain more than three days per week for at 
least three months) and a diagnosis of chronic pancreatitis based on the Mayo Clinic 
diagnostic criteria.5
The local institutional review board waived the need for formal ethics committee approval 
because the study was purely observational, and because the QST measurements were 
performed routinely in patients with chronic pain in these institutions. Subjects gave 
informed consent to participate. The study was conducted according to the guidelines 
of the Central Committee on Research involving Human Subjects in the Netherlands and 
the principles outlined in the Declaration of Helsinki.23
A healthy control group recruited for an earlier trial was used to confirm the presence 
of spreading hyperalgesia in the chronic pancreatitis group.18 Control subjects had no 
history of a medical condition that could alter pain processing or interfere with pain 
measurements.
Clinical data
Pain was assessed using a 0 – 100 visual analogue scale (VAS), with a score of zero 
being no pain and 100 the worst imaginable pain.24 Patients with chronic pancreatitis 
were allocated to either a poor (score above 30) or good (score 30 or less) pain outcome 
group based on their postoperative VAS score. The Izbicki pain score was measured 
during outpatient visits.25 Baseline characteristics consisted of age, sex, duration of pain 
symptoms before surgery, preoperative and postoperative use of opioid analgesics, type 
of surgical procedure, time from operation until measurement and continued alcohol or 
tobacco use.26-28
Quantitative sensory testing
QST was performed by technicians who were blinded for group allocation, using a standard 
temporal test sequence.10 Testing in women was not standardized with regard to phase 
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of the menstrual cycle because all of the female patients were amenorrhoeic. All patients 
were asked to fast before testing. After initial QST training, electrical pain detection 
(ePDT) and electrical pain tolerance (ePTT) thresholds to constant-current electrical skin 
stimulation (Digistim; Biometer, Copenhagen, Denmark), tetanic stimulation at 100 Hz, 
0.2 ms square waves, self-adhesive electrodes 3 cm apart, were obtained at each of 
the following sites on the dominant body side: lower neck (C5 dermatome) and knee 
(L4 dermatome), on the basis that both dermatomes are distant from the pancreatic 
dermatome and were chosen to observe spreading (or generalized) hyperalgesia.15
The conditioned pain modulation (CPM; previously known as diffuse noxious inhibitory 
control (DNIC)) paradigm was performed to test the ability of the patient to generate 
descending inhibitory modulation.29,30 The ePTT (test stimulus) was determined before 
and after the cold pressor task (conditioning stimulus), and the CPM effect was 
determined as the relative (percentage) change in ePTT. A negative CPM response implies 
pronociceptive descending pain modulation. For the cold pressor task, the dominant 
hand was immersed in ice-chilled water (1.0  °C ±  0.3 °C). The patient was told to 
remove their hand from the water after two min of immersion, or sooner if the pain was 
considered to be intolerable, and the immersion time was noted. Immediately after the 
cold pressor task, subjects rated the pain experienced during the test by use of a VAS 
for quality control purposes. The ePTT in the non-dominant L4 dermatome (knee) was 
obtained immediately before and after ice water immersion.
Outcome measures
The primary effect parameter for the study was the difference in the sum of electrical 
pain threshold values for all dermatomes between the two pain outcome groups and 
the healthy controls.15 Secondary endpoints were the differences in pain thresholds for 
the individual dermatomes and in CPM response between the pain outcome groups and 
healthy controls.
Statistical analysis
Statistical analysis was performed using the software package STATISTICA for Windows, 
release 7.0 (StatSoft, Tulsa, Oklahoma, USA). Non-normally distributed data are presented 
as median with interquartile ranges (IQR). The sum of electrical pain detection and 
tolerance thresholds for all dermatomes, and the CPM results were compared between 
healthy controls and all patients with chronic pancreatitis using the Mann–Whitney U 
test, to confirm spreading hyperalgesia in patients with chronic pancreatitis.
For the chronic pancreatitis group as a whole, correlations between VAS pain score 
and the sum of thresholds and individual dermatomal thresholds were determined by 
Spearman’s rank correlation coefficient. Statistical significance was set at P  ≤  0.050. 
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Subsequent comparisons between good and poor pain outcome groups, and healthy 
controls for (sum of) thresholds, change in (sum of) thresholds and CPM were conducted 
with the Mann–Whitney U test with the Bonferroni correction for multiple comparisons 
(good vs. poor outcome, healthy controls vs. good outcome, and healthy controls vs. 
poor outcome). Statistical significance was set at P ≤ 0.020.
The Mann–Whitney U test was used to analyze differences in QST pain thresholds 
between opioid and non-opioid users. The Kruskal–Wallis test was used for analysis of 
differences in QST pain thresholds for opioid and non-opioid users within the good and 
poor pain outcome groups (four groups). A similar analysis was performed for three 
other subgroups: cigarette smokers and non-smokers, alcohol and non-alcohol users, 
and patients with and without glucose levels above 10 mmol/l (180 mg/dl).
ResulTs
Enrollment and baseline characteristics
From September 2008 to March 2011, a total of 76 patients with chronic pancreatitis 
were screened and 48 recruited from a Dutch study describing clinical outcome in 
relation to timing of surgery in chronic pancreatitis.31 Patients declined to participate for 
a variety of reasons: travelling distance, no personal benefit and active relapse of chronic 
pancreatitis. All recruited patients (13 women and 35 men of median age 49 (IQR 42 – 
57)) years completed the measurements according to the protocol and were analyzed. 
The median pain VAS score at time of examination was 43 (IQR 12 – 68) and the median 
Izbicki pain score was 56 (IQR 25 – 70). Twenty-three patients (48%) used opioids, with 
a median opioid consumption of 45 (IQR 11 – 90) mg morphine equivalents per day. 
The median time from operation to QST measurement was 66 (IQR 44 – 115) months. 
Thirty-seven patients (77%) had a glucose level below 10 mmol/l immediately before 
testing. The healthy control group consisted of fifteen volunteers (7 women and 8 men 
of median age 38 (IQR 35 – 49)  years). Healthy controls were younger than chronic 
pancreatitis patients (P < 0.001).
Patients with chronic pancreatitis versus healthy controls
Electrical pain thresholds
The sum of threshold values for electrical pain detection and tolerance was significantly 
lower in the chronic pancreatitis group than in healthy controls (P = 0.024 and P = 0.001 
respectively).
Individual ePDT values in dermatome L4 and ePTT values in dermatome L4 were all 
significantly lower for patients with chronic pancreatitis than for healthy controls 
(P = 0.007 and P < 0.001 respectively). Individual ePDT values in dermatome C5 were 
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significantly lower in the chronic pancreatitis group than in the control group (P = 0.030). 
Only individual ePTT values for dermatome C5 were not significantly lower between the 
groups (P = 0.177).
Taken together, these results indicate that, compared with healthy controls, patients with 
chronic pancreatitis exhibit generalized hyperalgesia to electrical stimulation (Table 1).
Table 1 
baseline quantitative sensory testing values in all patients with chronic pancreatitis versus 
healthy controls
chronic pancreatitis Healthy controls P-value*
ePDT (mA)
 Sum of dermatomes 8.2 (5.1 – 11.4) 11.2 (8.8 – 17.7) 0.024
 Dermatome C5 3.7 (2.9 – 5.6) 4.9 (3.4 – 7.2) 0.030
 Dermatome L4 4.6 (2.8 – 5.9) 6.3 (4.7 – 11.1) 0.007
ePTT (mA)
 Sum of dermatomes 11.7 (9.4 – 15.3) 21.6 (13.7 – 27.9) 0.001
 Dermatome C5 5.6 (4.6 – 8.0) 8.2 (5.6 – 12.1) 0.177
 Dermatome L4 6.1 (4.3 – 7.2) 12.1 (8.1 – 15.9) < 0.001
CPM
 Latency (sec) 72 (26 – 180) 180 (180 – 180) < 0.001
 Response (%) −2.7 (−22.1 – 30.1) 32.6 (10.4 – 41.8) 0.004
Values are medians with interquartile ranges. ‘ePDT’ is electrical pain detection threshold, ‘ePTT’ is 
electrical pain tolerance threshold and ‘CPM’ is conditioned pain modulation. *Mann–Whitney U test.
Conditioned pain modulation response
At baseline, patients with chronic pancreatitis tolerated the cold pressor task for shorter 
periods than healthy controls (P < 0.001). Subjects in the healthy control group exhibited 
a significantly greater CPM response than patients with chronic pancreatitis (P = 0.004) 
(Table 1). These results indicate that patients with chronic pancreatitis have less effective 
descending inhibitory modulation than healthy controls.
Correlations
For the chronic pancreatitis group as a whole, a significant negative correlation was 
found between the VAS score and the sum of ePDT values (rs = −0.45, P = 0.016) and 
the sum of ePTT values (rs = −0.46, P = 0.011).
There were also significant negative correlations with ePDTs for L4 (rs = −0.48, P = 0.009) 
and ePTTs for C5 (rs = −0.50, P = 0.004), and a negative correlation between the VAS 
score and CPM response (rs = −0.43, P = 0.006).
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Table 2 
characteristics of patients with chronic pancreatitis with good versus poor pain outcome
Good pain outcome 
(n = 18)
Poor pain outcome 
(n = 30)
Age (years)* 53 (41 – 58) 48 (42 – 54)
Sex ratio, male:female - no. 14 : 4 21 : 9
Etiology
 Alcohol 9 (50) 18 (60)
 Biliary 3 (17) 6 (20)
 Other 6 (34) 6 (20)
Surgery
 Pancreaticojejunostomy 1 (6) 3 (10)
 Tail resection 4 (22) 6 (20)
 Frey procedure 6 (33) 4 (13)
 Beger procedure 6 (33) 10 (33)
 Pancreaticoduodenectomy 1 (6) 7 (23)
Body mass index (kg/m2)*
 Preop. 20.6 (18.9 – 22.8) 21.3 (18.8 – 23.3)
 Postop. 22.8 (20.8 – 24.1) 22.5 (19.5 – 26.8)
Preop. duration of symptoms (days)* 27 (11 – 78) 50 (17 – 100)
Relapse after operation (weeks)
 > 15 1 (6) 1 (3)
 8 - 15 1 (6) 2 (7)
 < 8 0 (0) 0 (0)
Postop. alcohol use 9 (50) 10 (33)
Postop. smoking 14 (78) 17 (57)
Opioid use
 Preop. 9 (50) 22 (73)
 Postop. 7 (39) 16 (53)
Postop. endocrine insufficiency 9 (50) 22 (73)†
Postop. exocrine insufficiency 13 (72) 23 (77)
New-onset diabetes mellitus 6 (33) 15 (50)
Postop. VAS score* 8 (0 – 16) 65 (49 – 74)‡
Postop. Izbicki pain score* 23 (0 – 54) 64 (53 – 77)‡
Postop. time to QST* (weeks) 88 (55 – 109) 59 (40 – 121)
 
Values in parentheses are percentages unless indicated otherwise; *values are medians with interquartile 
ranges. ‘VAS’ is visual analogue scale and ‘QST’ is quantitative sensory testing. †P = 0.038, ‡P < 0.001 
(Mann–Whitney U test).
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Good versus poor pain outcome group
Eighteen patients with chronic pancreatitis and a postoperative VAS score of 30 or 
less were allocated to the good pain outcome group. The other 30 patients had a VAS 
score above 30 and were allocated to the poor pain outcome group. The two groups 
were comparable for baseline characteristics, except for the incidence of postoperative 
endocrine insufficiency, which was significantly higher in patients with a poor pain 
outcome. VAS and Izbicki pain scores were also significantly higher in the poor pain 
outcome compared with the good pain outcome group (Table 2).
Electrical pain thresholds
The sum of ePDT values for all dermatomes was significantly lower in the poor pain 
outcome group than in the good pain outcome group (P = 0.008). The sum of ePTT 
values was also lower in patients with poor pain outcomes, although the difference was 
not significant (P = 0.051).
For individual dermatomes, electrical pain detection and tolerance thresholds were 
significantly lower (ePDT L4, P = 0.003), or lower without reaching significance (ePDT 
C5, P = 0.039; ePTT C5, P = 0.028; ePTT L4, P = 0.079), for poor pain outcome versus 
good pain outcome (Table 3).
Based on these results, patients with poor pain outcome are hyperalgesic compared with 
those with a good pain outcome for some measurements.
Conditioned pain modulation response
Clear differences were seen in the cold pressor task latency and CPM response, but these 
results did not reach statistical significance (Table 3).
Good pain outcome group versus healthy controls
Electrical pain thresholds
No difference in the sum of ePDT values was observed between patients with a good 
pain outcome and healthy controls. The sum of ePTT values was significantly lower 
in the good pain outcome group (P = 0.019), but individual dermatomal ePTTs were 
significantly lower only for dermatome L4 (P = 0.003).
Conditioned pain modulation response
Patients with a good pain outcome tolerated the cold pressor task for a much shorter 
time than healthy controls (P = 0.001), although the CPM response was comparable 
between these two groups (Table 3).
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Poor pain outcome group versus healthy controls
Electrical pain thresholds
The sum of ePDT and the sum of ePTT values were significantly decreased in patients 
with a poor pain outcome compared with healthy controls (P = 0.004 and P = 0.001 
respectively).
ePDTs in dermatome L4 and ePTTs in dermatomes C5 and L4 were all significantly lower 
in the poor pain outcome group compared with values in healthy controls (P = 0.001, 
P = 0.014 and P < 0.001 respectively).
Conditioned pain modulation response
The length of time for which patients with a poor pain outcome tolerated the cold 
pressor task was much shorter than that for healthy controls (P < 0.001). CPM response 
was decreased in patients with a poor pain outcome (P = 0.001) (Table 3).
Subgroup analysis
No significant differences for electrical pain thresholds (individual and sum of threshold 
values) or CPM response were observed for the subgroups of opioid and non-opioid 
users within the good and poor pain outcome groups. Neither were there any significant 
differences between cigarette smokers and non-smokers, alcohol and non-alcohol 
users, and patients with and without glucose levels above 10 mmol/l for electrical pain 
thresholds and CPM response. Testing for these three variables within the good and poor 
pain outcome groups revealed no differences in QST pain thresholds.
DIscussIon
Patients with chronic pancreatitis who had a good pain outcome (low VAS score) 
after pancreatic surgery still exhibited some signs of hyperalgesia compared with 
healthy controls. Those with poor pain outcome scores after surgery, however, showed 
generalized hyperalgesia and a reduced CPM response compared with healthy controls. 
When patient groups with a good or poor pain outcome were compared, the poor 
outcome group also showed lower pain thresholds, suggesting generalized hyperalgesia. 
Together with the negative correlations between VAS score and pain thresholds/CPM 
response, these data suggest that the degree of pain reported by patients with chronic 
pancreatitis after pancreatic surgery may correlate with the severity of pronociceptive 
changes in central pain processing.
Sensitization of the nervous system is a cardinal feature of most chronic pain disorders.13 
Nociception from the pancreas spreads via local nerves and the spinal cord to supraspinal 
structures including the cortex. Changes in peripheral nerves and the central nervous 
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system may cause an increase in nociception and failure of protective mechanisms 
to inhibit nociception, resulting in more intense pain and widespread hyperalgesia.9 
Neuroplastic changes in local nerves and the dorsal horn of the spinal cord result in 
increased neuronal excitability, synaptic strength and neuronal reorganization.9 
Subsequently, changes in supraspinal processing lead to hyperexcitability and firing 
of supraspinal neurons at lower thresholds, manifest as spreading and ultimately 
generalized hyperalgesia.9 Failure of systems that depress nociceptive activity (CPM) has 
been described for chronic pancreatitis.32,33 Such failure is linked to persistent pain, which 
is often difficult to manage. All of these changes, taken together, carry the potential of 
independence from peripheral nociceptive input, where pain and hyperalgesia are no 
longer driven by peripheral nociceptive input.11
Patients with chronic pancreatitis who have a poor pain outcome after pancreatic surgery 
for pain relief show more aggressive pronociceptive alterations in pain processing, 
compared not only with healthy volunteers but also with patients who have a good 
pain outcome. This may be interpreted as a sign of (relative) independence of central 
sensitization from peripheral nociceptive input.16 In these patients it might be that the 
source of nociceptive input (the pancreas) has been treated, but that changes in central 
pain processing persist, leading to ongoing pain. This subgroup of patients with poor 
pain outcomes is not uncommon in clinical practice, and is well described.34-36
Based on the theory described above, these patients should respond best to therapeutic 
measures targeting alterations in central nervous system processing, such as pregabalin 
for central sensitization or duloxetine to improve descending inhibitory modulation.18,37 
The present data also suggest that revisional surgery in patients with chronic pancreatitis 
with poor pain control is likely to have only limited effects on their pain. Increasing opioid 
doses in these patients often fails and may further enhance hyperalgesia.1,8,9 Although 
in the present series there was no difference in opioid use between the good and poor 
pain outcome groups, neither was there a relationship within those groups between 
opioid usage and pain detection or tolerance thresholds. This may simply reflect the 
small numbers in these subgroup analyses.
There were reduced differences in pain thresholds for dermatome C5 between chronic 
pancreatitis and healthy control groups in comparison with the thresholds in dermatome 
L4 and the sum of thresholds. A possible explanation could be the mix of patients with 
good and poor pain outcomes in a single pancreatitis group. Patients with few pain 
symptoms showed far fewer QST abnormalities in the C5 dermatome than those with 
severe pancreatic pain, thereby increasing the QST values for the whole group. Once 
again, this may simply reflect small numbers in these small subgroups.
Comparison of these results with those for other chronic pain disorders could be 
relevant, but caution needs to be exercised owing to differences in etiology, disease 
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progression, symptoms and therapy. A few studies have documented postoperative 
pain after abdominal surgery and accompanying changes in central nervous system 
processing; these show that persistent postoperative pain is linked to a more sensitized 
central nervous system.38-40 One study found that poorer preoperative inhibitory pain 
modulation was related to greater postoperative hyperalgesia and chronic pain.41 
Persistent pain after breast cancer surgery has been associated with alterations in central 
nervous system pain-modulatory processes39, and hypersensitivity on the operated 
side was more prominent in patients with chronic postoperative pain after total hip 
arthroplasty.40 Future work needs to identify prognostic factors related to changes in 
central nervous system processing that might then lead to effective strategies preventing 
pain persistence after surgery.
Limitations of this study are the retrospective data collection of patient characteristics 
and the single QST measurement after surgery. Prospective data collection and QST 
measurements before and after surgery would provide more complete insight into 
underlying mechanisms and processes. Owing to the absence of a control measurement 
before surgery, the impact of abdominal surgery alone on pain processing is difficult 
to assess and might be a confounding variable. Inability to determine the presence, 
absence or degree of hyperalgesia before intervention is a further weakness, as this 
is a feature that can affect chronic pain treatment outcomes.10,15,16 A prospective 
longitudinal observational study of chronic pancreatitis during disease progression with 
serial QST measurements would provide more insight into pain processing and how this 
is influenced by different therapies.16,41,42
It is unlikely that the presence of acute on chronic pancreatitis or local complications 
after surgery influenced pain scores, as all patients came from home and were tested in 
an ambulatory outpatient setting. No patient had received or was scheduled for further 
treatments for any specific pancreatic or late surgical complications based on recent 
imaging.
Technical failure of the surgical procedures might be a confounding factor. This is unlikely 
because patients were specifically recruited where surgeons considered the operation to 
have been a technical success. Despite this, only 18 of the 48 patients had good pain 
outcome after pancreatic surgery. This is likely to involve some selection bias, as only 
a small proportion of patients with chronic pancreatitis were eligible for the study and 
those with a poor outcome may have been more willing to participate in a pain processing 
study. Another confounding factor could have been a difference in treatments between 
hospitals, but within the limitations of small numbers there was no evidence for this.
The marked pronociceptive central pain processing state seen in patients with a poor 
outcome suggests that a subgroup of patients has been identified in whom changes in 
central pain processing have become relatively independent of peripheral nociceptive 
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input. The clinical consequence of this finding is that patients with chronic pancreatitis 
with poor pain outcomes after surgery should undergo QST, and targeted drug treatment 
should be instituted if altered central pain processing is confirmed. This might involve 
ketamine and gabapentinoids for central sensitization, and tricyclic antidepressants 
for inadequate descending inhibitory modulation.9,15,18,43 There is early evidence15,18 to 
support such an approach, which seems logical based on monitoring of central processing 
via serial QST measurement, as this is generally accepted as an appropriate method to 
measure pain processing, is well standardized and validated for chronic pancreatitis.10
Identifying patients with autonomous pain processing is essential to improve the 
management of pain in chronic pancreatitis. These patients are more likely to benefit 
from treatments that target altered central pain processing rather than surgery.
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Chapter 5
Has central sensitization become 
independent of nociceptive input in chronic 
pancreatitis patients who fail thoracoscopic 
splanchnicectomy?
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and Oliver H. Wilder-Smith2
Pain and Nociception Neuroscience Research Group, department of Surgery1 and department of 
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absTRacT
Background and Objectives
Central sensitization due to visceral pancreatic nociceptive input may be important in 
chronic pancreatitis pain. We investigated whether bilateral thoracoscopic splanchni-
cectomy to reduce nociceptive input in chronic pancreatitis patients with poor pain 
control affects supraspinal and spinal sensitization.
Methods
Seventeen chronic pancreatitis patients were studied preoperatively and six weeks after 
bilateral thoracoscopic splanchnicectomy. Pressure pain thresholds (PPT) were measured 
in clavicle (C5) and pancreatic dermatomes reflecting supraspinal and spinal central 
sensitization, respectively. Patients with increased PPT after bilateral thoracoscopic 
splanchnicectomy (hypoalgesic) were compared to those without (hyperalgesic) and PPT 
versus pain numeric rating scale (NRS) changes compared.
Results
After bilateral thoracoscopic splanchnicectomy, ten patients showed C5 PPT increases 
(hypoalgesic; median change 87 kPa), seven patients had unaltered/lower PPT 
(hyperalgesic; -135 kPa). Preoperative pain NRS was similar between groups (4 vs. 5, P = 
0.2). After bilateral thoracoscopic splanchnicectomy hypoalgesic group NRS was lower 
(1 vs. 6, P = 0.008) and NRS change greater (-2 vs. 0, P = 0.005). Whole group NRS and 
C5 PPT change correlated significantly and negatively (rs = 0.53, P < 0.05), but not for 
pancreatic PPT.
Conclusions
Reduced supraspinal – but not spinal – central sensitization after bilateral thoracoscopic 
splanchnicectomy was associated with significantly reduced pain scores in a majority of 
chronic pancreatitis patients. A subgroup showed no reductions in supraspinal central 
sensitization after bilateral thoracoscopic splanchnicectomy, coupled to no significant 
pain NRS reduction. Our results suggest that a subgroup of chronic pancreatitis patients 
with chronic pain has altered pain processing that may be independent of ongoing 
peripheral nociceptive input, resulting in persisting pain despite bilateral thoracoscopic 
splanchnicectomy. If confirmed, these results indicate the importance of sensory testing 
for indications and management of interventional pain treatments.
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InTRoDucTIon
Chronic pancreatitis is a disease characterized by progressive inflammation and irreversible 
fibrosis leading to destruction of pancreatic tissue.1 Pain is the leading symptom in patients 
with chronic pancreatitis and the main reason for seeking medical help. Pancreatic surgery 
is often considered for pain relief when an anatomical substrate such as pancreatic duct 
dilation, pseudocyst and inflammatory mass are present.2 Independently of the surgical 
treatment chosen, pain persists or relapses in 30% of the patients, leading to the need for 
ongoing analgesia and frequently to opioid dependence.2,3 In these patients, pancreatic 
deafferentation, interrupting nociceptive input may be considered.4 Such a minimally 
invasive procedure is bilateral thoracoscopic splanchnicectomy, which has high initial 
success rates and low morbidity rates.5
Ongoing nociceptive input, such as local inflammation or nerve damage, is now accepted 
to be one of the mechanisms that results in alterations of central sensory processing.6 
Loss of descending inhibitory control mechanisms or activation of descending facilitation 
favors nociceptive input and will lead to central sensitization, initially spinal and later on 
supraspinal.7,8 Ultimately, central sensitization may become independent of peripheral 
nociceptive input, thus providing a plausible mechanism for the maintenance of chronic 
pain states in visceral pain patients.7 Another mechanism could be opioid-induced 
hyperalgesia especially in patients on long-term opioid treatment.9
Using quantitative sensory testing (QST), we demonstrated that patients with chronic 
pancreatitis requiring long-term opioid therapy did have more central sensitization and 
generalized hyperalgesia than healthy controls.10 These results suggest that central 
sensitization, due to visceral pancreatic nociceptive input, plays an important role in the 
pain of chronic pancreatitis, and that this process is often not effectively impacted by 
chronic opioid therapy.10 There is evidence that bilateral thoracoscopic splanchnicectomy 
to reduce pancreatic nociceptive input may be effective in reducing central sensitization 
in such patients.11 However, the fact that such deafferentation is not effective in all 
patients could imply that in some patients, such neuroplastic changes are independent 
of peripheral nociceptive input.12,13
The aim of the present study was to investigate, using QST, whether such independence 
of neuroplastic central alterations from ongoing peripheral nociceptive input exists. Our 
hypothesis is that pain in some chronic pancreatitis patients is related to alterations in 
pain processing, explaining the failure of splanchnicectomy in some chronic pancreatitis 
pain patients.
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PaTIenTs anD MeTHoDs
Patients
At our unit we prospectively collect clinical and QST data from all chronic pancreatitis 
patients admitted. The present study is part of a clinical cohort of chronic pancreatitis 
patients scheduled for bilateral thoracoscopic splanchnicectomy and collected over the 
course of ten years. All these patients had severe continuous pancreatic pain (average 
daytime numeric rating scores (NRSs) ≥ 5) necessitating continuous opioid medication for 
the last six months. During this time, all had undergone several unsuccessful attempts to 
discontinue – or at least reduce – their opioid medication. Only patients on stable opioid 
therapy were selected to permit meaningful before-versus-after-surgery comparison.
In our hospital the performance of QST is part of routine clinical diagnostics and monitoring 
for the management of complex pain patients, for example chronic pancreatitis. Thus 
QST cannot be considered an intervention in the sense of an action that imposes extra 
risk or burden to the patient for study purposes. Hence no extra approval was necessary 
by our Ethics Committee (CMO region Arnhem-Nijmegen) because the study did not 
involve the collection of any extra data which was beyond standard clinical practice for 
our unit. Patients did provide informed consent for use of their clinical and QST data for 
study and publication purposes.
Patients with complications of chronic pancreatitis (e.g. biliary obstruction, pseudocysts) 
and patients with other acute or chronic pain syndromes (e.g. irritable bowel syndrome, 
migraine, complex regional pain syndrome I, fibromyalgia) were excluded. In cases of 
doubt an expert in chronic pain was consulted.
The patients’ medical and demographic data were obtained from the patient records. 
Opioid medication for each patient was converted to morphine equivalents per day using 
the Narcotic Analgesic Converter (Version 2.0, GlobalRPh Inc.; www.GlobalRPh.com). 
We documented evidence of endocrine or exocrine pancreatic insufficiency together 
with chronic pancreatitis etiology (i.e. alcohol or non-alcohol).
Bilateral thoracoscopic splanchnicectomy
We used a technique adapted from that described by Cuschieri et al.14 In summary, 
the procedure is performed under general anesthesia with double-lumen intubation 
for single lung ventilation. The patient is placed in the full prone jackknife position. 
The operating thoracoscope is introduced in the second intercostal space beneath the 
angle of the scapula. A second trocar is introduced one intercostal space above and 
a few inches towards the spine, and the pleural space opened from the 5th to the 
12th thoracic vertebra. To ensure complete denervation, the splanchnic nerves and 
all the potentially nerve-bearing tissue on each side as well as the sympathetic chain 
are carefully transected using the harmonic scalpel (Ultracision, Johnson & Johnson 
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Medicals, Amersfoort, and the Netherlands). At the end of the procedure the lungs 
are re-expanded, and the trocar sites closed, without routine chest drains. Technical 
success was defined as 1) definitive visual identification of the splanchnic nerve branches 
between C5 and T12, the sympathetic chain, and the relevant nerve-bearing tissue; and 
2) complete transection under visual control of these tissues.
All patients were treated according to a standard protocol for this intervention. So 
preoperative, perioperative and postoperative care was the same for every patient, as 
well for anesthetics used.
Clinical pain assessment and quantitative sensory testing
Measurements were performed one day preoperatively and six weeks after bilateral 
thoracoscopic splanchnicectomy. The clinical pain state was documented via verbal NRSs 
(0 = no pain and 10 = unbearable pain) obtained at the beginning of testing.
Pressure pain thresholds (PPTs) were determined for paraspinal muscles overlying bone 
at following left-sided sites: clavicle site (C5 dermatome) and pancreatic site (T10 BACK 
(dorsal) dermatome) using a pressure algometer with a 1.0 cm2 probe (Somedic Sales 
AB, Horby, Sweden). The clavicle site (the most remote from the pancreatic region) was 
chosen as reflecting generalized changes in pain processing, that is, supraspinal central 
sensitization. The pancreatic site was chosen as site reflecting spinal segmental hyper-
algesia. These QST techniques in relation to chronic pancreatitis have been described in 
detail previously.10
Statistical analysis
We performed statistical analysis using the Statistica for Windows Software Package 
(Release 7.0, Statsoft Inc., Tulsa, OK, USA). For all analysis nonparametric tests were 
used. The clavicle site was compared with the pancreatic site to visualize differences and 
changes in central spinal and supraspinal central sensitization. Change in pain processing 
due to bilateral thoracoscopic splanchnicectomy was quantified by calculating the 
difference between preoperative and postoperative clavicle site or pancreatic site PPT. 
Patients were divided in two groups based on the direction of changes in clavicle site or 
pancreatic site PPT due to bilateral thoracoscopic splanchnicectomy: group ‘hypoalgesic’ 
was the group which experienced an increase in PPT after bilateral thoracoscopic splan-
chnicectomy (suggesting a reduction in hyperalgesia with splanchnicectomy) and group 
‘hyperalgesic’ was the group not experiencing such an increase. Analysis for hypoalgesic 
versus hyperalgesic groups was performed based on both clavicle site and pancreatic 
site changes in PPT values. Preoperative and postoperative data within the group were 
compared using a Wilcoxon signed rank sum test; group comparisons (hypoalgesic vs. 
hyperalgesic for clavicle site and pancreatic site) were done using the Mann-Whitney 
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U test. To examine the relationships between the NRS change and clavicle site and 
pancreatic site PPT change perioperatively, we performed non-parametric correlation 
analysis (Spearman’s rank correlation coefficient). Statistical significance was set at P < 
0.05.
ResulTs
We studied seventeen consecutive patients (10 men and 7 women) with pain and chronic 
pancreatitis scheduled for thoracoscopic splanchnicectomy. Median age at the time of 
testing was 47 years (interquartile range (IQR) 45 - 56). Demographic data of the patients 
are listed in Table 1. All bilateral thoracoscopic splanchnicectomy procedures were 
technically successful. One patient had a postoperative pneumothorax that was treated 
with a chest tube. Five patients had postoperative neuralgia in the area of the upper 
abdomen; this was treated conservatively and diminished in the weeks after operation. 
These complications are common for this procedure and were mostly transient.
Table 1 
Demographic and baseline data of the chronic pancreatitis group
  Patients (n = 17)
Age (years) 47 (45 – 56)
Sex ratio - male:female (no.) 10 : 7
Diabetes mellitus (no.) 4
Pancreatic exocrine insufficiency (no.) 4
Etiology (no.)
 Alcohol 6
 Other 11
Median NRS* 4 (3 – 6)
Mean onset of chronic pancreatitis (years) 4 (1 – 6)
Regular opioid medication (no.) 17
Morphine equivalents/day (mg) 90 (35 – 133)
All are medians with interquartile ranges unless otherwise specified. Results are demographic details of 
patients included in this study. ‘NRS’ is numeric rating scale. *NRSs measured during quantitative sensory 
testing.
 
Clinical pain measures 
The median preoperative pain NRS of all pancreatitis patients was 4 (IQR 3 - 6). Six weeks 
after bilateral thoracoscopic splanchnicectomy the median pain NRS was 3 (IQR 0 – 5, 
P = 0.097 vs. preoperatively). No significant difference in preoperative PPT or pain NRS 
could be found for the hypoalgesic group versus the hyperalgesic groups as based on 
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clavicle and pancreatic site PPTs. All preoperative and postoperative NRS and PPT are 
given for hypoalgesic and hyperalgesic group in clavicle site and pancreas site in Table 2. 
For baseline data only age was significantly different (P = 0.04) between the hyperalgesic 
and hypoalgesic group for the pancreatic site (Table 3).
Table 2 
Pain levels and pain scores per group before and after intervention
Preoperative Postoperative
PPT clavicle site
 Hypoalgesic 404 (318 – 500) 510 (394 – 568)
 Hyperalgesic 468 (363 – 800) 351 (267 – 527)
PPT pancreas site
 Hypoalgesic 508 (345 – 642) 593 (476 – 760)
 Hyperalgesic 518 (431 – 626) 396 (309 – 525)
NRS* clavicle site
 Hypoalgesic 4 (3 – 5) 1 (0 – 3)
 Hyperalgesic 5 (4 – 6) 6 (5 – 7)
NRS* pancreas site
 Hypoalgesic 5 (4 – 5) 4 (0 – 5)
 Hyperalgesic 4 (3 – 6) 2 (0 – 6)
All are medians with interquartile ranges. ‘PPT’ is pressure pain threshold (kPa) and ‘NRS’ is numeric 
rating scale. Clavicle and pancreas are the dermatomes of measurements. Preoperative values were not 
significantly different between groups. *NRSs measured during quantitative sensory testing.
Clavicle site pressure pain thresholds and pain score
Ten patients (6 men and 4 women) had clavicle site PPT increases after bilateral 
thoracoscopic splanchnicectomy compared with preoperative values (hypoalgesic group; 
87 kPa (IQR 40 - 120), P = 0.0006); in seven patients, clavicle site PPT was unaltered or 
lower (hyperalgesic group; -135 kPa (IQR -193 – -31), P = 0.003). The postoperative NRS 
was significantly lower in the clavicle site hypoalgesic group (P = 0.008). The change in 
NRS was significantly greater in the clavicle site hypoalgesic group versus preoperatively 
(Figure 1; left: -2 (IQR -4 - 0) vs. 0 (IQR 0 – 1), P = 0.005). The NRS in the hypoalgesic 
group was significantly reduced with bilateral thoracoscopic splanchnicectomy (P = 0.03), 
compared with a nonsignificant increase in NRS in the hyperalgesic group (P = 0.1).
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Pancreatic site pressure pain thresholds and pain score
Regarding pancreatic PPT changes, six patients had an increase (hypoalgesic; 4 men, 2 
women; 127 (IQR 86 – 142), P = 0.028), and eleven patients did not (hyperalgesic; 6 men, 
5 women; -113 (IQR -132 – -65), P = 0.003). The postoperative NRS was similar in both 
groups (P = 0.8). The change in pain NRS after bilateral thoracoscopic splanchnicectomy 
was not significantly greater in the pancreatic hypoalgesic group versus preoperatively 
(Figure 1; right: 0 (IQR -3 – 1) vs. 0 (IQR -2 – 0), P = 0.5). In neither group was NRS 
significantly reduced with bilateral thoracoscopic splanchnicectomy (hypoalgesic, P = 
0.47 and hyperalgesic, P = 0.11).
Figure 1
‘NRS’ is numeric rating scale and ‘PPT’ is pressure pain threshold. Values are medians with interquartile 
ranges (IQR). Box plots of the change in NRSs and change in PPTs after bilateral thoracoscopic 
splanchnicectomy. Clavicle and pancreas are the dermatomes of measurements. The hypoalgesic group 
was the group who experienced an increase in PPT after bilateral thoracoscopic splanchnicectomy 
(suggesting a reduction in preoperative hyperalgesia), and the hyperalgesic group was the group not 
experiencing such an increase.
A) The change in NRS after bilateral thoracoscopic splanchnicectomy was significantly greater (marked 
with an asterisk) in the clavicle site hypoalgesic group versus preoperatively (median -2 (IQR -4 – 0) vs. 0 
(IQR 0 – 1), P = 0.005). 
B) The change in NRS after bilateral thoracoscopic splanchnicectomy was not significantly greater in the 
pancreatic hypoalgesic group versus preoperatively (median 0 (IQR -3 – 1) vs. 0 (IQR -2 – 0), P = 0.5). 
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Correlations between clinical pain measures and quantitative sensory testing
There was a significant negative correlation between the change in NRS and the PPT 
changes at clavicle site due to bilateral thoracoscopic splanchnicectomy for the group as 
a whole (rs = 0.53, P < 0.05) (Figure 2). There was no significant correlation between the 
change in NRS and the PPT changes at the pancreatic site. Also, no significant correlation 
could be observed between the clavicle site and the pancreatic site PPTs (Table 3).
Figure 2
‘NRS’ is numeric rating scale and ‘PPT’ is pressure pain threshold. On the y-axis, the change in pain NRS 
preoperatively versus postoperatively has been mentioned. On the x-axis the change in PPTs preoperatively 
versus postoperatively in clavicle site has been mentioned. A significant correlation was found between 
the change in NRS and PPT (rs = 0.53, P < 0.05). This correlation shows that a decrease in pain is 
correlated with an increase in PPTs. Pressure pain thresholds is in kPa.
DIscussIon
Only few published studies describe changes in central pain processing in patients with 
chronic pancreatitis after thoracoscopic splanchnicectomy.11 We found that an increase 
in PPTs at the clavicle site after bilateral thoracoscopic splanchnicectomy, distant from the 
pancreas and thus reflecting supraspinal processing,10 was associated with a significant 
reduction in pain scores six weeks postoperatively. This was not the case for the pancreas 
site, reflecting more segmental spinal processing.10 In patients in whom bilateral thora-
coscopic splanchnicectomy did not show any effect on clavicle site PPT, pain scores 
were unaltered. These results suggest that in the latter group, central changes in pain 
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processing might have become independent of ongoing peripheral nociceptive input, 
resulting in persisting pain despite nociceptive deafferentation via bilateral thoracoscopic 
splanchnicectomy.15
Sensitization of the nervous system is a cardinal feature of most chronic pain disorders.6 
Peripheral nociception at the site of the pancreas can be expected to spread via ascending 
pathways of the spinal cord to supraspinal structures including the cortex.12,13 Because 
of ongoing nociceptive input the dorsal horn of the spinal cord undergoes neuroplastic 
changes, resulting in an increase in neuronal excitability and, synaptic strength and 
neuronal reorganization8, characterized by segmental hyperalgesia at the site of injury.16 
Ultimately ongoing nociceptive drive on secondary neurons will lead to spreading and 
generalized hyperalgesia, caused by hyperexcitability and firing of supraspinal neurons 
at lower thresholds.8 Failure of activation of diffuse noxious inhibitory controls in 
turn depresses nociceptive activity in dorsal horn neurons; experienced by patients as 
a reduction in pain.17,18 All these changes carry the potential of independence from 
peripheral nociceptive input, where pain and hyperalgesia will then be present even 
when there is no peripheral nociceptive input.16
We found that deafferentation of the pancreas by bilateral thoracoscopic splanchni-
cectomy did not lead to a decrease in NRS or an increase in distant pain thresholds in a 
subgroup of pancreatitis patients. Thus, it would appear that we might have identified a 
subgroup of pancreatic pain patients where supraspinal central sensitization is no longer 
dependent on peripheral nociceptive input, resulting in absence of pain reduction. This 
would be the first time this phenomenon has been demonstrated in chronic pancreatitis 
pain patients, and may explain the relatively large proportion of such patients who 
fail to respond to typical surgical or pharmacological treatments designed to reduce 
nociceptive input.15 Conversely, this study also suggests there is a subgroup of chronic 
pancreatitis pain patients in whom supraspinal changes in pain processing do depend on 
peripheral nociceptive input, and in these patients peripheral nociceptive deafferentation 
via bilateral thoracoscopic splanchnicectomy appears effective in reducing both pain and 
central sensitization.
Methodological considerations
Alternative explanations for the failure of bilateral thoracoscopic splanchnicectomy to 
improve hyperalgesia or pain need to be considered. Technical failure due to difficult 
identification of all the splanchnic branches, variations in morphology, alternative pathways 
and localization of the greater and lesser splanchnic nerves have all been described in the 
literature.13,15 However, during our procedures all nerves and branches were visualized 
in all patients, and all procedures were classified as technically successful. The surgery of 
itself could have caused further central sensitization due to nerve destruction resulting 
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in increased central excitation and facilitation via descending pathways, where finally 
an autonomous state of chronic pain can be present.6 However, in our study only a 
minority of patients showed this phenomenon, and in fact almost two thirds of our 
chronic pancreatitis patients showed pain reduction due to deafferentation.4
Another possible explanation for bilateral thoracoscopic splanchnicectomy failure is that 
bilateral thoracoscopic splanchnicectomy does not treat the cause of the pain itself, 
the pancreatitis.19 Again, however, the question is why this should be true of some 
pancreatitis patients and not others. An explanation for the difference in pain sensation 
after the operation by imperfections in the QST protocol is also unlikely. The QST protocol 
we used is well-standardized and reliable and is generally accepted in the literature as an 
appropriate and effective method to measure and follow-up pain processing in multiple 
disorders and patient groups.10
In contrast to our previous study we were now able to positively link our QST results 
(presence or absence of hyperalgesia) to clinical effect.11 As clinical effect, we used pain 
scoring by NRS, which is an easy and reliable method of evaluating pain state in patients. 
In our previous study, success was defined as ceasing opioids within six weeks after the 
treatment.11 However, it would have been more appropriate to correlate differences in 
pain processing, measured by QST, to changes in NRS or VAS, rather than opioid usage, 
which is influenced by a multitude of factors. Many of these factors are only weakly 
related to changes in pain processing, which can be expected to occur in the first weeks 
after nociceptive deafferentation. 
An important limitation of this study is the sample size; therefore, important differences in 
baseline or postoperative measurements could have been missed. Because of the use of a 
single pain assessment instead of multiple assessments like questionnaires, we may also 
have missed important outcomes. In this study we only used one modality (mechanical 
pressure) for the QST, because central sensitization is best reflected by mechanical (e.g. 
pressure) pain thresholds. Other modalities for example, thermal pain thresholds, mainly 
reflect peripheral sensitization or nerve damage. Our data might have been different 
if we used an even more distal site, for example, the trigeminal dermatome, rather 
than the clavicle site as distant reference site reflecting generalized central sensitization. 
However, the use of the clavicle site for determining central sensitization has been 
described before and is more patient friendly.20
Clinical implications
This study has shown that there may be groups of patients with chronic pancreatitis that 
do not benefit from analgesic treatment and surgery that ‘deafferents’ the pancreas 
to control pain. It appears important to identify such patients, who are likely to have 
autonomous changes in supraspinal processing of pain, and might need specific treatment 
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of central sensitization to control their chronic pain. As suggested in other studies, QST 
can be used to demonstrate central changes in pain processing and to predict patients 
that are likely to have no benefit from common therapies modulating nociceptive input 
such as opioids.10,21 These data suggest that a local nerve block test (e.g. celiac plexus 
blockade or differential epidural anesthetic)22 in combination with a preblockade and 
postblockade QST before performing a bilateral thoracoscopic splanchnicectomy might 
be predictive and save these patients an unnecessary surgery, but this needs confirmation 
by future studies.
Pain control for chronic pain patients resistant to peripheral nociceptive deafferentation 
can likely be achieved by using medication influencing central changes in pain 
processing, for example, tricyclic depressants and gabapentinoids.8,23,24 Interestingly 
gabapentin has shown to potentiate the effect of opioids in an animal model of 
pancreatitis.25 Blockade of the N-methyl-d-aspartic acid receptor, which plays a central 
role in central sensitization, with ketamine has been proven to be effective in treating 
central sensitization and hyperalgesia.6,26 However, more research is needed on the use 
of ketamine, antidepressants and gabapentinoids in treating therapy resistant chronic 
pancreatic pain patients.20
In summary, pain scores were unaltered in chronic pancreatitis pain patients in whom 
bilateral thoracoscopic splanchnicectomy did not increase distant PPTs. These results 
suggest that, in this group, central changes in pain processing might have become 
independent of ongoing peripheral nociceptive input, resulting in persisting pain despite 
bilateral thoracoscopic splanchnicectomy. If confirmed in larger studies, these results 
indicate the importance of sensory testing in the interpretation of unsuccessful interven-
tional pain treatments. Ultimately, the ability to identify patients who have autonomous 
pain processing will be key to achieving improvements in the management of the 
disabling pain of chronic pancreatitis patients. More research is needed to achieve 
greater insight into the alterations of central pain processing accompanying the pain of 
chronic pancreatitis and thus to treat this pain more effective.
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absTRacT
Background and Objectives
Upper abdominal pain is a dominant feature of chronic pancreatitis. A key phenomenon 
in this context is hyperalgesia, typically associated with N-methyl-D-aspartate (NMDA) 
receptor activation. This exploratory study evaluates acute effects of S-ketamine, a 
noncompetitive NMDA antagonist, in modulating generalized hyperalgesia in chronic 
pancreatitis pain.
Methods
In a blinded crossover trial ten chronic pancreatitis pain patients received S-ketamine for 
three hours at 2 mcg/kg/min or placebo infusion at an equivalent rate in randomized 
order. Clinical pain was assessed via visual analog scale (VAS) and short Dutch Language 
Version McGill Pain Questionnaire (sf-MPQ-DLV). Pressure pain thresholds (PPT) were 
measured in dermatome C5, T4, T10 BACK (dorsal), L1 and L4, and the sum of PPTs 
(SOPPT) calculated before, at end of, and after infusion.
Results
Nine patients completed the study. Median pain VAS before infusion was 29 mm at rest, 
32 mm during activity; sf-MPQ-DLV score was four. For the S-ketamine session median 
SOPPT change at infusion end was significantly higher than in the placebo session (218, 
interquartile range (IQR), 116 - 527 vs. -123 (IQR, -330 – 24), P = 0.005), and significant 
versus preinfusion values (2109 (IQR, 964 – 3035) vs. 1914 (IQR, 842 – 2884), P = 0.03). 
SOPPT was unchanged versus preinfusion values and similar between groups one hour 
after infusion end. No significant changes in VAS and sf-MPQ-DLV occurred.
Conclusions
S-ketamine infusion is more effective than placebo in increasing PPTs in chronic pancreatitis 
pain patients immediately after infusion. This effect did not outlast the infusion. Further 
research is warranted into S-ketamine use for reducing generalized hyperalgesia and 
chronic pancreatitis pain.
S-ketamine in chronic pancreatitiS pain
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InTRoDucTIon
Chronic pancreatitis involves progressive inflammatory changes in the pancreas that 
damage its structure, leading to exocrine and endocrine dysfunction.1 In western countries, 
alcohol is the main cause of chronic pancreatitis. Upper abdominal pain, present in 80 - 
90% of patients, is a dominant feature and the best predictor for health-related quality 
of life.2 The relapsing painful attacks and severe pain accompanying chronic pancreatitis 
remains a major therapeutic challenge, often leading to opioid dependence, recurrent 
hospitalization, and medical interventions.3
The intense visceral nociception in chronic pancreatitis due to inflammation, nerve 
damage or elevated intrapancreatic pressure leads to relapsing painful attacks and 
often continuous pain.4 This often leads to central nervous system reorganization and 
sensitization, whose presence has been demonstrated using quantitative sensory testing 
(QST) and electroencephalography.5,6 Central sensitization increasess excitability of 
central nervous system nociceptive neurons amplifying signals coming from the periphery, 
manifest as generalized hyperalgesia.7 Another cause of hyperalgesia in pancreatitis may 
be opioid-induced hyperalgesia.8
A key mechanism in central sensitization and opioid-induced hyperalgesia is that of 
activation of N-methyl-D-aspartate (NMDA) receptors.9 S-ketamine is a non-competitive 
NMDA receptor antagonist.10 Multiple studies have consistently produced positive results 
regarding the use of S-ketamine in (chronic) pain patients with central sensitization and 
hyperalgesia.11 We therefore hypothesize that S-ketamine, with its ability to depress 
central nociceptive sensitization and opioid-induced hyperalgesia, will positively affect 
the generalized hyperalgesia present in chronic pancreatitis patients.5 At the moment 
there are no formal studies on the use of S-ketamine for this purpose. 
The aim of this hypothesis-generating exploratory study is to investigate the effects 
of S-ketamine infusion on the generalized hyperalgesia present in chronic pancreatitis 
patients on stable opioid therapy using somatic QST.
MeTHoDs
Study patients
The institutional medical Ethics Committee approved the protocol. All patients gave 
written consent. Patients were eligible if they were at least eighteen years of age, had 
chronic pancreatitis pain, had active but clinically stable chronic pancreatitis, and were on 
stable opioid therapy. Patients had no surgically treatable anatomic substrate for chronic 
pancreatitis pain. Patients with a psychiatric disorder or encephalopathy, sufficient to 
compromise data collection for example QST, were excluded. The patients’ medical and 
demographic data were obtained from the patient records. Opioid medication for each 
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patient was converted to morphine equivalents per day using the Narcotic Analgesic 
Converter (version 2.0, GlobalRPh! Inc.; www.GlobalRPh.com). 
To confirm the presence of generalized hyperalgesia at baseline in the pancreatitis 
patients, an age and sex matched normal values group consisting of nine patients without 
a painful condition scheduled for routine gynecologic or urologic elective surgery was 
chosen for comparison from our hospital QST database.
Study drug
S-ketamine (Ketanest-S, Pfizer, Capelle a/d IJssel, the Netherlands) was supplied to the 
nursing ward by the anesthesiology department. A dosage of 2 mcg/kg/min of S-ketamine 
is comparable with a dosage of 4 mcg/kg/min for racemic ketamine. The blinded syringes 
contained either a solution of 20 ml of S-ketamine with a concentration of 2.5 mg/ml 
or 20 ml of NaCl 0.9% as placebo. Experienced doctors administered all study drugs.
Clinical pain assessment
Mean pain and worst pain was scored by means of a visual analog scale (VAS; 0 mm 
represented no pain and 100 mm represented unbearable pain) at rest, during activity 
and during eating (only preinfusion). The short Dutch Language Version of the McGill Pain 
Questionnaire – sf-MPQ-DLV – was used to determine intensity and emotional impact of 
pain at rest. The sf-MPQ-DLV contains eleven items for assessing sensory dimensions of 
pain and four items for affective dimensions of pain. Only the sum of values for sensory 
and affective dimensions was used in the analysis.
Quantitative sensory testing
Quantitative sensory testing took place using a standard temporal test sequence. Testing 
in females was not standardized with regard to phase of the menstrual cycle because 
all were amenorrheic postmenopausal. Pressure pain tolerance thresholds were tested 
using a pressure algometer with a 1.0 cm2 probe (Somedic Sales AB, Horby, Sweden), at 
the following sites on the dominant body side: lower neck (C5 dermatome), sternum (T4 
dermatome), pancreatic site (T10 BACK (dorsal) dermatome), hip region (L1 dermatome) 
and knee (L4 dermatome). The sum of pressure pain threshold (SOPPT) was chosen for 
evaluation of generalized hyperalgesia as a simple method of including all dermatomes, 
thus reflecting total body hyperalgesia.
Study design
This was a blinded and placebo-controlled crossover trial that evaluated the influence 
of S-ketamine on generalized hyperalgesia in patients with chronic pancreatitis at one 
hospital in the Netherlands. Sealed envelopes were used for randomization and were 
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opened after data lock. Eligible patients randomly received placebo or S-ketamine on the 
first visit and at least one week later the opposite regimen during the second visit. During 
both sessions, at the same time of the day, patients received infusion for three hours at 
a rate equivalent to S-ketamine 2 mcg/kg/min or placebo. During the visits patients were 
only allowed to drink clear fluids without sugar. Before infusion was started, QST was 
performed, pain experience was measured by the sf-MPQ-DLV and pain intensity by a 
VAS score. This was repeated immediately after three hours of infusion and one hour 
after the end of infusion. Side effects and hemodynamic parameters were monitored.
Efficacy end points
The primary study endpoint was the difference in change versus before infusion values of 
SOPPT. This was compared for immediately after, or one hour after the end of, the three 
hour infusion for the S-ketamine versus placebo group. 
Secondary endpoints
1) Differences in the change versus baseline PPT values in the individual dermatomes 
before and after S-ketamine versus placebo infusion; 2) changes in subjective pain 
sensation measured by VAS scores (at rest or during activity) for S-ketamine versus 
placebo immediately after and one hour after the end of drug infusion; 3) (changes 
in) the sf-MPQ-DLV for S-ketamine versus placebo at the same time points; and 4) the 
observed adverse effects during study drug infusion.
Statistical analysis
We performed statistical analysis using Statistica (release 7.0, Statsoft Inc, Tulsa, Okla). 
Statistical significance was set at P ≤ 0.05. We used Mann-Whitney U test to analyze: 
1) generalized hyperalgesia by comparing the before infusion SOPPT of the normal 
values group and study group; 2) the change in SOPPT between the S-ketamine and 
placebo sessions immediately after and one hour after infusion; 3) before infusion 
differences in primary and secondary endpoints regarding study session (i.e. placebo vs. 
S-ketamine) and gender; and 4) differences in secondary endpoints for placebo versus 
S-ketamine immediately after and one hour after infusion. A Wilcoxon signed rank-test 
was performed to determine the difference between SOPPT, VAS and sf-MPQ-DLV scores 
before versus immediately after infusion or before versus one hour after infusion for the 
placebo and S-ketamine sessions. The relationship between QST results and VAS scores 
was examined with a Spearman’s rank correlation coefficient.
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ResulTs
Study population
Ten patients were randomized; the study was completed without any incident. One 
patient dropped out of the study after randomization for personal reasons. All patients 
(5 women, 4 men; mean age 53.2 ± 5.7 years) had pain due to chronic pancreatitis and 
were on a stable opioid therapy. Their median opioid consumption was 160 (interquartile 
range (IQR) 160 – 315) mg of morphine equivalents per day. Their median VAS scores 
before infusion were 29 (IQR 14 – 48) mm at rest and 32 (IQR 23 – 68) mm during 
activity. The median score of the sf-MPQ-DLV before infusion was four (IQR 2 – 6). More 
demographic data of the study population and normal values group are listed in Table 1.
Table 1 
Demographic and baseline data of the chronic pancreatitis group
Pancreatitis 
(n = 9)
normal values 
(n = 9)
Age (years) 52 (50 – 58) 52 (47 – 55)
Sex ratio, male:female 4 : 5 4 : 5
Diabetes mellitus 3 -
Pancreatic exocrine insufficiency 0 -
Previous abdominal surgery 5 -
 Frey procedure 1 -
 Partington-Rochelle procedure 1 -
 Whipple procedure 1 -
 Stent placement 1 -
 Pancreas tail resection 1 -
Etiology
 Alcohol 6 -
 Hypertriglyceridemia 1 -
 Unknown 2 -
PPT (dermatome), kPa
 C5 229 (198 – 533) 574 (470 – 740)
 T4 280 (219 – 490) 602 (473 – 827)
 L1 352 (179 – 564) 502 (417 – 576)
 T10 dorsal 341 (275 – 568) 666 (446 – 887)
 L4 355 (298 – 740) 735 (485 – 875)
Results are medians with interquartile ranges unless otherwise specified.
Baseline pain pressure thresholds
A significant difference was found in baseline measurements for SOPPT between the 
normal values group (9 patients) 2900 kPa (IQR 2349 - 3461) and the chronic pancreatitis 
group 1583 kPa (IQR 1221 - 3191), P = 0.04. More patient baseline PPT measurements 
are listed in Table 1. Before infusion, PPTs did not differ significantly between visits or sex.
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Immediately after end of infusion
The change in SOPPT was significantly higher in the S-ketamine session immediately after 
the end of infusion as compared to the placebo session 218 kPa (IQR 116 – 527) versus 
-123 kPa (IQR -330 – 24), P = 0.005 (Figure 1A). Only in the S-ketamine session were 
SOPPT values immediately after end of infusion significantly higher than pre-infusion 
2109 kPa (IQR 964 – 3035) versus 1914 kPa (IQR 842 – 2884), P = 0.03. A significantly 
more positive change in PPT was observed in dermatomes L1 and L4 in the S-ketamine 
versus placebo group immediately after the infusion end 121 kPa (IQR 1 - 254) versus 
-21 kPa (IQR -97 – 25), P = 0.04; and 107 kPa (IQR 68 – 148) versus -20 kPa (IQR, -97 – 
-3), P = 0.01; respectively; with the differences for the other dermatomes not reaching 
significance (Figure 2).
Figure 1
‘SOPPT’ is sum of pressure pain thresholds. Values are medians with interquartile ranges (IQR) and plotted 
in a box plot. 
A) The change in SOPPT immediately after the end of infusion versus pre-infusion of the trial medication 
compared for the placebo and S-ketamine groups. The placebo group has a median of -123 kPa (IQR 
-330 – -24), and the S-ketamine group has a median of 218 kPa (IQR 116 – 527). 
B) The change in SOPPT versus pre-infusion one hour after the end of infusion of the trial medication 
compared for the placebo and S-ketamine groups. The placebo group has a median of 127 kPa (IQR -235 
– 415) and the S-ketamine group has a median of 280 kPa (IQR -51 – 489).
One hour after end of infusion
One hour after end of infusion, there were no statistically significant differences between 
sessions for PPT (Figure 1B). Furthermore, SOPPT at one hour after infusion end was not 
higher than before infusion values in either session.
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Figure 2
All measurements for pressure pain thresholds (PPT) in kPa for all five dermatomes pre-infusion, 
immediately after the end of infusion, and one hour after infusion end of the trial medication are 
compared for placebo and S-ketamine groups. Results are medians with interquartile ranges. ‘T10D’ is 
T10 BACK (dorsal). Differences marked with an asterisk are statistically significant.
 
VAS scores and sf-MPQ-DLV
Neither session (S-ketamine vs. placebo) nor sex significantly influenced pain VAS scores 
at rest and during activity or sf-MPQ-DLV results before infusion. The only exception was 
that maximum pain during eating was significantly higher for men (P = 0.016).
Changes in VAS scores at rest and with activity and sf-MPQ-DLV immediately and one 
hour after infusion end were similar for both treatment sessions. Furthermore there were 
no significant changes in VAS and sf-MPQ-DLV scores within the sessions immediately 
after or one hour after infusion end as compared with before infusion. However, there 
was a significant difference for the sf-MPQ-DLV sensory scores of the placebo group pre- 
and immediately after infusion end (P = 0.018).
No significant correlations between VAS scores, sf-MPQ-DLV scores and the SOPPT were 
found before, immediately after and one hour after infusion end, for both sessions taken 
together or taken separately.
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Adverse effects
Adverse effects during infusion with S-ketamine were categorized as light and were 
no reason to stop the experiment. Light-headedness was reported by four patients 
and disappeared after the infusion ended. One patient felt dizzy at the end of infusion 
with stable hemodynamic values. Another patient mentioned an odd taste that also 
disappeared after stopping the infusion. No side effects were reported during the 
infusion with placebo.
DIscussIon
Current treatment concepts for pancreatic pain increasingly target control of hyperalgesia 
by using tricyclic antidepressants, gabapentin, or pregabalin.12 Opioids initially provide 
analgesia to chronic pancreatitis patients, but have considerable adverse effects. 
Indeed, opioid usage may induce and maintain hyperalgesia and thus become a part 
of this painful condition.8 Our patients had significantly lower pre-infusion SOPPT for 
all dermatomes versus normal values, compatible with generalized hyperalgesia. Ours 
is the first study to analyze (acute) antihyperalgesic effects of infusion with S-ketamine 
in chronic pancreatitis patients. The study demonstrates the tolerability and short-term 
effect of S-ketamine in the acute treatment of generalized hyperalgesia accompanying 
the pain of chronic pancreatitis. Further studies are necessary to determine optimum 
indications, treatment paradigms and long-term effects of S-ketamine in this context.
Hyperalgesia and ketamine 
Chronic pain is increasingly recognized to be characterized by altered pain processing, 
including spreading (or generalized) hyperalgesia and pronociceptive pain modulation.13,14 
This is also the case for chronic pancreatitis where neuroplastic changes at spinal and 
supraspinal sites due to chronic nociceptive input are increasingly being demonstrated.12 
Ongoing nociceptive input will ultimately lead to central sensitization and loss of 
descending inhibitory control mechanisms that may end in an autonomous pain state.15 
In our study we observed a significant increase in SOPPT with S-ketamine treatment, 
suggesting that S-ketamine may be successful in acutely treating the generalized 
hyperalgesia associated with chronic pancreatitis pain.5,16 This result is compatible with 
others demonstrating antihyperalgesic actions of S-ketamine on central sensitization and 
chronic pain.17,18 After the end of S-ketamine infusion the QST changes disappeared 
rapidly. This may be related to the relatively short infusion period and the low dosage 
chosen. Studies with infusion periods up to days show a more prolonged effect with 
ketamine.19 But long-term and high-dose ketamine therapy may have neurotoxic 
effects, as described in animal studies,19,20 but is unstudied in humans. Available human 
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data suggest that low ketamine infusions of up to seven days are without long-term 
deleterious effects.21 Unfortunately, studies describing other routes, for example oral or 
subcutaneous, have shown limited and unpredictable clinical effects.22,23 Clearly, further 
studies are needed to resolve these issues.
Methodological considerations
This small hypothesis-generating exploratory study focused on the acute effect of 
S-ketamine on hyperalgesia. A limitation of this study is the short time of infusion and lack 
of longterm follow-up. Thus we could have missed a delayed antihyperalgesic effect of 
S-ketamine infusion in reducing later pain scores and perhaps opioid consumption. Future 
studies should include more patients and document the long-term effects of S-ketamine 
infusion. Alternative application routes (e.g. oral and intranasal) or other forms of NMDA 
receptor blockade (e.g. memantine and amantadine) are interesting alternatives. A 
control group of healthy subjects was not included in the trial for the evaluation of the 
effect of S-ketamine for the simple reason that assessment of antihyperalgesic efficacy 
requires the presence of hyperalgesia – and this is not present in healthy subjects. QST 
provides objective and quantifiable data on pain processing and is a valuable tool for 
observing processes and mechanisms underlying chronic pain and its treatment.5,24 In 
contrast to VAS, QST measures an aspect of pain, sensory discrimination. SOPPT change 
immediately after S-ketamine infusion was not accompanied by significant changes 
in VAS and MPQ scores. However, numerous studies have shown weak relationships 
between VAS and QST.5
Conclusions and summary
Our study provides preliminary evidence that administration of S-ketamine may be more 
effective than placebo treatment in increasing PPT in patients with hyperalgesic painful 
chronic pancreatitis. However, this effect is limited to the period of infusion, and no 
improvement was seen in accompanying pain scores. The adverse effects reported in the 
S-ketamine group were transient and mild. More research is needed regarding the long-
term effects of infusion, dosage schemes and the relevance of the short-lasting elevation 
of pain thresholds.
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absTRacT
Background & aims
Pain is a disabling symptom for patients with chronic pancreatitis and difficult to treat. 
Evidence from basic science and human studies indicates that pain processing by the 
central nervous system is abnormal and resembles that observed in patients with 
neuropathic pain disorders. We investigated whether agents used to treat patients with 
neuropathic pain are effective in chronic pancreatitis.
Methods
We conducted a randomized, double-blind, placebo-controlled trial to evaluate the 
effects of pregabalin as an adjuvant analgesic. We measured pain relief, health status, 
quality of life and tolerability in 64 patients with pain from chronic pancreatitis; they were 
randomly assigned to groups given increasing doses of pregabalin or placebo (control) 
for three consecutive weeks. The primary endpoint was pain relief, based on a visual 
analogue scale documented by a pain diary. Secondary endpoints included patients’ 
global impression of change (PGIC) score, changes in physical and functional scales, pain 
character, quality of life, and tolerability.
Results
Pregabalin, compared with placebo, caused more effective pain relief after three weeks of 
treatment (36% vs. 24%; mean difference, 12%; 95% confidence interval, 22% - 2%, 
P = 0.02). The percentage of patients with much or very much improved health status 
(PGIC score) at the end of the study was higher in the pregabalin than the control group 
(44% vs. 21%, P = 0.048). Changes in physical and functional scales, pain character, 
and quality of life, and number of serious adverse events were comparable between the 
groups.
Conclusions
In a placebo-controlled trial, pregabalin is an effective adjuvant therapy for pain in 
patients with chronic pancreatitis.
pregabalin for pain treatment in chronic pancreatitis
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InTRoDucTIon
Upper abdominal pain is a dominant feature of chronic pancreatitis, and its treatment 
remains a major clinical challenge.1 Analgesic medication is part of the initial treatment 
and often includes opioids in the absence of pathology suitable for endoscopic or surgical 
interventions.2 However, opioid-based analgesia often only shows limited effectiveness 
in these patients and is frequently accompanied by undesirable side effects.3
Basic studies of pancreatic nerves and experimental human pain research have provided 
evidence that pain processing is abnormal in patients with chronic pancreatitis and in many 
patients resembles that seen in neuropathic pain disorders.4-7 Gabapentinoids, including 
pregabalin, have effectively been used to treat various neuropathic pain disorders, including 
diabetic neuropathy, postherpetic neuralgia, and neuropathic pain of central origin.8-13
Based on the limited effectiveness of conventional opioid-based analgesic approaches to 
chronic pancreatitis pain, and the finding that pancreatitis pain is accompanied by similar 
alterations of central pain processing as seen in neuropathic pain, we hypothesized that 
pregabalin could be effective as an adjuvant treatment to decrease pain associated with 
chronic pancreatitis. The aims of this study were to evaluate the effects of pregabalin on 
pain relief, health status, and quality of life, and to understand the tolerability in patients 
with chronic pancreatitis.
PaTIenTs anD MeTHoDs
Study oversight 
The study was an investigator initiated, double-blind, placebo-controlled, parallel-group 
study of increasing doses of pregabalin conducted in the Netherlands and Denmark. Pfizer 
donated pregabalin and identical capsules containing placebo but was not involved in 
study design, accrual, or analyses of data. The study was approved by the responsible 
Ethical Committees and medical agencies in both countries, and all patients provided 
written informed consent. The study is registered with ClinicalTrials.gov (NCT 00755573).
Patients
Inclusion criteria were a diagnosis of chronic pancreatitis based on the Mayo Clinic 
diagnostic criteria and chronic abdominal pain typical for pancreatitis (i.e. dull epigastric 
pain more than three days per week for at least three months).14 Patients taking concomitant 
analgesic medication and expected to stay on a stable regime during the trial were 
allowed to enter the study. Key exclusion criteria for patients were generalized painful 
conditions other than chronic pancreatitis, pregnancy or lactation, active (or history of) 
major depression, moderate to severe renal impairment, an abnormal electrocardiogram 
at screening, and hypersensitivity to pregabalin or any of it components.
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Randomization and blinding
Patients meeting eligibility criteria were randomly assigned in a one to one ratio to receive 
either pregabalin or placebo. Randomization blocks had a size of six and were computer 
generated by a pseudo-random code. Trial participants were stratified according to 
absence or presence of diabetes mellitus; no other actions were taken to match the 
groups. Patients and those administrating study medication, assessing outcomes, and 
analyzing data were blinded to group assignment. 
Outcomes
The primary endpoint was change in pain intensity after three weeks of study treatment 
versus baseline pain intensity recorded for one week prior to start of medication. Average 
and maximum daily pain intensities were recorded using a pain diary based on a visual 
analogue scale (VAS) where 0 = no pain and 10 = worst pain imaginable. Secondary 
efficacy parameters were patients’ global impression of change (PGIC) score at the end 
of the study period15 and changes in modified Brief Pain Inventory-Short Form (BPI) 
questionnaire scores.16 The BPI is a 14-item questionnaire that asks patients to rate pain 
during the prior week and the degree to which it interferes with daily activities on a 0 to 
10 scale. It can be summarized in a pain composite score and an interference composite 
score.16,17 Furthermore, changes in quality of life assessed by the European Organization 
for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ-C30) 
and tolerability of pregabalin compared to placebo were considered as secondary end 
points.18 Changes in as needed opioid analgesics (morphine equivalents per day) and 
body mass index were collected as exploratory end points.
Procedures
Screening procedures included a detailed patient history to determine pain localization 
and characteristics. To complement pain characterization, the Pain Detect Questionnaire 
(PDQ) was collected. This constitutes a simple screening tool to predict the likelihood 
of a neuropathic pain component being present in individual patients.19 Patients` pain 
medication history was documented in detail, including amount and frequency of any 
analgesics. Also, a physical examination, including measurement of weight, height, full 
blood count, urea, electrolytes, liver function tests, and electrocardiography was per formed 
at the screening visit. Eligible patients completed the BPI and QLQ-C30 question naires and 
were trained in the use of the pain diary. Patients returned for an enrollment visit one week 
after screening. During this visit, pain diaries were reviewed to ensure correct registration of 
baseline pain scores, information on analgesics was reassessed, and patients were instruc-
ted in proper administration and adjustment of the study medication. All patients received 
their initial dose of study drug and were monitored for 60 minutes for adverse events.
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During the study period, patients received increasing doses of either pregabalin or 
matching placebo. Initial dose was 75 mg pregabalin twice daily. After three days this 
was increased to 150 mg pregabalin twice daily, with a further increase to 300 mg twice 
daily after one week and for the rest of the study period. An equivalent regime was 
followed in the placebo arm. All patients followed the same oral dosing schedule. Daily 
dosages were split into two equivalent doses, one administered in the morning between 
7.00 a.m. and 10.00 a.m. and one in the evening between 7.00 p.m. and 10.00 p.m. 
If unacceptable side effects were experienced by the patient, a single downward dose 
titration was allowed, with the patient staying on that final dosage for the remaining 
study period. Telephone interviews were scheduled at four, seven, eleven, fourteen, and 
seventeen days to assess the presence, severity, and tolerability of adverse events. These 
were collected based on their occurrence and documented in individual case report 
forms. After completion of the three weeks study period, patients were seen for a final 
visit, which included change in measurements as described for screening and the PGIC 
questionnaire. At the final visit patients were instructed to taper their study medication 
by halving their dose for seven days and then to stop medication.
Patients were told to return surplus study medication. Any discrepancy in the number of 
pills returned from the expected number of pills to be used was noted in the patient’s 
case report form. Compliance was calculated as this discrepancy divided by the number 
of pills expected to be used by the individual patient.
Statistical analysis
The study was powered to detect a difference in average daily pain scores of 25% 
between groups during the three weeks of study treatment. On the basis of an assumed 
baseline average pain score of four and a standard deviation (SD) of 30%, we determined 
that a study with 30 patients per group was needed to provide a power of 90% with 
the use of a two-sided significance level of 0.05. Hence, the sample size was set at 64 
patients to allow for possible dropouts.
All data were analyzed according to the intention-to-treat principle. Data are presented 
as means with standard deviations unless otherwise indicated. Pain diary data were 
baseline corrected to offset individual differences in baseline pain scores. The retrieved 
changes were transformed to a relative scale (%) and subjected to analysis of variance 
with the factors study treatment (pregabalin vs. placebo) and study days (days 1 - 21) and 
the interaction of these factors. Wald tests were used for post hoc analysis. Changes in 
tabulated data were given as risk ratios and compared by a Chi-square test or Fisher’s exact 
test as appropriate. To examine the correlation between change in diary pain score and 
PGIC, we used the Pearson correlation coefficient. Changes in BPI scores, QLQ-C30 scales 
or items, as needed opioid analgesics, body mass index, and compliance were compared 
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by Student t-test or Mann-Whitney U test as appropriate. The software package Stata/IC 
version 11.1 (StataCorp LP, College Station, Tx) was used for the statis tical analyses.
ResulTs
Enrollment, baseline characteristics, and study treatments
From October 2008 to May 2010, a total of 236 patients were screened and 64 underwent 
randomization (Figure 1). The study was terminated as planned after randomization of 
64 patients. The two treatment groups were comparable with respect to demographic 
characteristics, clinical data, and baseline pain scores (Table 1). In the pregabalin group, 
20 patients (61%) tolerated a final dose of 600 mg pregabalin; in the placebo group, 26 
patients (90%) tolerated the maximal placebo dose (P = 0.01).
Figure 1 
study enrollment and randomization
Outcomes
Changes in primary and secondary endpoints are summarized in Table 2. For the whole 
treatment period, an overall difference in change of average pain score between 
pregabalin- and placebo-treated patients was evident (F = 8.8, P = 0.003). Post hoc 
analysis revealed a significant difference in pain reduction after three weeks of study 
treatment (36% vs. 24%; mean difference, 12%; 95% confidence interval (CI), 22% 
to 2%, P = 0.02) (Figure 2). In addition, an overall difference in change of maximal pain 
scores was seen for the whole treatment period (F = 8.9, P = 0.003), with a significant 
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difference between groups after three weeks (32% vs. 22%; mean difference, 10%; 
95% CI, 19% to 2%, P = 0.02). 
Table 1 
Demographic and clinical characteristics of patients at randomization
Pregabalin
(n = 34)
Placebo
(n = 30)
Age (years) 52 ± 10 55 ± 12
Males – no. (%)
Etiology – no. (%)
 Toxic-metabolic
 Idiopathic
 Genetic
 Autoimmune
 Recurrent and severe acute pancreatitis 
 Obstructive
Diary pain score (visual analogue scale 0-10)
 Average pain
 Maximal pain
BPI
 Pain score
 Interference score
PDQ – no. (%)
 Neuropathy unlikely
 Neuropathy possible/likely
Concomitant analgesics – no. (%)a
 None
 Weak analgesics 
 Strong analgesics 
21 (62)
16 (47)
11 (32)
2 (6)
1 (3)
2 (6)
2 (6)
4.2 ± 2.2
5.8 ± 2.3
4.4 ± 2.2
4.7 ± 2.1
19 (56)
15 (44)
3 (9)
7 (21)
24 (71)
19 (63)
17 (57)
11 (37)
0 (0)
0 (0)
1 (3)
1 (3)
3.9 ± 2.2
5.2 ± 2.3
4.1 ± 2.1
4.6 ± 1.7
10 (33)
20 (67)
2 (7)
11 (37)
17 (57)
Duration of chronic pancreatitis (months)
Diabetes mellitus – no. (%)
Previous interventions for chronic pancreatitis – no. (%)
 Pancreas resection/drainage procedures
 Thoracoscopic splanchnic denervation
 Celiac blockade
103 ± 75
10 (29)
6 (18)
2 (6)
1 (3)
111 ± 83
10 (33)
5 (17)
4 (13)
1 (3)
Patients treated with enzymes for pancreatic exocrine insufficiency – no. (%) 18 (53) 13 (43)
Ongoing alcohol abuse – no. (%)b
Current smoker – no. (%)
Body mass index (kg/m2)
7 (21)
26 (76)
22.2 ± 5.7
11 (37)
22 (73)
22.5 ± 3.1
Values are means with standard deviations. ‘BPI’ denotes Brief Pain Inventory Short Form and ‘PDQ’ 
denotes Pain Detect Questionnaire. Percentages may not total 100 due to rounding. 
a Weak analgesics were defined as NSAIDS, paracetamol, codeine and tramadol. Strong analgesics were 
defined as opioid-based therapies. bAlcohol abusing patients were defined as female patients drinking > 
14 units of alcohol per week or male patients drinking > 21 units of alcohol per week.
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figure 2 
Primary and secondary outcomes
A) Changes in average pain score on a visual analogue scale (VAS). The black circles and solid line 
represent pregabalin-treated patients, and the white circles and dashed line represent patients receiving 
placebo. Bars are standard errors. P = 0.02 comparing pregabalin and placebo. 
B) PGIC at the end of the study. Black bars represent pregabalin-treated patients, and white bars represent 
patients receiving placebo. There was a better treatment response in the pregabalin group (P = 0.048).
 
More patients rated their treatment response (PGIC) as much or very much improved 
in the pregabalin group (44%) compared with the placebo group (21%) (P = 0.048). 
The changes in average pain diary scores were correlated with PGIC scores for both 
the pregabalin group (r = 0.7, P < 0.001) and placebo group (r = 0.5, P = 0.002). No 
differences between treatments were seen for the BPI composite scores.
Changes in QLQ-C30 subscales and items are summarized in Table 3. An increase in 
quality of life of 9.7 points was observed in the pregabalin group compared to a decrease 
of 1.7 points in the placebo group (P = 0.12). No differences were seen for any of the 
other QLQ-C30 subscales or items.
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Table 2
changes in primary and secondary endpoints after three weeks of study treatment
Variable Pregabalin  
(n = 34)
Placebo  
(n = 30)
Pregabalin  
vs. placebo
P-value
Average diary pain score
Maximal diary pain score
PGIC
 Very much improved
 Much improved
 Minimally improved
 No change
 Minimal worse
 Much worse
 Very much worse
BPI
 Pain score
 Interference score
-36% (-43%- -29%)
-32% (-38%- -26%)
1 (3)
13 (41)
8 (25)
7 (22)
0 (0)
2 (6)
1 (3)
-1.2 (-2.2- -0.2)
-1.3 (-2.2- -0.3)
-24% (-31%- -16%)
-22% (-28%- -16%)
2 (7)
4 (14)
7 (24)
11 (38)
4 (14)
1 (3)
0 (0)
-0.4 (-1.1- -0.4)
-1.0 (-1.7- -0.2)
-12% (-22%- -2%)
-10% (-19%- -2%)
-0.8 (-2.0- -0.4)
-0.3 (-1.5- -0.9)
0.02
0.02
0.048
0.19
0.61
Pain diary data were available for 33 patients (97%) in the pregabalin group and 29 patients (97%) in 
the placebo group; two patients in the pregabalin group left the study after eleven days and eighteen 
days; their data were included until then. Patients’ Global Impression of Change (PGIC) and Brief Pain 
Inventory-short Form (BPI) were available for 29 patients (97%) in the placebo group. In the pregabalin 
group, PGIC data were available for 32 patients (97%) and BPI data for 31 patients (94%). Changes in 
pain diary data and BPI scores are reported as mean changes (95% confidence interval). PGIC is reported 
as numbers (%).
 
Table 3
changes in eoRTc QlQ-c30 questionnaire scales and items
Variable Pregabalin
(n = 34)
Placebo
(n = 30)
Pregabalin  
vs. placebo
P value
Global health status 
(quality of life)
Functioning scales
 Physical functioning
 Role functioning
 Emotional functioning
 Cognitive functioning
 Social functioning
Symptom scales / items
 Fatigue
 Nausea and vomiting
 Pain
 Dyspnea
 Insomnia
 Appetite loss
 Constipation
 Diarrhea
 Financial difficulties
9.7 (-0.5-19.9)
0.2 (-7.0 - 7.4)
2.2 (-9.6 - 14.0)
6.7 (-2.8 - 16.1)
4.8 (-4.4 - 14.1)
11.5 (-2.3 - 25.3)
-12.2 (-23.8 - -0.6)
-7.0 (-15.6 - 1.6)
-17.2 (-30.3 - -4.1)
-2.2 (-9.8 - 5.5)
-18.3 (-33.4 - -3.2)
-18.9 (-34.0 - -3.7)
-1.1 (-16.0 - 13.9)
-7.5 (-14.4 - 0.7)
-12.9 (-23.7 - -2.1)
-1.7 (-12.4 - 8.9)
-2.0 (-8.6 - 4.6)
1.7 (-9.7 - 13.1)
5.4 (-3.7 - 14.4)
5.2 (-5.0 - 15.4)
16.1 (4.3 - 27.8)
2.4 (-9.5 - 14.3)
0.0 (-11.0 - 11.0)
-4.0 (-16.7 - 8.6)
-4.6 (-13.4 - 4.2)
-13.8 (-30.6 - 3.0)
-18.4 (-33.8 - -3.0)
4.6 (-6.5 - 15.7)
0.0 (-10.7 - 10.7)
-13.8 (-27.6 - 0.0)
11.4 (-3.0 - 25.8)
2.2 (-7.4 - 11.8)
0.5 (-15.6 - 16.6)
1.3 (-11.5 - 14.1)
-0.3 (-13.8 - 13.1)
4.6 (-22.3 - 13.2)
-14.6 (-30.9 - 1.7)
-7.0 (-20.5 - 6.6)
-13.2 (-31.0 - 4.7)
2.4 (-8.9 - 13.8)
-4.5 (-26.5 - 17.5)
-0.5 (-21.7 - 20.7)
-5.7 (-24.1 - 12.8)
-7.5 (-19.8 - 4.7)
0.9 (-16.1 - 17.9)
0.12
0.65
0.95
0.84
0.96
0.61
0.08
0.31
0.14
0.67
0.69
0.96
0.54
0.22
0.92
QLQ-C30 data were available for 31 patients (94%) in the pregabalin group and for 29 patients in the pla-
cebo group (97%). Changes in subscales or items are reported as mean changes (95% confidence interval).
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An average reduction in as needed opioid analgesics of 30 mg was observed in the 
pregabalin group compared to a reduction of 4 mg in the placebo group (P = 0.02). The 
average body mass index increased 0.5 kg/m2 in the pregabalin group and decreased 0.2 
kg/m2 in the placebo group (P < 0.001).
Adverse events 
During the study period, four patients (12%) in the pregabalin group and two patients 
(7%) in the placebo group had a serious adverse event (P = 0.7). Two patients in the 
placebo group and one patient from the pregabalin group were admitted to the hospital 
due to worsening of abdominal pain. They were treated with additional opioids as rescue 
medication to reduce pain. One patient receiving pregabalin had pneumonia during the 
downward taper medication period after study end, one patient receiving pregabalin 
injured his shoulder in the swing door at the hospital (screening visit; i.e. no study drug 
administered), and one patient receiving pregabalin experienced worsening of eczema 
during the trial.
In the pregabalin group 35% of patients reported a feeling of being drunk compared 
to 7% in the placebo group (P = 0.007). Light-headedness was reported by 24% in the 
pregabalin group compared to 3% in the placebo group (P = 0.03). Taken together, 
these significant central nervous system related side effects were present in 29% of 
patients not taking opioids compared with 52% of patients using opioid analgesics (P = 
0.4). Patients with central nervous system related side effects used on average 146 ± 124 
mg of morphine per day compared to 92 ± 139 mg in the group not experiencing central 
nervous system related side effects (P = 0.23). All other adverse events were comparable 
between groups. Two patients from the pregabalin group stopped the study medication 
before the end of the study period due to adverse events (confusion and dizziness), and 
no other patients withdrew the study. Detailed information on adverse events is given 
in Table 4.
Compliance
In the placebo group, 97% ± 5% of all study medication were taken correctly compared 
with 91% ± 17% in the pregabalin group (P = 0.4). The number for the pregabalin group 
envelopes two patients with poor compliance (< 50%), of whom one was withdrawn 
from the study due to side effects (see Adverse events).
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Table 4
adverse events during the study period
event n (%) Risk ratio 
(95% cI)
P-value
Pregabalin
(n = 34)
Placebo
(n = 30)
Central nervous 
system
Gastrointestinal/
metabolic
Musculoskeletal
Other
Any adverse event
Feeling drunk
 mild/moderate/severe
Light-headedness
 mild/moderate/severe
Dizziness
Drowsiness
Trouble concentrating
Headache
Amnesia
Migraine attack
Myoclonus
Tremor
Dry mouth
Worsening of abdominal pain
Nausea and vomiting
Decreased glucose tolerance
Muscle cramp
Back pain
Injured shoulder
Urine retention
Change in sexual function
Blurred vision
Pneumonia
Worsening of eczema
31 (91)
12 (35)
4 / 7 / 1
8 (24)
6 / 2 / 0
13 (38)
12 (35)
3 (9)
4 (12)
2 (6)
1 (3)
2 (6)
1 (3)
4 (12)
3 (9)
3 (9)
1 (3)
0 (0)
1 (3)
1 (3)
1 (3)
2 (6)
2 (6)
1 (3)
1 (3)
16 (53)
2 (7)
0 / 2 / 0
1 (3)
1 / 0 / 0
5 (17)
6 (20)
1 (3)
4 (13)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
4 (13)
6 (20)
0 (0)
1 (3)
1 (3)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
1.7 (1.2-2.4)
5.3 (1.3-21.8)
7.1 (0.9-53.2)
2.3 (0.9 - 5.7)
1.8 (0.8-4.1)
2.6 (0.3-24.1)
0.9 (0.2-3.2)
-
-
-
-
-
0.7 (0.2-2.7)
0.44 (0.1-1.6)
-
-
0.9 (0.1-13.5)
-
-
-
-
-
-
0.001
0.007
0.03
0.09
0.27
0.62
1.00
0.49
1.00
0.49
1.00
0.12
0.70
0.28
1.00
0.47
1.00
1.00
1.00
0.49
0.49
1.00
1.00
DIscussIon
Our study demonstrates the efficacy and tolerability of pregabalin as an adjuvant 
analgesic for the treatment of pain caused by chronic pancreatitis. A dosage of pregabalin 
between 150 mg and 300 mg twice daily resulted in clinically significant reductions in 
pain. Entries in daily pain diaries indicated that differences between pregabalin therapy 
and placebo were apparent three weeks after the first medication administration. The 
majority of adverse events that were reported by patients taking pregabalin, including 
feeling of being drunk and light-headedness, were mild to moderate in severity.
As far as we are aware, there are no published studies to date describing the use of 
pregabalin for pain in patients with chronic pancreatitis. A pain reduction of 36% was 
seen in the pregabalin group after three weeks of study treatment. Several studies have 
examined the clinical importance of changes in chronic pain as assessed by a VAS score, 
and reductions in chronic pain intensity of more than 30% appear to reflect at least 
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moderately important clinically relevant differences.15,20 The clinical importance of the 
observed pain reduction was further supported by the association to self-reported health 
status (PGIC).15 Comparable findings have been reported from randomized controlled 
trials in diabetic polyneuropathy, postherpetic neuralgia, and central neuropathic pain, 
where maximal analgesic effects were seen after two weeks of treatment.8,11-13 Also, 
these findings are in agreement with a recently published meta-analysis where the 
efficacy and side effects of pregabalin were determined for various neuropathic pain 
disorders.9
The extensive placebo response (24%) seen in the present study was unexpected. In 
most pregabalin trials, a placebo response of less than 10% has been reported.8,11-13 
A large pain reduction in the group receiving placebo treated may mask the genuine 
efficacy of pregabalin.9 It is most likely that this phenomenon explains the discrepancy 
between the expected effect of 25% pain reduction between groups and the retrieved 
effect of 12%.
Central nervous system adverse effects were experienced by a number of patients in the 
pregabalin group, with an incidence comparable to previous studies of gabapentinoids.9 
The adverse effects were mild to moderate in severity and, as seen in the clinic and in 
previous reports, declined to a tolerable level during the trial course for most patients.9 
This was illustrated by the fact that only two patients had to stop pregabalin treatment 
before the end of the study period. Furthermore, two-thirds of patients in the pregabalin 
group rated their global health score as improved after pregabalin treatment, thus 
emphasizing beneficial analgesic effects over adverse effects for most patients. Patients 
should, however, be informed of potential central nervous system side effects before 
the start of pregabalin treatment, including a feeling of being drunk and light-headed, 
dizziness, and drowsiness.
The majority of patients in the current study were treated with opioids, and one-fourth 
of patients (N = 19) had undergone interventional therapies for chronic pancreatitis 
pain. Despite these aggressive treatment approaches, patients still had severe pain 
at enrollment. Hence, the study population was at the lower end of the treatment 
algorithm suggested by the American Gastroenterological Association guidelines and 
thus comprised a patient group that is very difficult to treat.1 In light of this, the observed 
treatment response are considered clinical relevant.
The rationale for the present study was based on the hypothesis that the alterations 
in peripheral and central pain processing underlying pain in patients with chronic 
pancreatitis resemble those accompanying neuropathic pain. Thus, enhanced neural 
density and hypertrophy of pancreatic nerves along with up-regulation of pronociceptive 
mediators in the pancreatic gland were previously reported in patients with chronic 
pancreatitis.4,21 In addition, widespread or generalized hyperalgesia has been shown 
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in chronic pancreatitis pain, along with cortical reorganization and impairments of 
descending inhibitory control mechanisms, suggesting the presence of aggressive 
central sensitization in these patients.5,7,22,23 Taken together, these alterations are similar 
to those accompanying neuropathic pain and respond poorly to traditional opioid-based 
approaches.24,25 On the contrary, gabapentinoids, such as pregabalin, have been shown 
to be successful in treating pain associated with such nerve damage and hyperalgesia.9,26
As suggested by the current guidelines from the Initiative on Methods, Measurement, and 
Pain Assessment in Clinical trials (IMPACCT recommendations), we used several outcome 
measures to assess the efficacy of pregabalin.20,27 By using a multidimensional test battery 
the complex nature of pain can be explored and associations between quantifiable 
outcomes (such as changes in pain diary scores) can be associated with changes in 
qualitative outcomes (such as PGIC), and thereby a comprehensive multidimensional 
impression of the clinical importance of the analgesic efficacy may be obtained. We 
closely monitored patients using telephone interviews every third day throughout the 
study period to accurately document side effects and permit dose adjustment in case 
unacceptable adverse effects were experienced. This approach may explain the good trial 
adherence, with only two patients leaving the study before the end of the trial period 
due to side effects.
There are important limitations to this study. First, the follow-up period of three weeks 
is likely too short to detect changes in functional scales and quality of life. Whether an 
effect would have been detected on these parameters if the study period was prolonged 
is unknown, although studies with longer observation periods have reported an improved 
quality of life in patients with neuropathic pain treated with pregabalin.8,11,13 Second, 
the fact that only half of patients had alcohol abuse as cause of chronic pancreatitis 
may compromise the external validity of the study. In northern Europe, two-thirds of 
patients with chronic pancreatitis have alcohol abuse as the leading cause of chronic 
pancreatitis.28 Third, it would have been of great interest to compare the effects of 
pregabalin between patients with and without previous pancreatic surgery. However, 
only one-fifth of patients (N = 11) had previous surgery for pain. Therefore, the study is 
unlikely to be powered for a sub analysis with stratification on previous surgery. Fourth, 
the PDQ questionnaire was originally developed and validated in somatic pain (patients 
with lower back pain) and has never been validated for assessment of visceral pain.19 
Consequently, it may be questioned whether the PDQ is valid for documentation of 
neuropathic pain in patients with chronic pancreatitis and future studies are awaited 
to answer this question. For these reasons, the number of patients with neuropathy 
documented by the PDQ at baseline should be interpreted with caution. Finally, this 
study does not assess whether pregabalin is suitable for use as a first-line analgesic 
for treatment of pain in chronic pancreatitis. This important clinical question should be 
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explored in a future head-to-head study comparing pregabalin with standard analgesics 
such as opioids and/or interventional treatments. Further studies will also be necessary 
to document whether pregabalin improves quality of life for patients with chronic 
pancreatitis pain.
Our study provides evidence that the adjuvant administration of pregabalin for the 
treatment of pain in patients with chronic pancreatitis is superior to placebo. The side 
effects reported in the pregabalin group were moderate and in general well tolerated. In 
conclusion, pregabalin can be used in combination with other analgesics or interventional 
therapies to obtain better control of the disabling pain in chronic pancreatitis.
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Background
Intense abdominal pain is the dominant feature of chronic pancreatitis. During the disease 
changes in central pain processing, e.g. central sensitization manifest as spreading 
hyperalgesia, can result from ongoing nociceptive input. The aim of the present study is 
to evaluate the effect of pregabalin on pain processing in chronic pancreatitis as assessed 
by quantitative sensory testing (QST).
Methods
This randomized, double-blind, placebo-controlled trial evaluated effects of pregabalin 
on pain processing. QST was used to quantify pain processing by measuring thresholds 
to painful electrical and pressure stimulation in six body dermatomes. Descending 
endogenous pain modulation was quantified using the conditioned pain modulation 
paradigm to elicit a DNIC (diffuse noxious inhibitory controls) response. The main effect 
parameter was the change in the sum of all body pain threshold values after three weeks 
of study treatment versus baseline values between both treatment groups.
Results
Sixty-four patients were analyzed. No differences in change in sum of pain thresholds 
were present for pregabalin versus placebo after three weeks of treatment. For individual 
dermatomes, change versus baseline pain thresholds was significantly greater in 
pregabalin versus placebo patients for electric pain detection threshold in C5 (P = 0.005), 
electric pain tolerance threshold in C5 (P = 0.04) and L1 (P = 0.05), and pressure pain 
tolerance threshold in T4 (P = 0.004). No differences were observed between pregabalin 
and placebo regarding conditioned pain modulation.
Conclusion
Our study provides first evidence that pregabalin has moderate inhibitory effects on 
central sensitization manifest as spreading hyperalgesia in chronic pancreatitis patients. 
These findings suggest that QST can be of clinical use for monitoring pain treatments in 
the context of chronic pain.
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InTRoDucTIon
The treatment of chronic pancreatitis patients can be a major clinical challenge.1 
Achieving control of pain, one of the main symptoms in this disease, can be difficult, 
and is often unsatisfactory for patients and doctors.2 An evidence based approach to 
this pain for these patients does not exist, and to date there are no uniformly accepted 
guidelines for treatment.
One of the main factors contributing to this problem is the lack of evidence regarding 
the origin of chronic pancreatitis pain.3 Complications of pancreatic inflammation such 
as dilated pancreatic duct, ductal stones and enlarged pancreatic head can be treated 
endoscopically or surgically, but numerous patients continue to suffer from pain despite 
technically successful interventions.4,5 Even bilateral splanchnicectomy, interrupting 
ascending nociceptive pathways, fails in a substantial number of patients.6 In the last 
decade research has suggested that ongoing nociceptive input from the pancreas is 
not the only explanation for the debilitating abdominal pain in chronic pancreatitis. It is 
increasingly accepted that changes in central pain processing, e.g. central sensitization 
or a shift towards pronociceptive pain modulation, may result from chronic nociceptive 
input, manifest as spreading hyperalgesia.7-9 Ultimately, this process may become 
entirely independent of nociceptive input and inhibitory pain modulation, leading to an 
autonomous pain state.10
Medication targeting altered central pain processing, e.g. gabapentinoids such as 
pregabalin, has been used successfully to treat other chronic pain disorders such as 
postherpetic neuralgia and neuropathic pain of central origin.11-13 In a recent publication, 
we demonstrated that pregabalin has a significant clinical analgesic effect in chronic 
pancreatitis patients.14 Quantitative sensory testing (QST) is a useful tool to quantify 
pain processing in chronic pain patients, also in relation to the effectiveness of analgesic 
interventions.15,16 Apart from one recent study on S-ketamine for chronic pancreatitis 
pain and one using gabapentin for visceral pain in irritable bowel syndrome12,17, we are 
not aware of any studies having used QST to describe the influence of centrally active 
medication on pain processing in patients suffering from chronic pain disorders.
The aim of the present study is to evaluate the effect of pregabalin as adjuvant pain 
treatment on pain processing, measured by somatic QST, in patients with chronic 
pancreatitis. We hypothesized that the hyperalgesia in chronic pancreatitis patients 
with pain will undergo reduction under pregabalin treatment, but not under placebo 
treatment.
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MeTHoDs
Study overview
This study was part of an investigator initiated double-blind, placebo-controlled, parallel-
group study of increasing doses of pregabalin conducted in the Netherlands (department 
of Surgery, Radboud university nijmegen medical center) and Denmark (department of 
Gastroenterology and Hepatology, Aalborg Hospital, Aarhus University Hospital).14 The 
study was approved by the responsible Ethical Committees in both countries (CMO 
region Arnhem-Nijmegen, Nijmegen, the Netherlands and The local Ethics Committee 
North Region, Aalborg, Denmark) and all patients provided written informed consent. 
This article presents a secondary and further analysis of the data obtained in a previous 
trial focusing primarily on experimental (QST) endpoints.14
Patients
For trial inclusion, patients needed to have chronic abdominal pain typical for pancreatitis 
(i.e. dull epigastric pain more than three days per week for at least three months) and a 
diagnosis of chronic pancreatitis based on the Mayo Clinic diagnostic criteria.18 Another 
inclusion criterion was the use of a stable regime of concomitant analgesic medication 
during the trial. Exclusion criteria were: painful conditions other than chronic pancreatitis, 
an abnormal electrocardiogram at screening visit, severe renal impairment, active (or 
history of) major depression, hypersensitivity to pregabalin or any of it components and 
pregnant or lactating patients. All patients that participated in this trial were included in 
this study and analyzed in an intention-to-treat analysis.
Clinical endpoints i.e. pain scores and side effects of the main study are presented in 
more detail in the original manuscript.14
Healthy controls
A control group was recruited in Denmark for comparison with our chronic pancreatitis 
group to confirm the presence of spreading hyperalgesia at the baseline pre-medication 
measurement in the pancreatitis group. The controls were completely healthy and had 
no history of a medical condition that could interfere with our pain measurements.
Randomization and treatment
Eligible patients at our outpatient departments were randomly assigned in a one to one ratio 
to receive either pregabalin or placebo. A pseudo-random code was computer generated 
for the randomization blocks that had a size of six. Stratification of trial participants 
was based on the absence or presence of diabetes mellitus to minimize unbalance in 
distribution of undiagnosed diabetic polyneuropathy. Patients received increasing doses of 
either pregabalin or matching placebo for the study period of three weeks. Initial dose was 
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75 mg pregabalin twice daily. After three days this was increased to 150 mg pregabalin 
twice daily, with a further increase to 300 mg twice daily after one week and for the rest 
of the study period. An equivalent regime was followed in the placebo arm. The same oral 
dosing schedule was prescribed to all patients. Daily dosages were split into two equivalent 
doses, one administered in the morning between 7.00 a.m. and 10.00 a.m. and one in 
the evening between 7.00 p.m. and 10.00 p.m. In the case of unacceptable side effects 
experienced by patients, a single downward dose titration was allowed. Patients had to 
stay on that final dosage for the remaining study period. Patients were instructed to taper 
their study medication after three weeks of treatment, by halving their dose for seven 
days, and then to stop medication. Patients and those administrating study medication, 
assessing outcomes, and analyzing data were blinded to group assignment.
Study visits
Patients considered for participation in this trial were screened for eligibility and physical 
fitness. A systematic physical examination including a neurological examination was 
performed to assess for any relevant conditions and neurological disorders. If eligible, 
they were randomized by their treating physician for placebo or pregabalin on their 
second visit, one week after their screening visit. During their second visit all patients had 
a baseline QST measurement, followed by another QST measurement at the end of the 
study period of three weeks, i.e. before they were instructed to taper their medication. 
During the whole study period patients were instructed not to change their daily pain 
medication. They were only allowed to take extra pain medication in the case of a painful 
exacerbation of their chronic pancreatitis.
Quantitative sensory testing
QST took place using a standard temporal test sequence.7 Testing in females was not 
standardized with regard to phase of the menstrual cycle because all female pancreatitis 
patients were amenorrhoeic. Both the examiners (one in Denmark and one in the 
Netherlands) were trained in and used the same QST protocol. They performed the 
measurements in the same way and setting. Pressure pain thresholds were based on two 
measurements and electrical pain thresholds were based on three measurements.
After initial QST training per participating subject, pressure pain thresholds were obtained 
for muscles overlying bone using a pressure algometer with a 1.0 cm2 probe (Somedic 
Sales AB, Horby, Sweden), at each of the following sites on the dominant body side: 
clavicle (C5 dermatome), sternum (T4 dermatome), pancreatic site (dorsal (BACK) and 
ventral T10 dermatome), hip region (L1 dermatome) and knee (L4 dermatome) (Figure 
1). The pancreas and more distant dermatomes were chosen to observe segmental 
and spreading hyperalgesia respectively. Two thresholds were measured: pressure pain 
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detection threshold (pPDT) and pressure pain tolerance threshold (pPTT). As the primary 
endpoint, the sum of all the thresholds across dermatomes was calculated.17
Figure 1 
Dermatomes of measurement for quantitative sensory testing
Quantitative sensory testing was performed on the following sites on the dominant body side (black 
dots): clavicle (C5 dermatome), sternum (T4 dermatome), pancreatic site (T10 dorsal (BACK) and ventral 
dermatome), hip region (L1 dermatome) and knee (L4 dermatome).
 
Thresholds to electric constant current skin stimulation (Digistim; Biometer A/S, 
Copenhagen, Denmark; tetanic stimulation at 100 Hz, 0.2 ms square waves, self-
adhesive electrodes 3 cm apart) were measured on the dominant side of the body at the 
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same sites as for pressure pain thresholds. Two thresholds were measured: electric pain 
detection threshold (ePDT) and electric pain tolerance threshold (ePTT). As the primary 
endpoint, the sum of all the thresholds was again calculated.17
The conditioned pain modulation (CPM, previously known as diffuse noxious inhibitory 
control (DNIC)) paradigm was performed to test the ability of the patient to generate 
descending inhibitory modulation.19,20 Thus pressure pain thresholds (pPTT, the test 
stimulus) were determined before and after the cold pressor task (the conditioning 
stimulus), and the CPM effect was determined as the relative change (%) in pressure 
pain thresholds. For the cold pressor task the dominant hand was immersed in ice-
chilled water (1.0 °C ± 0.3 °C) continuously stirred by a pump. The patient was told to 
remove the hand from the water after two minutes of immersion – or sooner if the pain 
was considered to be intolerable – and the immersion time noted. Immediately after 
the cold pressor task, the subjects rated the pain experienced during the test by use 
of a visual analogue scale for quality control purposes. Pressure pain thresholds were 
obtained in the non-dominant L4 dermatome (knee) immediately before and after ice 
water immersion.
Outcome measures
The primary effect parameter for the study was the between group difference (change) 
in sum of electric or pressure pain thresholds after three weeks of study medication 
versus baseline values.17 Between group differences in change in individual dermatome 
thresholds and CPM paradigm results were secondary endpoints.
Statistical analysis
A pre hoc power calculation based on QST as an endpoint was not performed because 
the study was a part of a randomized clinical trial that investigated pregabalin, powered 
for a clinical primary endpoint; i.e. change in clinical pain score.
For this mechanistic study we performed an intention-to-treat analysis. We performed 
statistical analysis using the Statistica for Windows Software Package (Release 7.0, Stat-
soft Inc, Tulsa, OK, USA). All baseline characteristics and measurements are given as 
medians with interquartile ranges (IQR). In view of the non-Gaussian data distribution 
purely non-parametric analysis was performed. Statistical significance was set at P ≤ 0.05.
The sum of all dermatomes for electric and pressure pain detection and tolerance 
thresholds and the conditioned pain modulation results were compared between 
the control and the study group using Mann-Whitney U testing to confirm spreading 
hyperalgesia and pronociceptive pain modulation shift in the pancreatitis patients.14,17
We calculated differences (change) in sum of thresholds or individual thresholds between 
values at pre-medication baseline and after three weeks’ medication. We then compared 
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these differences between the groups using Mann-Whitney U testing. Further analysis 
consisted of comparison of placebo versus pregabalin groups at pre-medication baseline 
and after three weeks’ treatment for the sum of thresholds, for individual thresholds, or 
for conditioned pain modulation values using Mann-Whitney U testing.
Figure 2 
study enrollment and randomization
The majority of patients not meeting inclusion criteria had passed away, were free of pain or were no 
longer being treated in either of the hospitals.
ResulTs
Enrollment and baseline characteristics
From October 2008 to May 2010 a total of 236 patients diagnosed with chronic 
pancreatitis in the last five years in one of both hospitals were screened and 64 patients 
were randomized; the study was completed without any incident. The majority of 
patients not meeting inclusion criteria were free of pain, had passed away or were no 
longer being treated in either of the hospitals. 64 patients completed the study and 
were finally analyzed in the intention-to-treat analysis (Figure 2). The number of patients 
randomized to pregabalin or placebo treatment was equally distributed between both 
hospitals. All patients (24 women, 40 men; median age 53 years (IQR 45 – 62) had pain 
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due to chronic pancreatitis and were on a stable analgesic therapy. Their median opioid 
consumption was 60 mg (IQR 11 – 150) of morphine equivalents per day. Their median 
VAS score before start of trial medication was 4 (IQR 2 – 5) at rest and 5 (IQR 4 – 7) 
during activity. Demographic data of the placebo and pregabalin group are provided 
in Table 1. The healthy control group consisted of fifteen volunteers (7 women, 8 men; 
median age 38 years (IQR 35 – 49). Only age was significantly different between the 
healthy controls and chronic pancreatitis patients (P = 0.0001).
Table 1 
Demographic and clinical characteristics of patients
Pregabalin (n = 34) Placebo (n = 30)
Age (years) 52 (46 – 58) 55 (42 – 65)
Males - no. (%) 20 (59) 19 (63)
Etiology - no. (%)
 Toxic-metabolic 16 (47) 17 (57)
 Idiopathic 11 (32) 11 (37)
 Genetic 2 (6) 0 (0)
 Autoimmune 1 (3) 0 (0)
 Recurrent and severe acute pancreatitis 2 (6) 1 (3)
 Obstructive 2 (6) 1 (3)
Diary pain score (visual analogue scale 0 - 10)
 Average pain 4 (2 – 6) 3 (2 – 5)
 Maximal pain 6 (4 – 8) 5 (4 – 7)
Concomitant analgesics - no. (%)†
 None 3 (9) 2 (7)
 Weak analgesics 7 (21) 11 (37)
 Strong analgesics 24 (71) 17 (57)
Morphine equivalents per day (mg) 80 (10 – 158) 49 (13 – 128)
Duration of chronic pancreatitis (months) 92 (55 – 132) 83 (60 – 147)
Diabetes mellitus - no. (%) 10 (29) 10 (33)
Previous interventions for chronic pancreatitis - no. (%)
 Pancreas resection / drainage procedures 6 (18) 5 (17)
 Thoracoscopic splanchnic denervation 2 (6) 4 (13)
Patients treated with enzymes for pancreatic exocrine 
insufficiency - no. (%)
18 (53) 13 (43)
Ongoing alcohol abuse - no. (%)‡ 7 (21) 11 (37)
Current smoker - no. (%) 26 (76) 22 (77)
All values are medians with interquartile ranges unless mentioned otherwise. Percentages may not total 
100 due to rounding. †Weak analgesics were defined as NSAIDS, paracetamol, codeine and tramadol. 
Strong analgesics were defined as opioid-based therapies. ‡Alcohol abusing patients were defined as 
female patients drinking > 14 units of alcohol per week or male patients drinking > 21 units of alcohol 
per week. ‘Pregabalin’ is pregabalin study group and ‘placebo’ is placebo study group. No statistical 
differences between groups were observed.
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Baseline measurements
Pancreatitis versus healthy controls
The sum for pressure and electric pain detection and tolerance thresholds of all 
dermatomes was significantly lower for the pancreatitis group at baseline versus healthy 
controls (Table 2). At baseline chronic pancreatitis patients tolerated the cold pressor task 
for 35 seconds (IQR 24 – 70) and the healthy controls for 180 seconds (IQR 180 – 180), 
(P = 0.000004). The healthy control group exhibited a significantly greater CPM response 
than the pancreatitis patients (P = 0.008) (Table 2). These results confirm hyperalgesia 
and a shift to more pronociceptive pain modulation in our pancreatitis patients.
Table 2 
baseline data for conditioned pain modulation and sum of pain thresholds for pancreatitis 
patients versus healthy controls
Pancreatitis control P-value
SUM ePDT (mA) 28 (21 – 41) 47 (21 – 65) 0.026
SUM ePTT (mA) 44 (34 – 62) 68 (48 – 92) 0.017
SUM pPDT (kPa) 1912 (951 – 2551) 2285 (2018 – 3018) 0.008
SUM pPTT (kPa) 2694 (2110 – 3185) 3234 (2785 – 4018) 0.005
CPM (%) 4.2 (0.0 – 22.4) 32.6 (10.4 – 41.8) 0.008
 
All values are medians with interquartile ranges. ‘Control’ is healthy control group and ‘pancreatitis’ is 
chronic pancreatitis group. ‘ePDT’ is electric pain detection threshold, ‘ePTT’ is electric pain tolerance 
threshold, ‘pPDT’ is pressure pain detection threshold, ‘pPPT’ is pressure pain tolerance threshold and 
‘CPM’ is conditioned pain modulation.
Pregabalin versus placebo patients
The sum of all dermatomes for pressure and electric pain detection and tolerance 
thresholds at baseline was similar for the pregabalin versus placebo groups (Table 3). The 
same applied to the individual dermatomal thresholds (Table 4).
Table 3 
sum of pain thresholds for pregabalin versus placebo before and after treatment
before after
Pregabalin Placebo Pregabalin Placebo
SUM ePDT (mA) 33.4 (23.6 – 43.5) 23.4 (18.9 – 33.8) 37.3 (27.9 – 51.6) • 26.1 (17.2 – 39.7)
SUM ePTT (mA) 53.4 (39.2 – 67.1) 41.7 (32.6 – 51.6) 52.3 (38.9 – 73.9) 44.0 (34.9 – 55.2)
SUM pPDT (kPa) 1936 (1063 – 2574) 1759 (902 – 2449) 1817 (1109 – 3312) 1817 (844 – 2585)
SUM pPTT (kPa) 2677 (2043 – 3136) 2720 (2307 – 3230) 2798 (2355 – 3945) 2853 (2131 – 3264)
 
All values are medians with interquartile ranges. ‘ePDT’ is electric pain detection threshold, ‘ePTT’ is 
electric pain tolerance threshold, ‘pPDT’ is pressure pain detection threshold and ‘pPTT’ is pressure pain 
tolerance threshold. • = Measurements after study treatment were significantly higher in the pregabalin 
group compared to the placebo group.
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Table 4 
conditioned pain modulation and pain thresholds for pregabalin versus placebo before and 
after study treatment
before after
Pregabalin Placebo Pregabalin Placebo
ePDT (mA)
 C5 3.9 (2.5 - 5.1) 3.5 (2.4 - 6.0) 4.5 (3.4 - 5.6) 3.1 (2.1 - 6.0)
 T4 5.0 (3.0 - 7.0) 3.5 (2.7 - 6.3) 6.2 (4.2 - 8.5) • 3.9 (3.3 - 7.6)
 T10 5.8 (4.3 - 8.1) 3.7 (3.0 - 7.7) 6.5 (4.7 - 9.2) 4.9 (3.2 - 7.9)
 L1 4.8 (3.6 - 6.4) 4.3 (3.1 - 5.9) 6.6 (4.4 - 8.9) 4.7 (2.7 - 8.4)
 L4 5.7 (4.0 - 8.5) 4.1 (3.2 - 6.5) 5.8 (4.1 - 9.1) • 4.4 (3.2 - 6.6)
 T10 BACK 5.9 (3.8 - 7.2) 4.8 (3.8 - 6.9) 5.8 (4.3 - 10.3) • 4.3 (2.8 - 7.8)
ePTT (mA)
 C5 6.9 (5.4 - 10.7) 5.4 (4.1 - 9.9) 9.6 (5.4 - 14.4) • 6.3 (5.0 - 10.7)
 T4 8.9 (5.6 - 13.0) 7.6 (5.1 - 10.7) 10.9 (7.5 - 16.2) 8.6 (5.6 - 11.6) 
 T10 10.6 (6.1 - 12.7) 7.3 (3.7 - 10.7) 8.8 (6.1 - 15.1) 7.9 (5.6 - 12.6)
 L1 9.5 (6.5 - 13.5) 7.2 (5.2 - 11.1) 9.5 (7.0 - 14.8) • 7.1 (5.8 - 12.9)
 L4 9.9 (6.7 - 13.3) 7.4 (5.1 - 10.0) 9.1 (6.6 - 14.9) 7.2 (5.7 - 10.9)
 T10 BACK 11.7 (6.5 - 16.3) 9.3 (6.4 - 12.6) 9.1 (6.6 - 14.9) 8.9 (6.9 - 12.5)
pPDT (kPa)
 C5 263 (142 - 334) 232 (106 - 380) 228 (130 - 321) 245 (115 - 398)
 T4 281 (195 - 392) 289 (139 - 409) 277 (169 - 421) 268 (147 - 359)
 T10 166 (97 - 302) 154 (85 - 264) 129 (65 - 328) 157 (61 - 306)
 L1 376 (207 - 511) 340 (197 - 571) 292 (207 - 566) 424 (168 - 528)
 L4 406 (235 - 601) 396 (176 - 613) 447 (177 - 689) 332 (204 - 641)
 T10 BACK 378 (211 - 474) 276 (162 - 522) 332 (132 - 549) 313 (161 - 480)
 PTT (kPa)
 C5 421 (313 - 523) 378 (309 - 563) 451 (310 - 614) 459 (358 - 599)
 T4 481 (307 - 555) 422 (335 - 528) 431 (352 - 691) 371 (284 - 530)
 T10 246 (165 - 493) 257 (176 - 402) 280 (173 - 570) 236 (156 - 432)
 L1 578 (454 - 675) 548 (407 - 706) 551 (437 - 716) 581 (479 - 649)
 L4 608 (530 - 776) 614 (437 - 776) 733 (526 - 933) 700 (508 - 866)
 T10 BACK 574 (403 - 699) 561 (476 - 731) 612 (397 - 838) 537 (395 - 635)
CPM response (%) 0.9 (0.0 - 22.0) 8.9 (0.0 - 23.8) 0.0 (0.0 - 22.4) 0.0 (-4.0 - 19.8)
 
All values are medians with interquartile ranges. ‘ePDT’ is electric pain detection threshold, ‘ePTT’ is 
electric pain tolerance threshold, ‘pPDT’ is pressure pain detection threshold, ‘pPTT’ is pressure pain 
tolerance threshold and ‘CPM’ is conditioned pain modulation.• = Measurements after study treatment 
were significantly higher in the pregabalin group compared to the placebo group.
At baseline, patients in the placebo group tolerated the cold pressor task for 32 seconds 
(IQR 23 – 98) and in the pregabalin group for 40 seconds (IQR 23 – 60), this was not 
statistically different between groups. Also no significant difference was found in baseline 
CPM response between the placebo and pregabalin group (Table 4).
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Table 5 
change and percentage change in conditioned pain modulation and pain thresholds for 
pregabalin versus placebo after study treatment
Pregabalin Placebo
change Percentage change 
(%)
change Percentage change 
(%)
ePDT (mA)
 C5 0.8 (0.2 – 1.9) • 24 (5 – 55) -0.1 (-0.9 – 0.5) 2 (-25 – 16)
 T4 1.5 (-0.7 – 3.0) 39 (-13 – 83) 0.7 (-1.1 – 1.5) 17 (-16 – 49)
 T10 0.8 (-0.7 – 3.1) 12 (-11 – 52) 0.4 (-0.7 – 1.4) 8 (-9 – 40)
 L1 1.2 (-0.2 – 3.8) 25 (-6 – 71) 0.3 (-0.5 – 2.3) 11 (-11 – 51)
 L4 0.9 (-0.8 – 2.3) 14 (-16 – 46) 0.7 (-0.9 – 1.7) 18 (-22 – 37)
 T10 BACK 0.6 (-1.2 – 4.3) 16 (-22 – 75) -0.6 (-1.4 – 1.3) -14 (-29 – 14)
ePTT (mA)
 C5 2.0 (-0.1 – 3.7) • 25 (-1 – 64) 0.7 (-2.4 – 1.9) 12 (-27 – 40)
 T4 2.6 (-0.6 – 5.1) 41 (-5 – 60) 1.5 (-0.9 – 2.9) 15 (-12 – 46)
 T10 1.0 (-0.8 – 2.4) 10 (-10 – 27) 0.8 (-1.2 – 2.4) 17 (-9 – 53)
 L1 1.9 (-0.8 – 4.9) • 29 (-7 – 59) -0.2 (-2.3 – 2.1) -3 (-28 – 38)
 L4 1.5 (-2.0 – 5.2) 22 (-20 – 53) -0.3 (-1.2 – 3.0) 0 (-14 – 83)
 T10 BACK 1.1 (-1.9 – 4.8) 10 (-20 – 57) -0.5 (-2.8 – 2.7) -5 (-21 – 36)
pPDT (kPa)
 C5 12 (-79 – 89) 7 (-39 – 34) -13 (-51 – 50) -7 (-19 – 31)
 T4 9 (-91 – 72) 4 (-34 – 26) -3 (-89 – 45) -1 (-29 – 13)
 T10 13 (-31 – 77) 6 (-31 – 53) -1 (-51 – 26) 0 (-24 – 15)
 L1 63 (-137 – 117) 18 (-39 – 53) 12 (-99 – 135) 9 (-19 – 40)
 L4 80 (-129 – 176) 18 (-30 – 37) 0 (-50 – 88) 0 (-13 – 23)
 T10 BACK 41 (-63 – 89) 9 (-7 – 31) 34 (-73 – 90) 9 (-24 – 24)
pPTT (kPa)
 C5 19 (-65 – 152) 3 (-17 – 40) 17 (-32 – 103) 5 (-9 – 31)
 T4 83 (-24 – 169) • 18 (-7 – 43) -48 (-108 – 43) -13 (-21 – 12)
 T10 10 (-56 – 111) 5 (-15 – 53) 20 (-103 – 56) 7 (-34 – 23)
 L1 -7 (-82 – 136) -1 (-16 – 32) 69 (-149 – 144) 16 (-19 – 28)
 L4 17 (-253 – 278) 6 (-30 – 53) 75 (15 – 225) 12 (3 – 33)
 T10 BACK 41 (-74 – 194) 5 (-15 – 40) 14 (-165 – 81) 3 (-27 – 21)
SUM ePDT 6.0 (-1.2 – 15.0) 19 (-6 – 62) 2.3 (-1.9 – 5.8) 9 (-8 – 19)
SUM ePTT 7.6 (-7.1 – 13.5) 13 (-14 – 25) 2.7 (-7.1 – 10.9) 7 (-15 – 28)
SUM pPDT 311 (-155 – 526) 16 (-9 – 39) 131 (-330 – 329) 11 (-14 – 20)
SUM pPTT 226 (-265 – 593) 10 (-14 – 20) 193 (-192 – 380) 8 (-6 – 17)
CPM response (%) 1 (-4 – 18) -18 (-100 – 134) -2 (-23 – 6) -100 (-136 – 16)
 
All values are medians with interquartile ranges. ‘ePDT’ is electric pain detection threshold, ‘ePTT’ is 
electric pain tolerance threshold, ‘pPDT’ is pressure pain detection threshold, ‘pPTT’ is pressure pain 
tolerance threshold and ‘CPM’ is conditioned pain modulation.• = Measurements after study treatment 
were significantly higher in the pregabalin group compared to the placebo group. 
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Effects of treatment - change in measurements after three weeks’ study medication
Electric pain thresholds
There was no significant difference in differences (change) in sums of electric pain 
detection and tolerance thresholds between the groups (Table 5).
For individual electric pain detection thresholds, difference (change) in dermatome C5 
was significantly higher in the pregabalin group (0.8 vs. -0.1, P = 0.005), with a trend for 
T10 (P = 0.055) (Table 5).
For individual electric pain tolerance thresholds, threshold differences (change) for 
dermatome C5 (2.0 vs. 0.7, P = 0.04) and L1 (1.9 vs. -0.2, P = 0.05) were significantly 
higher in the pregabalin group (Table 5). 
Pressure pain thresholds
There was no significant difference in differences (change) in sums of pressure pain 
detection and tolerance thresholds between the groups (Table 5). 
There was no significant difference in differences (change) in individual dermatomal 
pressure pain detection thresholds between the groups (Table 5).
For individual pressure pain tolerance thresholds, threshold differences (change) for 
dermatome T4 (83 vs. -48, P = 0.004) were significantly higher in the pregabalin group 
(Table 5). 
CPM response
The difference (change) in cold pressor task latency and CPM response was not 
significantly different between the study groups (Table 5).
Effects of treatment - absolute values after three weeks’ study medication
Electric pain thresholds
After three weeks’ study medication, sum of all dermatomes for electric pain detection 
thresholds was significantly higher in the pregabalin versus placebo group (P = 0.01), but 
not for electric pain tolerance thresholds (Table 3).
For individual dermatomes, electric pain detection thresholds were significantly higher in 
the pregabalin group (T4; P = 0.04, L4; P = 0.05 and T10 BACK; P = 0.05) (Table 4). For 
individual dermatomal electric pain tolerance thresholds, C5 (P = 0.05) and L1 (P = 0.03) 
were significantly higher in the pregabalin group.
Pressure pain thresholds
Sums of – or individual dermatome – pressure pain detection and tolerance thresholds 
were similar between groups (Table 3 and 4) after three weeks’ study medication.
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CPM response
After three weeks of study medication patients in the placebo group tolerated the cold 
pressor task for 42 seconds (IQR 21 – 116) and in the pregabalin group for 46 seconds 
(IQR 27 – 77); this was not statistically significant. Also no significant difference could be 
found between groups for CPM response after study medication (Table 4).
DIscussIon
Our study is the first to demonstrate that a three week treatment with pregabalin in 
chronic pancreatitis patients results in a moderate antihyperalgesic effect compatible 
with a reduction of central sensitization. A shift toward more anti-nociceptive pain 
modulation appears less likely as mechanism due to the unaltered CPM response. 
Interestingly, this early treatment effect is 1) visible only in dermatomes distant from 
the referred pancreatic area; and 2) more pronounced for electric skin thresholds than 
for pressure muscle thresholds. This implies 1) better effects on distant as compared 
to segmental central sensitization; and 2) more effective hyperalgesia reduction in skin 
compared to deeper tissues. These results suggest that measuring pain sensitivity using 
QST may prove useful in monitoring the effects of pain treatment in chronic pancreatitis 
and help us to diagnose and manage altered pain processing in chronic pain disorders.
Nociceptive input from the pancreas spreads via ascending pathways to spinal and 
supraspinal central nervous system structures in chronic pancreatitis.21,22 Ongoing 
nociceptive input increases neuronal excitability and synaptic strength, initially at the 
spinal level, a state characterized by hyperalgesia near the site of injury (segmental 
hyperalgesia).3,23 With persis ting disease and nociception central sensitization spreads 
rostrally in the central nervous system.8 This progression is more marked when descending 
inhibitory control mechanisms fail or in the presence of descending facilitation, and may 
in due course result in a widespread hyperalgesic state.9 Ultimately, these central changes 
may become inde pendent of peripheral nociceptive input, ending in an autonomous 
state.6 Sensitization of the nervous system is not specific for chronic pancreatitis, but is 
common among other chronic pain disorders.24-26 Congruently with the described course 
of events, chronic pancrea titis patients in our study did exhibit widespread hyperalgesia 
compared to healthy controls.
The treatment of pain in chronic pancreatitis patients is usually based on the World 
Health Organization pain treatment ladder, which ends with opioid treatment. Opioids 
can provide effective analgesia in some pancreatitis patients, but may have considerable 
side effects or even induce hyperalgesia.27 Recently, pain treatments more directly 
targeting the central nervous system, e.g. tricyclic antidepressants or gabapentinoids, 
have been introduced to better control disabling pain and hyperalgesia in chronic pain 
pregabalin effect on sensitization in chronic pancreatitis
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syndromes.28 Particularly the use of gabapentinoids has shown clinical results in chronic 
pain disorders.12,29,30 The clinical analgesic effect of pregabalin in chronic pancreatitis 
patients was recently published by our research group.14 Two studies in an experimental 
pain model in healthy volunteers showed a reduction of hyperalgesia and central 
sensitization after gabapentin treatment.31,32 Only two studies, one with S-ketamine 
in chronic pancreatitis and one with pregabalin in irritable bowel syndrome, showed 
comparable reductions of hyperalgesia in patients treated with medication active in the 
central nervous system.12,17 To date a more prolonged reduction of somatic hyperalgesia 
and thus central sensitization has not been demonstrated in chronic pain patients in 
relation to pregabalin treatment.
In this study we failed to show a significant difference between groups regarding our 
primary outcome measure (change in sum of thresholds). The significant result regarding 
secondary outcome measure (change in individual dermatomal thresholds) suggests a 
moderate effect on spreading hyperalgesia. Interestingly, antihyperalgesic treatment 
with pregabalin resulted in a greater increase of electric pain thresholds than of pressure 
pain thresholds after three weeks treatment. A possible explanation is that pregabalin is 
initially more effective in reducing skin sensitization, as reflected by electric thresholds, as 
compared to deep tissue sensitization, as reflected by pressure thresholds.32,33 If this were 
true, one might expect greater decreases in deep tissue sensitivity with longer treatment 
periods in future studies.
In this study no significant improvement in CPM could be found, suggesting that the 
main effect of pregabalin is to directly target central sensitization reflected by hyperalgesia, 
rather than the pro/anti-nociceptive balance of endogenous modulation. We did, however, 
demonstrate that before treatment, pancreatitis patients showed less inhibitory pain 
modulation than healthy controls in accordance with other studies.9 However, it should 
be noted that CPM results exhibited considerable variability and are influenced by multiple 
factors. More research is clearly needed to define the relations between CPM, disease-
related changes in central pain processing, and pain treatment effects.9,34
A limitation of this study is the relatively small size of the chronic pancreatitis group. A 
larger sample of chronic pancreatitis patients would appear necessary to provide more 
detailed and significant evidence of the relation between pregabalin treatment, changes 
in pain scores and changes in hyperalgesia. While we did find parallel, separate reductions 
in pain scores and pain sensitivity in our patient collective, the study was not adequately 
powered to formally study – or prove – correlations between clinical pain reduction and 
reduction in hyperalgesia. Definitive proof of such a relationship awaits future larger and 
longer-lasting trials. It should be noted that most chronic pancreatitis studies are small 
due to the difficulties in recruiting large groups of uniform chronic pancreatitis patients. 
Better and larger national and international collaborations are necessary to permit larger 
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and longer population based trials in chronic pancreatitis.
In this study an intention-to-treat analysis was performed conform the international 
standard for randomized clinical trials. It can be argued that for the mechanistic endpoints 
an analysis including only patients fully compliant with the study protocol should be 
performed (per-protocol analysis). We therefore also performed a per-protocol analysis, 
but we did not present these data in this manuscript, because there were no major 
differences compared to the intention-to-treat analysis. We checked variability between 
the study groups and found that standard deviations were comparable between both the 
groups at the different times. The presence of diabetes mellitus, alcohol consumption and 
the wide range of morphine dosages might have influenced our results. Certainly some 
patients might have shown diabetic polyneuropathy or morphine induced hyperalgesia, 
which could have biased our results. However during the physical examination of trial 
participants no peripheral sensory or motor disturbances were detected and all baseline 
characteristics were equally distributed between both treatment groups. There was a 
significant difference in age between the healthy controls and the chronic pancreatitis 
patients. The importance of this difference is difficult to assess. Some studies described 
an increase of pain thresholds during aging35, others showed no effect36 and some 
showed a decrease in thresholds during aging.37
Another limitation of the study is the absence of a long-term follow-up. We only 
measured effects after a relatively short treatment period of three weeks. At this time, 
modest reductions in distant skin hyperalgesia were already noticeable and significant, 
albeit without return to normal values (i.e. as in healthy volunteers). This reduction in 
hyperalgesia occurred in a patient population with a long history of chronic pancreatitis, 
generally regarded as being particularly difficult to manage.
In conclusion our study provides first evidence that pregabalin modestly reduces the 
spreading hyperalgesia as manifestation of central sensitization associated with chronic 
pancreatitis pain. This effect was evident after three weeks of pregabalin treatment and 
was most evident for electric skin pain thresholds. However more research is needed to 
predict the long-term effects and define effective dosage schemes for pregabalin use in 
different stages of chronic pancreatitis. 
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absTRacT
Background
Pain control in chronic pancreatitis is a major challenge; the mechanisms behind 
analgesic treatment are poorly understood. The study aims to investigate differences 
in pain sensitivity and modulation in chronic pancreatitis among responders and non-
responders to placebo or pregabalin treatment.
Methods
This study was part of a randomized, double-blind, placebo-controlled trial evaluating 
analgesic effects of pregabalin and placebo in chronic pancreatitis. Post hoc, patients 
were assigned to one of four groups, i.e. responders and non-responders to pregabalin 
(N = 16 and N = 15) or placebo (N = 12 and N = 17) treatment. Responders were defined 
as > 30% pain reduction after three weeks’ treatment. We measured change in pain 
sensitivity before and after treatment, using electric pain detection thresholds (ePDT) in 
dermatomes C5 (generalized effects) and ventral T10 (segmental effects). Descending 
endogenous pain modulation was quantified via conditioned pain modulation (CPM) 
paradigm.
Results
Sixty patients were analyzed in a per-protocol analysis. ePDT change in C5 was significant 
versus baseline and greater in pregabalin (1.3 mA) versus placebo responders (-0.1 mA, 
P = 0.015). This was not so for ePDT in ventral T10. CPM increased more in pregabalin 
(3%) versus placebo responders (-17%, P < 0.001). CPM changed significantly versus 
baseline only for pregabalin responders (P = 0.006).
Conclusions
Our study provides first evidence that pain relief with pregabalin is associated with 
antihyperalgesic effects and increased endogenous inhibitory modulation. No such 
effects were observed in patients experiencing pain relief with placebo treatment. 
The mechanisms underlying analgesic response to placebo versus drug treatments are 
different and, together with their interactions, deserve further study.
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InTRoDucTIon
Morphological changes of the pancreas due to chronic pancreatitis may cause intense 
pain necessitating surgical or endoscopic intervention. However, many patients remain 
symptomatic even after surgically successful interventions.1,2 The majority of these 
patients have a long history of treatments with opioid-based analgesia with limited 
effectiveness and undesirable side effects.3 A good explanation for treatment failure in 
these patients is lacking to date. Hence, to gain a better control of pain, more evidence 
is needed on the origin of chronic pain and how this is influenced by pain treatment.
Our study with pregabalin and placebo treatment in chronic pancreatitis showed better 
pain relief in the pregabalin group compared to placebo treatment. Interestingly a 
significant pain reduction on average pain could also be observed in the placebo group.4 
Secondary analysis of this trial confirmed that chronic pancreatitis patients showed signs 
of altered central pain processing which was related to disease stage5, and inhibitory 
effects on central sensitization by pregabalin.6 The impact and the magnitude of placebo 
analgesia has been described in recent studies and meta-analyses, and is evolving from 
experimental pain to clinical pain.7-10 Analysis of the placebo effect has shown that 
anti-nociceptive placebo effects may be mediated by opioid receptor ligands and that 
specific brain areas are involved.11-13 However, more information is needed regarding the 
mechanisms involved in possible antihyperalgesic and analgesic placebo effects.
Our trial also showed that some patients had a large pain reduction to pregabalin 
or placebo (responders) and some experienced hardly any pain reduction (non-
responders).14 In animal models, variability in response to pain treatment was related to 
activity of different pain pathways e.g. the inhibitory GABA(γ-aminobutyric acid)-ergic 
system or activation of excitatory N-methyl-D-aspartate (NMDA) receptors in the central 
nervous system.15-17 Another explanation might be that ongoing nociceptive input by 
inflammation of the pancreas produces changes in central pain processing which are 
no longer dependent on ongoing peripheral nociceptive input.18,19 Exploration of basic 
pain mechanisms in responder and non-responder groups by quantitative sensory testing 
(QST) might also help us understand the variable clinical response to pain and placebo 
treatment between individual patients.
The aim of this study was to investigate the difference in pain sensitivity and modulation 
by QST in chronic pancreatitis patients who are responders and non-responders to placebo 
or pregabalin treatment. This study is a secondary analysis of our original randomized 
controlled trial4, the population and the design is similar to one of our previous studies.14
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MeTHoDs
Study oversight
This study was part of an investigator initiated double-blind, placebo-controlled, parallel-
group study of increasing doses of pregabalin or placebo conducted in the Netherlands 
(department of Surgery, Radboud university medical center) and Denmark (department of 
Gastroenterology and Hepatology, Aalborg University Hospital). The study was approved 
by the Ethical Committees in both countries (CMO region Arnhem-Nijmegen, Nijmegen, 
the Netherlands and The local Ethics Committee North Region, Aalborg, Denmark) and all 
patients provided written informed consent. This article presents a secondary and further 
analysis of the data obtained in the previous trial focusing primarily on experimental 
(QST) endpoints.4
Patients
Patients needed to have chronic abdominal pain typical for pancreatitis (i.e. dull 
epigastric pain more than three days per week for at least three months) and a diagnosis 
of chronic pancreatitis based on the Mayo Clinic diagnostic criteria to be included in this 
trial.20 Use of a stable regime of concomitant analgesic medication during the trial was 
another inclusion criterion. Exclusion criteria were: other painful conditions than chronic 
pancreatitis, active (or history of) major depression, allergy to pregabalin or any of its 
components, an abnormal electrocardiogram at screening visit, severe renal impairment, 
and pregnant or lactating patients. Only the patients completely complying with the 
described treatment protocol were analyzed in the present per-protocol analysis.
More details regarding clinical endpoints, i.e. pain scores and side effects, is provided in 
the original manuscript of the main study.4
Randomization and treatment
The randomization and study procedures have been described in detail in the original 
study.4
The study consisted of a three week study period of pregabalin or placebo treatment. 
During the study period patients received either escalating doses of pregabalin (300 to 
600 mg/day) or placebo. In the case of unacceptable side effects, a single downward 
dose titration was allowed. When patients reached their final dosage they had to stay 
on that regime for the remaining study period. Patients and those administrating study 
medication, assessing outcomes, and analyzing data were blinded to group assignment.
For the whole study period patients were instructed not to change their daily pain 
medication. Extra pain medication was only allowed in the case of a painful exacerbation 
of their chronic pancreatitis.
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Patients wrote down their average and maximum pain on a visual analogue scale in a 
pain diary (VAS), where 0 = no pain and 10 = worst pain imaginable.
Study visits
Eligible patients were randomized for placebo or pregabalin on their second visit, one 
week after their screening visit. After randomization all patients had a baseline QST 
measurement, followed by another QST measurement at the end of the study period of 
three weeks, i.e. before they were instructed to taper their medication.
Quantitative sensory testing
QST took place using a standard temporal test sequence. Testing in females was not 
standardized with regard to phase of the menstrual cycle because all female patients 
were amenorrhoeic. After initial training, electric pain detection thresholds (ePDT) to 
electric constant current skin stimulation (Digistim; Biometer A/S, Copenhagen, Denmark; 
tetanic stimulation at 100 Hz, 0.2 ms square waves, self-adhesive electrodes 3 cm apart) 
were measured on the dominant side of the body at the following sites: lower neck (C5 
dermatome) and pancreatic site (ventral T10 dermatome) (Figure 1). The ventral T10 
dermatome was chosen because painful stimuli delivered on this skin area are likely to be 
processed by the same dorsal horn neurons onto which the nociceptive stimuli coming 
from the pancreas converge. The C5 dermatome was chosen as a dermatome distant 
from the pancreas to observe generalized effects on pain thresholds.18,21
The conditioned pain modulation (CPM, previously known as diffuse noxious inhibitory 
controls (DNIC)) paradigm was performed to test the ability of the patient to generate 
descending inhibitory pain modulation.22,23 Pressure pain tolerance thresholds (pPTT, the 
test stimulus) were determined before and after the cold pressor task (the conditioning 
stimulus), and the CPM effect was determined in the non-dominant L4 dermatome 
(quadriceps muscle 5 cm proximal to the patella) as the relative change (%) in pPTT. For the 
cold pressor task the dominant hand was immersed in ice-chilled water (1.0 °C ± 0.3 °C) 
continuously stirred by a pump. The patient was told to remove the hand from the water 
after two minutes of immersion - or sooner if the pain was considered to be intolerable – 
and the immersion time noted. Immediately after the cold pressor task, the subjects rated 
the pain experienced during the test with a VAS for quality control purposes.18
Outcome measures
Changes in the following parameters (baseline values vs. after three weeks of study 
medication) were endpoints of our study:
1. ePDT for dermatomes C5 and ventral T10
2. CPM response
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We have chosen ePDT as a QST endpoint for altered pain sensitivity based on publications 
describing QST measurements before and after pregabalin treatment. These publications 
showed a strong ePDT response when measurements were compared before and after 
pregabalin treatment in chronic pancreatitis.6,14
Figure 1 
Dermatomes of measurement for quantitative sensory testing
Quantitative sensory testing was performed on the following sites on the dominant body side (closed 
dots): lower neck (C5 dermatome) and upper abdominal area (ventral T10 dermatome). Conditioned pain 
modulation was determined in the non-dominant L4 dermatome (open dot).
 
Patient groups
Patients in the pregabalin and placebo groups with more than thirty percent pain 
reduction on their average daily VAS score after three weeks of study medication versus 
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baseline values were defined as responders. Patients with thirty percent or less pain 
reduction on their average daily VAS score after three weeks of study were defined as 
non-responders. The cut-off point was based on clinical pain studies using a numeric 
rating scale or VAS.4,14,24,25 Based on study medication and pain reduction, four treatment 
groups of patients were thus defined: 1) responders placebo group; 2) non-responders 
placebo group; 3) responders pregabalin group; and 4) non-responders pregabalin group.
Statistical analysis
A pre hoc power calculation based on QST as an endpoint was not performed because 
the study was a part of a randomized clinical trial that investigated pregabalin, powered 
for a clinical primary endpoint; i.e. change in clinical pain score. For this mechanistic 
study we performed a per-protocol analysis.
All baseline characteristics and measurements are given as medians with interquartile 
ranges (IQR) unless mentioned otherwise.
We performed statistical analysis using the Statistica for Windows Software Package 
(Release 7.0, Statsoft Inc, Tulsa, OK, USA). Statistical significance was set at P ≤ 0.05.
Baseline characteristics were compared between groups with Kruskal–Wallis one-way 
analysis of variance with post hoc analysis using Mann-Whitney U test.
Analysis of incidence of responders and non-responders within the population was by 
Chi-square Test.
Within the four treatment groups, baseline values and values after three weeks of study 
medication were analyzed by Wilcoxon signed-rank test for: 1) ePDT in the individual 
dermatomes and 2) CPM response.
Between the four treatment groups, baseline values and their change after three weeks’ 
treatment were compared using the Kruskal–Wallis one-way analysis of variance with 
post hoc analysis using Mann-Whitney U for: 1) ePDT in the individual dermatomes; and 
2) CPM response. Four subgroups comparisons were performed: 1) placebo responders 
versus placebo non-responders; 2) placebo responders versus pregabalin responders; 3) 
placebo non-responders versus pregabalin non-responders; and 4) pregabalin responders 
versus pregabalin non-responders. Subgroup (post hoc) analysis was conservatively 
Bonferroni corrected for multiple comparisons (three comparisons, P ≤ 0.016).
ResulTs
Enrollment and baseline characteristics
From October 2008 to May 2010 a total of 236 patients were screened and 64 patients 
were randomized. Sixty patients completed the study according to treatment protocol 
and were finally analyzed (Figure 2). All patients (23 women, 37 men; median age 53 
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years (IQR 46 – 62)) had pain due to chronic pancreatitis and were on a stable analgesic 
therapy. Their average daily VAS score before start of trial medication was 4 (IQR 2 – 5) 
and their maximum daily VAS score was 5 (IQR 4 – 7). Their median opioid consumption 
was 60 (IQR 9 – 146) mg of morphine equivalents per day. Demographic data of all four 
patient groups are provided in Table 1 and showed no significant differences, only for 
VAS after three weeks of study treatment.
Figure 2 
study enrollment and randomization
 
The majority of patients ‘not meeting inclusion criteria’ had died, were pain free or were no longer being 
treated in either of the hospitals.
The medians of the average and maximum VAS scores in the pain diaries were 
comparable at baseline for all (four) treatment groups. Also the pain medication and 
morphine equivalents per day were comparable at baseline. No significant difference 
in demographics was found in the incidence of responders and non-responders within 
the whole group of 60 patients and within the pregabalin and placebo groups (Table 1).
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Table 1 
Demographic and clinical characteristics of patients
Placebo 
responders  
(n = 12)
Placebo  
non-responders 
(n = 17)
Pregabalin 
responders 
(n = 16)
Pregabalin 
non-responders 
(n = 15)
Age (years) 54 (41 – 63) 59 (49 – 64) 52 (50 – 59) 49 (43 – 57)
Males - no. (%)
Etiology - no. (%)
 Toxic-metabolic
 Idiopathic
 Genetic
 Autoimmune
  Recurrent and severe acute 
pancreatitis
 Obstructive
Diary pain score (VAS before)
 Average pain
 Maximum pain
Diary pain score (VAS after)*
 Average pain
 Maximum pain
Concomitant analgesics  
- no. (%)†
 None
 Weak analgesics
 Strong analgesics
MEQ/day (mg)
9 (75)
9 (75)
2 (17)
0 (0)
0 (0)
0 (0)
1 (8)
4 (2 – 5)
5 (2 – 7)
1 (0 – 2)#
1 (0 – 4)#
2 (17)
3 (25)
7 (58)
45 (23 – 135)
10 (59)
7 (41)
9 (53)
0 (0)
0 (0)
1 (6)
0 (0)
4 (2 – 5)
5 (4 – 7)
4 (2 – 6)
5 (4 – 7)
0 (0)
8 (47)
9 (53)
48 (8 – 120)
9 (56)
6 (38)
6 (38)
1 (6)
1 (6)
1 (6)
1 (6
4 (3 – 5)
6 (4 – 9)
1 (0 – 2)#
2 (1 – 5)#
2 (13)
4 (25)
10 (63)
71 (4 – 127)
9 (60)
9 (60)
5 (33)
1 (7)
0 (0)
0 (0)
0 (0)
4 (2 – 7)
7 (4 – 8)
4 (2 – 6)
5 (4 – 7)
1 (7)
3 (20)
11 (73)
80 (10 – 180)
Duration of chronic pancreatitis 
(months)
Diabetes mellitus - no. (%)
Previous interventions for 
chronic pancreatitis – no. (%)
  Pancreas resection / drainage 
procedures 
  Thoracoscopic splanchnic 
denervation
 Celiac blockade
151 (77 – 212)
6 (50)
2 (17)
1 (8)
1 (8)
84 (73 – 112)
4 (24)
3 (18)
3 (18)
0 (0)
83 (54 – 131)
7 (44)
3 (19)
0 (0)
1 (6)
117 (100 -166)
3 (20)
3 (20)
2 (13)
0 (0)
Enzyme treatment for pancreatic 
exocrine insufficiency - no. (%)
6 (50) 6 (35) 7 (44) 8 (53)
Ongoing alcohol abuse  
- no. (%)‡
Current smoker - no. (%)
4 (33)
9 (75)
6 (35)
13 (76)
3 (19)
12 (80)
3 (20)
12 (75)
 
All values are medians with interquartile ranges unless mentioned otherwise. Percentages may not total 
100 due to rounding. ‘VAS’ is Visual Analogue Scale (0 – 10). †Weak analgesics were defined as NSAIDS, 
paracetamol, codeine and tramadol. Strong analgesics were defined as opioid-based therapies. ‘MEQ’ 
is morphine equivalents per day, ‘pregabalin’ is pregabalin study group and ‘placebo’ is placebo study 
group. ‡Alcohol abusing patients were defined as female patients drinking 14 units of alcohol per week or 
male patients drinking 21 units of alcohol per week. #A significant reduction in mean and maximum VAS 
score was observed within the treatment group after study treatment (P ≤ 0.010). *Statistical differences 
between groups where the placebo responders and pregabalin responders differed significantly (P ≤ 
0.010) from the placebo non-responders and pregabalin non-responders.
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Pain characteristics
Within the treatment groups both responder groups showed a decline in the average 
and maximum VAS score after treatment (less pain), this was significant for the responder 
placebo group for average (P = 0.003) and maximum (P = 0.003) VAS score and for the 
pregabalin responder group for average (P = 0.001) and maximum (P = 0.001) VAS score 
(Table 1). The median percentage reduction in average VAS score after three weeks of 
study treatment was 75% (IQR 54 – 100) for the placebo responder group and 69% (IQR 
48 – 94) for the pregabalin responder group. Between all treatment groups these results 
were significantly different compared to the non-responder placebo and pregabalin 
groups (P ≤ 0.001) (Table 1).
Electric pain detection thresholds in Individual dermatomes
At baseline ePDT in the C5 and ventral T10 dermatomes were comparable between 
treatment groups. Within treatment groups, only pregabalin responders showed a 
significant increase in electric pain detection thresholds (less hyperalgesia following 
pregabalin treatment) for the C5 dermatome (P = 0.009) and ventral T10 dermatome (P 
= 0.009) (Table 2).
C5 dermatome (widespread hyperalgesia): Changes in ePDT for the C5 dermatome were 
significantly different between the four treatment groups overall (H=10.63, P = 0.014). 
Post hoc analysis showed that the pregabalin responders group differed significantly (less 
hyperalgesia following pregabalin treatment) from the patients in the placebo responders 
group (P = 0.015) (Table 2) (Figure 3).
Ventral T10 dermatome (segmental hyperalgesia): No significant differences between 
groups were seen for changes in ePDT in the ventral T10 dermatome (H = 5.14, P = 0.162) 
(Table 2) (Figure 4).
Conditioned pain modulation
The CPM response was comparable for all four patient groups at baseline. Within groups 
the pregabalin responders showed a significant increase in CPM response, i.e. a more 
effective response, after three weeks of treatment (P = 0.006). In contrast the placebo 
responders showed a non-significant trend for a decrease in CPM response, which is 
a less effective response (more pronociceptive pain modulation), after three weeks of 
treatment (P = 0.028) (Table 2).
The changes in CPM responses were significantly different between groups (H = 11.3, P 
= 0.01). Post hoc analysis showed that the pregabalin responders had a CPM response, 
which differed significantly from that of patients in the placebo responders group (P < 
0.001) (Table 2) (Figure 5).
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Table 2 
Pain thresholds and conditioned pain modulation response at baseline, after three weeks’ 
treatment and the change in values for all groups
Placebo 
responders 
(n = 12)
Placebo 
non-responders 
(n = 17)
Pregabalin 
responders 
(n = 16)
Pregabalin 
non-responders 
(n = 15)
ePDT (mA) (baseline)
 C5
 T10V
3.5 (2.4 – 7.6)
6.1 (3.5 – 7.8)
3.5 (2.2 – 5.5)
3.5 (2.5 – 6.8)
3.8 (2.7 – 4.7)
5.7 (4.5 – 7.6)
3.6 (2.2 – 5.1)
5.2 (4.5 – 10.4)
ePDT (after treatment)
 C5
 T10V
5.0 (2.0 – 6.3)
7.0 (5.0 – 8.2)
2.3 (2.1 – 4.5) 
3.4 (3.0 – 6.1) 
4.8 (3.5 – 6.3)*
6.8 (5.8 – 10.1)†
4.5 (3.3 – 5.4)
6.4 (3.9 – 7.5)
Change ePDT
 C5
 T10V
-0.1 (-1.3 – 0.5)
0.7 (-0.6 – 1.9)
-0.3 (-0.7 – 0.6)
-0.2 (0.8 – 1.2)
1.3 (0.4 – 2.0)
1.7 (0.0 – 3.4)
0.4 (-0.9 – 1.3)
-0.3 (-1.1 – 1.9)
CPM response (%)
(baseline)
13 (-3 – 25) 14 (5 – 44) 11 (-12 – 23) 12 (-19 – 39)
CPM response (%)
(after treatment)
-3 (-12 – 9) 17 (-2 – 36) 15 (0 – 50)‡ 0 (-1 – 23)
Change CPM response (%) -17 (-35 – -6) 3 (-22 – 10) 9 (4 – 55) -7 (-35 – 16)
All values are medians with interquartile ranges. ‘ePDT’ is electric pain detection threshold, ‘CPM’ 
is conditioned pain modulation. C5 is the C5 dermatome (lower neck) and T10V is the ventral T10 
dermatome (upper abdominal area). Statistical difference between baseline and after treatment values: 
*: P = 0.009, †: P = 0.009 and ‡: P = 0.006.
Figure 3 
change in electric pain detection thresholds at dermatome c5
Values are medians with interquartile ranges. ‘ePDT’ is electric pain detection thresholds. ‘pla-resp’ is 
the placebo responders, ‘preg-resp’ is the pregabalin responders group, ‘pla-nonr’ is the placebo non-
responders group and ‘preg-nonr’ is the pregabalin non-responders group. Significant differences are 
marked with an asterisk (P = 0.015).
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Figure 4 
change in electric pain detection thresholds at dermatome ventral T10
Values are medians with interquartile ranges. ‘ePDT’ is electric pain detection thresholds. ‘pla-resp’ is 
the placebo responders, ‘preg-resp’ is the pregabalin responders group, ‘pla-nonr’ is the placebo non-
responders group and ‘preg-nonr’ is the pregabalin non-responders group.
 
 
Figure 5 
change in conditioned pain modulation response
Values are medians with interquartile ranges. ‘CPM’ is conditioned pain modulation response. ‘pla-resp’ 
is the placebo responders, ‘preg-resp’ is the pregabalin responders group, ‘pla-nonr’ is the placebo non-
responders group and ‘preg-nonr’ is the pregabalin non-responders group Significant differences are 
marked with an asterisk (P < 0.001).
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DIscussIon
This is the first study to describe the relation between the clinical analgesic response; 
defined as responders and non-responders, to placebo or pregabalin treatment and 
changes in pain processing using QST measures in patients with chronic pancreatitis. 
Our study shows the presence of significant antihyperalgesic effects (decrease in pain 
sensitivity) in pregabalin responders and no significant antihyperalgesic effects in 
placebo responders. Pregabalin responders showed significantly more antihyperalgesic 
effects compared to pregabalin non-responders. With treatment pregabalin responders’ 
descending pain modulation (CPM response) became significantly more inhibitory – 
while that of placebo responders showed a trend towards becoming more facilitatory.
Our results indicate that both underlying mechanisms and the placebo effect need to 
be taken into account in the clinical management of pain in chronic pancreatitis. Firstly, 
the response to placebo analgesia was not accompanied by significant anti-hyperalgesia. 
Thus mechanisms other than anti-hyperalgesia appear to operate in placebo analgesia. 
Secondly, only in the pregabalin responders did pain thresholds within and distant from 
the pancreatic segment increase significantly. Distant from the pancreatic segment, this 
antihyperalgesic effect was significantly larger in pregabalin responders versus non-
responders. In the pancreatic segment the antihyperalgesic response to pregabalin 
treatment did not differ significantly between pregabalin responders and non-responders. 
This suggests that analgesic response to pregabalin treatment is linked to antihyperalgesic 
effect, although other mechanisms may also be operating. Furthermore, generalized 
antihyperalgesic effects appear more prominent than segmental antihyperalgesic 
effects. Thirdly, it would appear that endogenous descending pain modulation plays an 
important role in analgesic response and may be fundamentally different for placebo 
versus pregabalin treatments.
Effect of pregabalin
Treatments targeting the central nervous system e.g. gabapentinoids or tricyclic 
antidepressants are increasingly being demonstrated to improve management of chronic 
pain disorders.26 For chronic pancreatitis we have shown pregabalin to be effective in 
reducing pain scores after three weeks of treatment together with a positive overall 
treatment response as rated by patients.4 Accompanying the clinical effect we found 
an antihyperalgesic effect of pregabalin for electric stimuli.6 The present study further 
elucidates these results, by showing that anti-hyperalesic effects in responders to 
pregabalin are significant particularly in a dermatome distant from the pancreas. The 
overall size of the effect in the pancreatic segment was comparable between pregabalin 
responders and non-responders. In another study we showed that chronic pancreatitis 
patients with segmental hyperalgesia had a superior clinical response to pregabalin.27 
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Taking these two results together, this suggests that the major antihyperalgesic effect 
of pregabalin is on ascending spinal sensitization rather than directly on sensitization 
within the pancreatic spinal segment. Clearly further research is needed regarding sites 
of action of pregabalin within the nervous system. Although baseline CPM values were 
similar, modulatory responses were greater and significantly inhibitory in pregabalin 
(vs. placebo) responders. This outcome could be construed as a direct, anti-facilitatory 
effect of pregabalin on CPM, or an indirect one based on reduction of ascending central 
nociceptive transmission.22 If pregabalin affects ascending central pathways, it might 
also affect descending ones, an explanation which could support direct effects on 
CPM. A further possible explanation could be other differences between the pregabalin 
responder and non-responder patients, i.e. regarding the use of more strong analgesics 
or a history of more pain reducing previous interventions. Responders and non-
responders to gabapentin have been described in a rat study where rats with selective 
nerve injury (spinal level) showed differences in descending inhibition. The extent of 
suggested changes in the central nervous system may predict the effect of pregabalin 
and gabapentin treatment.28
Effect of placebo
The placebo effect on clinical pain has been described extensively.29-31 Imaging studies 
of the brain have shown increased activity in pain-related areas during painful stimuli 
and placebo analgesia.32 A relation has been demonstrated between desire for pain 
relief or expected pain levels and opioid-related activity in certain brain areas. These 
psychological factors and placebo effect can be antagonized by naloxone.33 The effect of 
placebo analgesia appears to be highly variable and depends on contextual factors.11,34,35 
In our clinical study we found a strong placebo response albeit significantly lower than 
with pregabalin treatment.4 This placebo response may be explained by the psychosocial 
context and in the suggestion of treatment effect.30,31,36 Chronic pancreatitis patients, 
with their extensive medical history, their expectation or desire for pain relief, and the 
possibility of being randomized for pregabalin may be particularly susceptible to placebo 
effects.
Our study showed that the placebo responders had a significant strong clinical effect on 
clinical pain compared with placebo non-responders. However we also demonstrated no 
significant antihyperalgesic effects for both responders and non-responders to placebo. 
Since effects on skin pain sensitivity were similar in placebo responders and non-
responders, central anti-hyperalgesia is unlikely to be the mechanism underlying placebo 
analgesia, at least in chronic pancreatitis patients. Furthermore, a trend to decrease in 
inhibitory CPM response was seen only in placebo responders. Theoretically, this finding 
could be linked to a negative interaction of placebo effect with CPM. This unexpected 
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trend result further suggests that anti-hyperalgesia is not a major mechanism underlying 
analgesia in this context. Clearly, more research is necessary.
Limitations
A limitation of this study is the relatively small size of the four patient groups. 
Nevertheless, significant differences could be observed between the groups. Furthermore, 
we may have introduced bias by using a per-protocol analysis. However we think that 
analyzing only the patients that fully complied to the study protocol i.e. used all their 
study medication and had measurements after study treatment is the proper way to 
investigate mechanisms in responders and non-responders to the trial medication. It 
should be noted that the majority of patients in both study arms where compliant and 
all study medication was taken correctly. The duration of study medication in the initial 
trial was three weeks; perhaps a longer study period would have given a more distinct 
difference between both groups. In our clinical study 39% of pregabalin patients did not 
tolerate 300 mg pregabalin twice daily, and were treated with 150 mg twice daily. The 
distribution of patients not tolerating 300 mg twice daily was not significantly different 
between the pregabalin responders and non-responders. Perhaps in a larger population 
this difference could be off significance. Another source of bias could have been that the 
groups were not comparable at baseline for factors we didn’t measure, i.e. expectations 
regarding study effect or other psychological measures. However this seems unlikely 
because no significant differences could be found in the clinically relevant baseline 
characteristics between the four groups. Also no differences in baseline values were 
found for use of strong analgesics, morphine equivalents per day, prevalence of diabetes 
mellitus, nicotine exposure or alcohol consumption (possible confounding effects on 
pain perception) between all four groups.
Summary
Our study provides first evidence that patients treated with placebo show no 
antihyperalgesic effects paralleling pain relief after a treatment period of three weeks in 
chronic pancreatitis. Patients with a positive effect on clinical pain following pregabalin 
treatment were the only ones to show significant antihyperalgesic effects, particularly in 
the dermatome distant from the pancreas, with comparable antihyperalgesic effects for 
pregabalin responders and non-responders in the pancreatic dermatome itself. Pregabalin 
responders showed an increase in endogenous inhibitory modulation compared to a 
trend to decrease in placebo responders. Both the existence of a potent placebo effect 
and the difference between responders and non-responders regarding underlying pain 
sensitivity and modulation need to be taken into account in the management of pain in 
chronic pancreatitis.
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absTRacT
Pain in chronic pancreatitis shows similarities with other visceral pain syndromes (i.e. 
inflammatory bowel disease and esophagitis), which should thus be managed in a similar 
fashion. Typical causes of chronic pancreatitis pain include increased intrapancreatic 
pressure, pancreatic inflammation and pancreatic/extrapancreatic complications. 
Unfortunately, chronic pancreatitis pain continues to be a major clinical challenge.
It is recognized that ongoing pain may induce altered central pain processing, e.g. central 
sensitization or pronociceptive pain modulation. When this is present conventional pain 
treatment targeting the nociceptive focus, e.g. opioid analgesia or surgical/endoscopic 
intervention, often fails even if technically successful. If central nervous system pain 
processing is altered, specific treatment targeting these changes should be instituted 
(e.g. gabapentinoids, ketamine or tricyclic antidepressants).
Suitable tools are now available to make altered central processing visible, including 
quantitative sensory testing (QST), electroencephalography (EEG) and (functional) 
magnetic resonance imaging ((f)MRI). These techniques are potentially clinically useful 
diagnostic tools to analyze central pain processing and thus define optimum management 
approaches for pain in chronic pancreatitis and other visceral pain syndromes.
The present review proposes a systematic mechanism-orientated approach to pain 
management in chronic pancreatitis based on a holistic view of the mechanisms involved. 
Future research should address the circumstances under which central nervous system 
pain processing changes in chronic pancreatitis, and how this is influenced by ongoing 
nociceptive input and therapies. Thus we hope to predict which patients are at risk for 
developing chronic pain or not responding to therapy, leading to improved treatment of 
chronic pain in chronic pancreatitis and other visceral pain disorders.
General discussion and future perspectives
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InTRoDucTIon
Chronic pancreatitis involves progressive inflammatory changes of the pancreas 
resulting in morphological alterations and loss of pancreatic endocrine and exocrine 
function.1 Quality of life is impaired and life expectancy is reduced.2,3 The two main 
clinical manifestations of chronic pancreatitis are pancreatic insufficiency and (chronic) 
abdominal pain. Pancreatic insufficiency is marked by exocrine dysfunction resulting in 
impaired food digestion and absorption, and endocrine dysfunction which results in 
diabetes mellitus.1 Pain in chronic pancreatitis is considered to be of visceral origin. When 
compared to other (chronic) visceral pain syndromes there are many similarities with 
the pain presentation of chronic pancreatitis patients. The pain of chronic pancreatitis 
is typically present as chronic epigastric pain, often radiating to the back, severe, dull, 
worse after eating and exhibiting episodic flares. This conforms to typical clinical 
characteristics of visceral pain which are: 1) the pain is not always simply or directly linked 
to morphological changes of the diseased organ; 2) pain is diffuse and poorly localized; 
3) the pain may be referred to other locations; and 4) the pain is accompanied by motor 
and autonomic reflexes (vomiting, nausea and muscle tension).4 These parallels suggest 
that chronic pancreatitis pain provides a useful model for the diagnosis and treatment of 
visceral pain syndromes with an identifiable nociceptive source in general.
Pain management in chronic pancreatitis is at present mostly aimed at the nociceptive 
source, the pancreas. General recommendations include correction of pancreatic 
insufficiency and management of local complications, flanked by dietary modifications 
and cessation of alcohol use and smoking.1 Currently a conservative step-up approach 
is advocated for pain treatment in chronic pancreatitis, consisting of symptomatic pain 
relief and dealing with the pancreas as nociceptive source. For symptomatic pain relief, 
patients are treated with analgesics based on the ‘pain relief ladder’ provided by the 
World Health Organization.5 When such analgesic therapy is not successful, patients 
usually are referred for endoscopic interventions to attempt to reduce nociceptive input 
from the diseased pancreas. Eventually, patients may be referred for invasive surgical 
intervention if pain still persists despite prolonged analgesic (usually opioid) use and 
multiple endoscopic interventions (up to 75% of all patients).
Usually endoscopic interventions are performed for pancreatic duct strictures (stenting) 
and pancreatic duct stones (extracorporal shockwave therapy). Multiple surgical 
procedures have been described in the literature, all with different indications and 
success rates.6 Drainage procedures like the pancreaticojejunostomy are performed for 
an enlarged pancreatic duct. When an enlarged pancreatic duct with an inflammatory 
mass in the pancreatic head is present, usually a Frey or Beger procedure is performed. 
Indications for (partial) pancreatic resections, i.e. pancreaticoduodenectomy, distal 
pancreatectomy and total pancreatectomy, are inflammatory masses in the head or tail 
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of the pancreas, or failure of other therapies. Alternative approaches for dealing with 
the pancreas as a nociceptive source include deafferentation techniques such as nerve 
blocks and denervation procedures like bilateral thoracoscopic splanchnicectomy, which 
have shown to be beneficial for pain reduction in chronic pancreatitis patients.7 The 
success rate in terms of pain reduction after endoscopy or surgery is highly variable.6 
The optimal timing of interventions and which patients should be treated endoscopically 
or surgically continues to be intensively debated.6 Despite these many management 
options, a significant number of chronic pancreatitis patients continue to experience 
pain even after conventional successful treatments, resulting in recurrent hospitalization, 
opioid dependence and severely impaired quality of life.8,9 
It is increasingly accepted that in many patients with refractory chronic pain, the pain 
may be the result of abnormal central pain processing which should be taken into 
account and targeted when pain management is planned.10 This is in line with the key 
new insight of the last two to three decades of pain research, demonstrating that the 
central nervous system is not hard-wired, but rather highly plastic in the face of ongoing 
nociceptive input, exhibited as extensive alterations in central pain processing.10 These 
changes typically involve increased pain sensitivity and facilitatory changes in modulation 
of painful inputs.11-13 Further support for this view comes from recent successful studies 
with non-classical analgesic medication, i.e. S-ketamine and pregabalin, which targets 
mainly the central nervous system, and which has been shown to be effective in both 
visceral and somatic chronic pain syndromes.11,14,15
To optimize (pain) treatment in chronic pancreatitis, it is thus evident that we need to 
move away from approaches exclusively based on dealing with peripheral nociceptive 
input from the pancreas towards more holistic strategies taking into account alterations 
in central pain processing due to ongoing nociceptive inputs. The aim of this review is 
to highlight the recent progress in understanding the central mechanisms underlying 
chronic pain in chronic pancreatitis and its impact on pain management. We present 
the evidence presently available that such central changes take place and operate in the 
human clinical context. Next, we focus on the diagnostics that are currently available 
to measure/visualize changes in central pain processing and how these are related to 
chronic pain in chronic pancreatitis and other chronic abdominal visceral pain syndromes. 
Finally, based on these diagnostics we propose a new systematic mechanism-orientated 
approach to diagnosing and treating pain in chronic pancreatitis as an example of an 
abdominal visceral pain syndrome.
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a sysTeMaTIc MecHanIsM-oRIenTaTeD aPPRoacH To cHRonIc PaIn
Even after tissue healing, pain may persist as chronic pain with a major impact on quality 
of life. To date, the majority of publications on chronic pain adopt an empirical approach 
to the treatment of such pain, primarily based on dealing with the putative peripheral 
nociceptive source of the pain. At present, a holistic systematic mechanism-orientated 
approach to the prevention and treatment of chronic pain is lacking.
The key: altered pain processing
A key insight has been that nervous system processing of pain is not hardwired: sensory 
processing in the central nervous system typically changes as a result of noxious sensory 
inputs.16 Acute nociception initially results in increased pain sensitivity (hyperalgesia) 
affecting the peripheral and central nervous system. When ongoing nociception (due 
to ongoing damage to tissues and nerves) is present, it initially sensitizes the peripheral 
nervous system. Subsequently, such ongoing nociceptive barrage will excite the spinal 
cord, brainstem and brain leading to central sensitization. In the end the whole 
nervous system may become sensitized, leading to exaggerated pain with minor stimuli 
(hyperalgesia) or even pain without nociceptive input (allodynia).16-18 Counteracting 
modulatory responses to nociceptive input like descending inhibition may fail as well, or 
even become facilitatory, resulting in more pain.8
The four key questions
To achieve a holistic and systematic mechanism-orientated approach to chronic pain four 
key questions need to be answered.18
1) What is the source of nociception? The majority of chronic pain disorders start off 
with a nociceptive source. Knowledge of the source enables us to aim our therapy at it 
and provides us with information regarding the type and intensity of nociception (e.g. 
visceral vs. somatic pain).
2) Is nociceptive transmission altered? A common reason for altered nociceptive 
transmission by peripheral nerves to the central nervous system is peripheral nerve 
sensitization and damage. Nerve damage is a strong predictor for pain that is difficult to 
control or treat and can become a source of nociceptive input in itself. Nerve damage is 
associated with extensive and aggressive alteration in central nervous system function.19 
In addition, cytokines, hormones and other acute phase proteins may be released due 
to pathological processes and may facilitate sensitization of the central nervous system, 
e.g. via humoral pathways.8,20
3) Is central pain processing altered? The first alteration in central nervous system 
processing to be taken into account is central sensitization, defined as an increased 
responsiveness of central pain transmitting neurons.8 The presence and persistence 
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of central sensitization affects both disease prognosis and effectiveness of therapy in 
chronic pain conditions. More extensive spread of central sensitization (generalized 
hyperalgesia) is associated with more pain. When central sensitization is present, therapy 
targeting only the source of nociception (the disease site) will be relatively ineffective. 
Thus drug treatment modulating the sensitization of the central nervous system need to 
be instituted. Examples of agents achieving this are gabapentinoids and antidepressants. 
Secondly, the state of descending central pain modulation must also be taken into 
account. If there is a pronociceptive (facilitatory) shift in central pain modulation, this has 
a negative effect on prognosis and requires specific treatment strategies.21
4) Is altered central processing (still) dependent on peripheral nociceptive drive? If 
altered central processing becomes independent of peripheral nociceptive drive this 
further worsens the prognosis for controlling pain, and therapies aimed at controlling 
the nociceptive input from the source of disease are highly prone to failure. In this 
context, specific treatment dealing with altered central pain processing is mandatory 
e.g. gabapentinoids and antidepressants.18
Implications
In summary, increasing evidence shows that (ongoing) nociceptive input results in 
altered central pain processing and should be taken into account in the management 
of chronic pain. However, knowledge is lacking on how chronic painful inputs leads 
to altered central pain processing, and how this is influenced by disease progression 
and therapeutic interventions. Hence, the key to better treatment of chronic pain is 
measuring or visualizing the changes in the central nervous system – or neuroplasticity 
– that accompany the development and existence of chronic pain conditions. Together 
with measurements before and after treatment, the introduction of such systematic 
mechanism-orientated diagnostics will provide the basis for optimization of treatment 
indications and schedules.
a sysTeMaTIc MecHanIsM-oRIenTaTeD aPPRoacH To 
DIaGnosInG alTeReD PaIn PRocessInG In cHRonIc PaIn
Quantitative sensory testing (QST), electroencephalography (EEG) and (functional) 
magnetic resonance imaging ((f)MRI) have increasingly been used in chronic pain 
disorders to describe changes in structure and function of the central nervous system. In 
the next paragraphs we will give a short introduction to QST, EEG and (f)MRI and their 
use in chronic pain conditions.
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Quantitative sensory testing
The basis for QST was laid by Ulf Lindblom in the 1950s.22 He was one of the first to 
describe the use of physiologic stimulation of the peripheral afferent unit in animals 
to test sensory processing. Later on he applied his experience in patients with sensory 
abnormalities i.e. chronic pain, which was the start of the use of QST in humans.23
QST gives clinicians and researchers the opportunity to study abnormalities in the sensory 
system and characterize mechanisms underlying pathologic pain disorders. Compared 
to bedside clinical tests, QST is reliable and quantifies both the test stimulus (i.e. heat 
or pressure) and the patient’s response (i.e. pain).24,25 Somatosensory evoked responses 
to electrical, mechanical, thermal or chemical test modalities are involved in QST.26 The 
stimulus is applied in a systematic fashion to an anatomical site (skin, muscle, joint or 
viscera like the esophagus or sigmoid). Stimulus intensity is gradually increased until 
the subject reaches a predefined sensory threshold (e.g. sensation or pain). By using 
multiple stimuli with differing intensities it is possible to construct a stimulus-response 
relationship (or curve) characterizing the subjects’ state of pain processing. This stimulus-
response relationship is particularly useful as it also involves suprathreshold stimulation, 
particularly relevant to clinical pain. Measurements at the affected site or sites more 
distant are used to differentiate between signs of peripheral and (spinal or supraspinal) 
central sensitization.
Descending pain modulation (‘pain inhibits pain’, a response to a noxious stimulus 
is inhibited by another noxious stimulus) is measured using the conditioned pain 
modulation paradigm (CPM, formerly known as diffuse noxious inhibitory controls or 
DNIC). In the case of CPM a test stimulation is applied (e.g. pain threshold, pain score), 
afterwards a conditioning stimulus is applied (e.g. cold pressor task via ice water bucket 
immersion) and then again the test stimulation is applied. The difference between the 
two test stimuli signals the size of inhibitory or facilitatory descending modulation. 
When central sensitization is present descending modulatory mechanisms often fail, due 
to a decreased activity in the inhibitory pathway of the spinal cord and an increase in 
facilitatory pathway activity, resulting in a further increase in pain (Figure 1).27,28 QST is 
increasingly used to compare pain sensitivity before and after interventions for patients 
and healthy controls in acute and chronic pain disorders.
Electroencephalography
Electroencephalography (EEG) is the recording of electrical brain activity, generated by 
synchronous activity of thousands of millions of neurons in the cortex. Neural networks 
are usually randomly active at any given time in a resting state, and can be synchronized 
in response to an external stimulus. Therefore, EEG can be used in chronic pain conditions 
to study the brains’ default state reflected by the resting state EEG (static element) and 
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brain activity due to external stimuli reflected by event related or evoked brain potentials 
(dynamic element).29 As early as 1953, the EEG was already being studied in patients with 
pain due to peptic ulcers and functional gastric disorders by Kirschbaum and colleagues.30 
Their study is an early example of the recognition of the brain-gut axis as a possible 
substrate for visceral pain syndromes. Although the use of EEG can be demanding and 
complex, this technique is a potentially useful noninvasive method for clinical practice. 
EEG has a poor spatial resolution, but superior millisecond-range temporal resolution 
compared to other neurodiagnostic instruments such as positron emission tomography 
(PET) or fMRI, enabling direct measurements of neuronal processing.29
Figure 1
summary of the views presented above regarding the mechanisms underlying pain
This figure illustrates the concept of spread of altered central pain processing (progression marked via 
letters) following ongoing nociceptive input due to tissue and nerve damage (progression marked by 
numbers). This figure is based on the original figure of ref 18.18
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Resting state electroencephalography
The resting state EEG is commonly analyzed by transforming data from the time domain 
into the frequency domain. Spontaneous brain activity in the frequency domain is divided 
into different frequency bands (delta = 1-3.5 Hz, theta = 3.5-7.5 Hz, alpha = 7.5-13 Hz, 
and beta = 13-32 Hz). The awake human brain activity recorded during rest is typically 
dominated by oscillations in the alpha frequency band. This dominant alpha activity is 
most prominent over parietal and occipital cortices, and is largest when the eyes are 
closed.31 Recent developments in cognitive neuroscience suggests that alpha activity 
reflects selective cortical inhibition, rather than neural idling.32
Alterations in the brains’ default state as reflected by resting state EEG, particularly in the 
alpha band, have been observed in multiple studies in various chronic pain conditions. 
Typically these changes consist of a shift of peak alpha or theta frequency to lower 
frequencies and/or a reduction in alpha or theta power.33-35 It seems unlikely that alpha 
activity is directly related to the pain experience, as a correlation between pain intensity 
and alpha power is absent.35
Evoked brain potentials
Event-related potentials or evoked potentials (EPs) are voltage polarity changes in the 
EEG time-locked to the onset of an external stimulus. They reflect the summed activity of 
postsynaptic potentials produced when a large number of similarly oriented neurons fire 
in synchrony while processing information.36 EPs are traditionally extracted from the EEG 
by averaging similar repetitive stimuli within a stimulus block. Human EPs can be divided 
into two parts. The early components peaking roughly within the first 100 milliseconds 
after stimulus presentation are termed ‘sensory’ or ‘exogenous’ as they depend largely 
on the physical parameters of the stimulus. In contrast, later components of EPs reflect 
the manner in which the subject evaluates the stimulus and are termed ‘cognitive’ 
or ‘endogenous’ EPs as they examine information processing.37 Alterations in evoked 
potentials are traditionally studied in the amplitudes and latencies of the (positive and 
negative) potential peaks, and can also be studied in the time frequency domain.38
In order to obtain evoked potentials that are specific to nociceptive input, such input 
should be the result of physiological processing of nociceptive stimuli, i.e. involving 
selective activation of nociceptive Aδ/ C-fibers in the periphery and recording resultant 
EPs generated in the cortex.39 Brain mapping studies have established a positive 
relationship between the intensity of pain reported to nociceptive selective laser stimuli 
and EP amplitude.40 In the context of evoked EEG studies, it must be noted that the 
experimental visceral electrical stimulation of large and small peripheral afferents that 
is generally applied to different gut segments is painful but not nociception specific.41 
Whether EPs resulting from stimuli entirely selective for nociceptive peripheral afferents 
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represent the experience of pain or a more generalized response of heightened attention 
or arousal to afferent stimuli is current topic of debate.40,42,43 Mouraux and Lannetti 
demonstrated that laser-evoked EEG responses reflect neural activities equally involved 
in processing nociceptive and non-nociceptive sensory inputs.42 Thus, a stimulus entirely 
selective for nociceptive peripheral afferents does not imply that the elicited brain activity 
is nociception specific. However, even if EPs reflect neuronal activities that are unspecific 
for the nociceptive system, their generation still relies on the consequences of nociceptive 
activation and resultant changes in central nervous system state at both peripheral and 
central levels.42 
(functional) Magnetic resonance imaging
(f)MRI has been increasingly used to describe brain activity and structural changes in 
chronic pain disorders. (f)MRI uses different techniques to measure functional brain 
activity. Changes in oxygenated and deoxygenated hemoglobin can be measured by the 
blood oxygenation level dependent technique (BOLD).44 By this technique the change in 
oxygenation (reflecting neuronal activity) in different areas of the brain can be estimated. 
Recently diffusion tensor imaging (DTI) has been used to measure changes in gray and 
white matter microstructure, and connectivity between brain areas.45 Other functional 
techniques are signal enhancement by extravascular water protons (SEEP) and arterial 
spin labeling (ASL) which allows the measurement of whole brain cerebral blood flow.46,47
Taken together, the (f)MRI techniques allow assessment of the neural activation induced 
by stimuli like pain, and the structural neuroplastic changes induced by a long-lasting 
pain input. Compared to QST and EEG the advantage of (f)MRI is that it can take into 
account anatomy and can quantify the area of neuronal activity. The downside of 
the technique is that it is difficult to assess whether neural activity has a facilitatory 
or inhibitory effect on the pain processing. The main use for fMRI lies in anatomical 
resting state and activation studies.48 Increasing evidence from studies using these tools 
has provided us with more information on central pain processing and how it can be 
influenced by disease progression and treatments.
Clinical diagnostics of pain processing
For implementation in the clinical context, a suitable tool to diagnose altered pain 
processing in chronic pain should fulfill the following criteria.18
1) The tool should be validated and suitable for a clinical setting with a minimal burden 
for the patient. Measurements should be easy to reproduce and stimuli should be 
standardized so data can be compared between patients and populations. A tool that is 
easy to use can be used in an outpatient setting and has a low burden, increases patient 
compliance and makes the method more practical for clinical use.
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2) The tool should reveal altered pain processing for both superficial and deep tissue 
stimulation. Differences in deep and superficial tissue stimulation may help discriminate 
between somatic and visceral origin of pain and the extent of central sensitization (e.g. 
somato-somatic, viscero-visceral and viscero-somatic spread of hyperalgesia).
3) The tool should contain static (pain sensitivity) and dynamic (pain modulation) elements. 
Static measurements provide insights into basal pain sensitivity (e.g. central sensitization) 
and dynamic measurements test how the body actively modulates nociceptive input.
4) The tool should sensitively assess changes in sensitization of pain processing as well 
as alterations in state of cortical/descending modulation. In the context of sensitized 
signal processing by the central nervous system, this will help differentiate e.g. between 
a situation of ongoing nociceptive input directly sensitizing central processing and 
pronociceptive alterations of descending nociceptive control by brainstem and brain 
(Figure 1). 
Application of such a holistic approach to chronic pain is the basis for systematic 
mechanism-orientated pain management enabling: 1) diagnosis and prognosis of chronic 
pain; 2) rationale for treatment choice and responder identification; and 3) monitoring of 
chronic pain and its treatment.18
eVIDence foR a sysTeMaTIc MecHanIsM-oRIenTaTeD aPPRoacH 
To cHRonIc PaIn
In the next paragraphs we will focus on QST, EEG and (f)MRI research documenting 
the reality of altered pain processing in chronic visceral pain disorders such as chronic 
pancreatitis and thus providing further evidence for the feasibility of achieving a 
systematic mechanism-orientated approach in clinical practice.
What is the source of nociception?
In the literature the following pathophysiological mechanisms have most commonly 
been suggested as causes of pain in chronic pancreatitis: 1) increased intrapancreatic 
pressure within the parenchyma and/or pancreatic duct causing tissue ischemia (due to 
pancreatic duct strictures and stones); 2) inflammation of the pancreas; and 3) pancreatic 
and extrapancreatic complications (i.e. pseudocysts, bile duct/duodenal strictures and 
peptic ulcers).49-53 The exact pathophysiology of chronic pancreatitis is still unknown and 
which mechanisms starts first are still subject to debate i.e. are duct strictures caused by 
tissue ischemia or inflammation or both?
Is nociceptive transmission altered?
In the past years, increasing evidence has been published regarding altered nociception 
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transmission (e.g. nerve damage, peripheral sensitization) in chronic pain patients 
like chronic pancreatitis.12,16,28,54 In chronic pancreatitis transmission of nociceptive 
input from the pancreas to the spinal cord can be altered and influenced by lesions 
in intrapancreatic and peripheral nerves, as described in histological studies.55,56 These 
changes are comparable with other neuropathic pain disorders.8,57 Not only an increase 
of excitability of nerves innervating the pancreas, but also structural changes of nerves in 
the pancreas may be a part of the problem. Hence, hypertrophy, increased neural density 
and neuritis of intrapancreatic nerves have been reported to be associated with pain in 
chronic pancreatitis patients.58,59 Ongoing nociceptive input due to the inflammation of 
the pancreas and its local complications may lead to nociceptors becoming more sensitive 
to further stimulation. This peripheral sensitization may be caused by up regulation of 
nerve growth factors, brain-derived neurotrophic factors and proinflammatory cytokines, 
and lead to increased pain intensity.60,61 Pancreatic neuroplasticity (remodeling) and 
peripheral sensitization (increased excitability) will increase the nociceptive drive to the 
central nervous system resulting in an increased reaction of pain transmitting neurons 
(increase of pain).59 Finally, this process may result in spontaneous nociceptive activity 
without the presence of nociceptive inputs and to an aggressive increase of pain signals 
to the spinal cord.16,62
Is central pain processing altered?
Quantitative sensory testing – chronic pancreatitis
Increasing evidence has been published on segmental and generalized hyperalgesia 
and referred pain as a sign of spinal and supraspinal central sensitization in chronic 
pancreatitis. Accordingly, decreased pain thresholds (i.e. hyperalgesia) for somatic 
stimulation in dermatomes near and distant to the pancreas in chronic pancreatitis 
patients are evident.7,11,13,28,54 In agreement with this, other studies report increased 
areas of referred pain to electrical stimulation of viscera of upper gastrointestinal organs 
and decreased pain thresholds to visceral stimulation of the rectosigmoid.63,64 These 
results suggest that peripheral visceral and somatic nerves converge at spinal levels in 
the central nervous system to elicit (somatic) referred pain as a sign of spinal central 
sensitization.65,66 Failure of descending inhibitory pain modulation (CPM) has also been 
observed in chronic pancreatitis patients.11,25,27,28,54 Probably this is due to a decreased 
activity in descending inhibitory pathways to the spinal cord as well as an increase in 
facilitatory activity projecting to the posterior spinal horn.
Quantitative sensory testing – visceral pain conditions
Similar to chronic pancreatitis, sensitization of the central nervous system is seen in 
other inflammatory visceral pain conditions e.g. esophagitis and inflammatory bowel 
General discussion and future perspectives
10
171
disorders, where it can be local in the viscera, spreading in the surrounding area or 
more distant in the case of referred pain. Drewes et al showed segmental sensitization 
to thermal stimulation of the distal esophagus in esophagitis patients, together with 
a larger referred somatic pain area to mechanical stimulation, both reflecting central 
sensitization.67 Comparable results were found in ulcerative colitis and Crohn’s disease 
patients, who showed decreased pain thresholds to balloon dilation of the colon or rectal 
stimulation again suggesting visceral hypersensitivity as a sign of central sensitization.68-70 
Evidence for descending counter-regulatory mechanisms has been described for patients 
with peptic ulcer and Crohn’s disease, both of whom showed hypoalgesia to visceral 
stimulation as a sign of effective tonic descending inhibition.71-73
Clinical application of quantitative sensory testing
In addition to characterization of the pain mechanisms underlying visceral pain disorders, 
QST has been used to study the effects of pain treatment on pain processing. In a study 
of S-ketamine, a noncompetitive NMDA receptor antagonist whose activity is related 
to central sensitization, infusions in chronic pancreatitis patients were associated with 
a short-lasting increase in pain pressure thresholds, without a reduction in clinical 
pain. However, this study was not powered on clinical endpoints and had a short 
infusion time.11 Another study showed that pregabalin reduced clinical pain in chronic 
pancreatitis and was associated with a moderate antihyperalgesic effect. Interestingly 
patients treated with placebo also showed a reduction in clinical pain, but this effect 
came without changes in pain thresholds measured by QST.12,14
The role of disease progression in chronic pancreatitis and how it is influenced by 
interventions has not been well studied. Just one exploratory study in chronic pancreatitis 
patients showed a relation between a more severe disease stage and lower pain thresholds 
(more hyperalgesia) compared to a moderate disease stage and healthy controls.28 
Interestingly, a study in chronic pancreatitis patients after pain-relieving pancreatic 
surgery showed that patients with a poor pain outcome after surgery showed more 
central sensitization and more pronociceptive descending pain modulation compared to 
patients with a good pain outcome and healthy controls.74
To summarize: chronic pancreatitis and other abdominal visceral pain syndromes show 
similarities in pain mechanisms and physiology. In the area of tissue damage and its 
surrounding tissue there is typically hypersensitivity to all kinds of different stimuli as 
signs of segmental hyperalgesia. When pain is ongoing, tissues more distant of the area 
of injury also become sensitized as (generalized hyperalgesia) as a sign of spreading 
central sensitization. Failure of counter-regulatory mechanisms such as DNIC, measured 
via e.g. CPM, also leads to hyperalgesia and pain increases. Treatments aimed at 
central pain mechanisms may reduce pain and hyperalgesia in such patients. Evidence 
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regarding the role of disease progression and treatments aimed at reducing pain and 
central sensitization is still scarce. However, it is evident that QST can play a useful role 
in quantifying pain processing and its impact on clinical pain before and after pain 
treatment.75,76
Resting state electroencephalography – chronic pancreatitis
Olesen et al reported an increase in amplitude strength in the theta and alpha band 
in patients with chronic pancreatitis compared to healthy controls, reflecting slowed 
EEG rhythmicity in patients with chronic pancreatitis compared to controls.77 Another 
study demonstrated a significant shift toward lower frequencies in patients with chronic 
pancreatitis compared with healthy controls.34 This was observed as a decrease in peak 
alpha frequency (PAF) over all scalp electrodes. Interestingly, these changes correlated 
with duration of pain, further supporting alterations in resting state EEG as a potential 
biomarker in chronic pain conditions.
The mechanisms underlying these observations are still poorly understood. One hypothesis 
is that of thalamocortial dysrythmia (TCD), where damage or lesions to afferent neural 
pathways results in deafferentation and a decrease in excitatory input to the thalamic 
relay cells. This results in disfacilitation and cell membrane hyperpolarization due to 
activation of T-type calcium channels. In this hyper-excitatory state thalamic relay neurons 
fire low threshold spike bursts and the normal thalamo-cortical rhythmicity is disturbed.29 
Application of drugs that interfere with T-type calcium channel function may prevent low 
frequency bursting, reverse TCD, and alleviate pain in conditions with underlying TCD. 
Thus resting state EEG may be of value not only as a potential biomarker for chronic pain 
progression via shifts in oscillatory activity, but also in treatment decisions and evaluation 
via identification of TCD. Another hypothesis is based on recent experiments indicating 
that the phase of alpha activity modulates perception and that alpha oscillations are 
produced by periodic pulses of inhibition. It was suggested that posterior alpha 
oscillations provide a mechanism for prioritizing and ordering unattended visual input 
according to ‘relevance’ or saliency.32 However, it is unclear whether the proposed role 
of alpha activity can be generalized to other modalities, such as the somatosensory and 
nociceptive system.
Evoked brain potentials electroencephalography – chronic pancreatitis
Dimcevski et al recorded EPs after stimuli given with a constant current electric stimulator 
at the three different sites of the upper gastrointestinal tract. Patients with chronic 
pancreatitis had a significantly decreased latency for the N1 and P1, while N2 latency 
was borderline significant compared to healthy subjects. No differences were found in 
the amplitudes of the N1, P1, and N2 potentials.63 In another study using evoked visceral 
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pain of the upper gastrointestinal tract, patients showed higher activity than controls in 
the theta band, with prolonged persistence of the signal and at lower frequency (4.4 Hz 
in patients compared to 5.5 Hz in controls).10 In a second study, patients with chronic 
pancreatitis showed hyperalgesia to electrical stimulation and prolonged latencies of 
early visceral EPs components in the frontal region of the cortex compared to healthy 
controls. Additionally, scalp distributions of EP amplitudes were more scattered and more 
posteriorly located in the patient group.27 As the changes in cortical processing were 
correlated to the pain this further validates the findings. To date, no comparable data are 
available for other types of abdominal focus-related chronic pain.
Clinical application of electroencephalography
Studies using EEG to identify patients who may benefit from treatment strategies 
targeting central pain mechanisms are limited. Graversen et al studied the resting state 
EEG after a three week regimen of pregabalin or matching placebo in patients with 
chronic pancreatitis.78 Patients in the pregabalin group showed a significant increase 
in theta activity after pregabalin treatment, while no changes were observed for the 
other frequency bands, nor were any changes found in the placebo group. The authors 
concluded that quantitative pharmaco-EEG can be used to monitor central analgesic 
mechanisms of pregabalin and may in the future be used to predict treatment effects.78
To summarize, studies in chronic visceral pain have investigated both the resting state as 
well as the evoked EEG. The use of multiple analysis techniques and different stimulation 
methods makes these results difficult to compare. Alpha activity in the resting state 
EEG has been shown to be affected in multiple chronic pain states including chronic 
pancreatitis, suggesting a change in the default state of the brain as a result of chronic 
pain. Pain-evoked EEG studies in chronic pancreatitis patients demonstrate alterations in 
dynamic pain processing reflected by prolonged latencies of visceral EPs and higher theta 
activity with prolonged persistence of the signal at a lower frequency during experimental 
visceral pain. Taken together, these EEG findings further support the concept that chronic 
visceral pain conditions such as chronic pancreatitis are associated with significant and 
ubiquitous alterations in resting state and evoked central nervous system processing, 
both nociceptive and non-nociceptive.
(functional) Magnetic resonance imaging 
The cortical and subcortical structures that are involved in visceral pain are the thalamus 
from which signals further ascend to different parts of the brain i.e. the limbic system 
(insula, cingulate cortex and prefrontal cortex), the primary (discriminating pain) and 
secondary (recognizing and remembering pain) somatosensory cortex.29 In particular 
the insula has an important function in pain perception from the gut.79 The functional 
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relationship between these areas was described with DTI for healthy controls who 
underwent rectal distension.80 Important areas for pain experience, influenced by 
cognitive, affective and emotional components, are processed in the limbic system. Other 
structures involved are: the amygdala, periaquaductal gray matter, reticular formation 
and hypothalamus. These structures are mostly related to pro- and antinociceptive 
control such as descending pain control.81
(functional) Magnetic resonance imaging – chronic pancreatitis
A MRI study with DTI in chronic pancreatitis patients showed increased diffusivity in grey 
matter regions of the insula and cingulate cortex suggesting microstructural changes 
of pain associated brain areas. These observations appeared to be directly correlated 
to the pain experienced by patients. Another MRI volumetry chronic pancreatitis study 
supported these findings and showed cortical thinning in similar brain areas (the limbic 
system).82 Brain areas that are associated with descending pain modulation e.g. the 
cingulate cortex, hypothalamus and periaqueductal grey matter showed cortical thinning 
in some studies with chronic pancreatitis patients. These results might explain impaired 
descending inhibition in chronic pancreatitis.27,82 Overall, in chronic pancreatitis patients 
different brain areas that are involved in visceral pain processing showed a decrease 
in cortical thickness. Whether these changes are due to chronic pain and how these 
changes influence pain processing is unknown at the moment.
(functional) Magnetic resonance imaging – visceral pain conditions
Studies in other abdominal visceral pain syndromes are scarce. However, similar results to 
studies in chronic pancreatitis were found in patients with inflammatory bowel disease 
when they were compared to healthy controls.83 
Clinical application of (functional) magnetic resonance imaging
At present there are no studies using (f)MRI to observe therapeutic effects or disease 
progression in chronic pancreatitis. 
To summarize: similarly to EEG studies, (f)MRI studies have shown for chronic pancreatitis 
patients and other visceral pain syndromes that changes in brain activity are present 
particularly in areas that are related to pain processing such as the limbic system, 
hypothalamus and periaqueductal regions. However the role of pain in these changes 
and how this influences pain perception is poorly understood at the moment.
Is altered central processing (still) dependent on peripheral nociceptive drive?
Central sensitization manifest as spreading hyperalgesia can ultimately become 
independent of peripheral nociceptive input and no longer respond to treatments 
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targeting the source of nociception and/or achieving peripheral deafferentation i.e. 
nerve blocks and opioids. Changes in central pain processing independent of peripheral 
nociceptive input were supported by a study involving chronic pancreatitis patients 
who had a splanchnic denervation to reduce pain, but where ca. 75% continued to 
experience painful and exhibit widespread hyperalgesia (four years) after a technically 
successful procedure, suggesting real central autonomy.54,84 Further literature on the 
reversibility of central sensitization is scarce. One study described two different groups of 
patients with osteoarthritis after hip replacement surgery, one that showed reversibility 
of hyperalgesia and a descending inhibitory modulation deficit and another group that 
had ongoing pain without changes in hyperalgesia and no changes in central inhibition 
suggesting the presence of central autonomy.85
IMPleMenTInG a sysTeMaTIc MecHanIsM-oRIenTaTeD 
aPPRoacH To cHRonIc PaIn In clInIcal PRacTIce
Source of nociception
QST performed at the site of the nociceptive focus can help identify the source of 
nociception and provide insight into the nature and aggressiveness of the nociceptive 
input involved (e.g. visceral pain). EEG and (f)MRI diagnostics have no role in this context.
Altered nociceptive transmission
QST performed close to the site of nociception can be used to help diagnose peripheral 
sensitization (local, primary hyperalgesia, usually thermal) and nerve damage (classically 
thermal hypoalgesia and hypoesthesia in the territory of the nerve in question).86-88 
Theoretically, evoked potential EEG studies (EPs) could be used to quantify alterations 
in nociceptive transmission. However, most EP studies only involve large fiber non-
nociceptive somatosensory processing; there are only a few such studies involving 
nociception-relevant small fibers (e.g. laser EPs).
Role of quantitative sensory testing in describing altered central pain processing
QST measured close and distant to the site of pain allows differentiation between 
segmental (spinal central sensitization) or generalized (supraspinal central sensitization) 
hyperalgesia. Stimulation of different tissues (e.g. electrical skin stimulation, mechanical 
stimulation of muscle by pressure algometry) can further help understand the source of 
pain and spread of associated altered pain processing. Dynamic QST measurements such 
as the conditioned pain modulation (CPM) paradigm are helpful in diagnosing shifts in 
descending nociceptive modulation.
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Is altered central processing (still) dependent on peripheral nociceptive drive?
In this case, central sensitization is present but no longer dependent on ongoing 
nociceptive input. Thus (trial) treatments aiming to deafferent the nociceptive source 
(e.g. nerve block or nerve transection) will not be accompanied by changes in central 
pain processing (e.g. spreading hyperalgesia) as measured by QST. As flanking – mainly 
experimental – procedures, EEG and (f)MRI have made it possible to directly demonstrate 
cortical reorganization, altered connectivity and modulation in chronic pain conditions.
Clinical use
Diagnostics
At our institution, QST has proven useful to diagnose and monitor changes in pain 
processing accompanying chronic pain. Our research and clinical experience suggest 
that implementation of a systematic mechanism-orientated approach to pain based on 
a simple diagnostic QST is both feasible and desirable in clinical pain practice. To this 
end we have instituted a simple QST screening paradigm, which all difficult chronic pain 
patients undergo (the Nijmegen-Aalborg Screening QST (NASQ)).18 The NASQ paradigm 
includes four measurement points measured bilaterally (close and distant to the site of 
pain, thus providing topographical information), two stimulation modalities (electric and 
pressure stimulation) and a CPM paradigm (cold pressor task). Details are provided in 
Table 1.18
Table 1 
The nijmegen-aalborg screening QsT paradigm
standard QsT
Sites (bilateral) Trapezius muscle, thenar eminence, rectus femoris, 
abductor hallucis, site of pain
Thresholds Pressure pain, electric detection, electric pain detection, 
electric pain tolerance
conditioned Pain modulation
Sites 1. ice water bucket (non-dominant hand)
2. thresholds on rectus femoris
Thresholds (before ice water/180s after) Pressure pain, electric pain tolerance
 
Quantitative sensory testing (QST) measurements to detect central sensitization and pro- or anti-
nociceptive shifts in descending pain modulation.18
The NASQ paradigm is well accepted by patients, easy to perform and learn, and can be 
completed within 30 minutes. Thermal QST testing can be added to test specifically for 
peripheral nerve damage.18,89
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Regarding clinical use of EEG and (f)MRI in chronic pain, the literature remains scarce. 
Furthermore both investigations are onerous, time consuming and expensive. Therefore 
we do not at present recommend their use in daily clinical practice for chronic pain 
patients, reserving these techniques for research.
Therapeutics
The new approach to pain in chronic pancreatitis presented here allows for holistic and 
systematic management of chronic pancreatitis pain. Such a systematic mechanism-
orientated approach not only facilitates the diagnosis and prognosis of chronic pain, it 
also provides the possibility of monitoring signs of chronic pain progression. As such, it 
forms the basis for more rational choice of treatment options to maximize treatment 
response, together with subsequent ongoing monitoring of effectiveness of chronic pain 
treatment.
Figure 2 provides a summary of our systematic mechanism-orientated approach to chronic 
pain, such as pancreatitis pain, as implemented at our institution. The scheme is based on 
the literature discussed in this review and our own clinical experience and practice.
Figure 2 
schematic for systematic mechanism-orientated approach to chronic pancreatitis pain
Autonomy means that alterations in central pain processing have become independent of peripheral 
nociceptive drive. ‘CS’ is central sensitisation, ‘CPM’ is conditioned pain modulation, ‘DI’ is descending 
inhibition, ‘TCA’ is tricyclic antidepressant, ‘NRI’ is noradrenaline reuptake inhibitor.21 This figure is based 
on the original figure of ref 18.18
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conclusIons
Intense abdominal pain is the dominant feature of chronic pancreatitis. In this review we 
propose a new systematic mechanism-orientated approach to the chronic pain of chronic 
pancreatitis. Multiple studies support that pain in chronic pancreatitis is similar to other 
visceral pain syndromes such as inflammatory bowel disease. Increasing evidence has 
shown that changes in central pain processing are present and comparable in chronic 
pancreatitis and other abdominal visceral pain syndromes. The data suggest that changes 
in pain processing due to chronic visceral pain are common and necessitate a targeted 
and mechanism-orientated diagnostic and therapeutic approach. This management 
approach needs to be holistic, including not only traditional treatments addressing the 
pancreas as a nociceptive source, but also specifically searching for – and therapeutically 
targeting – alterations in central nervous system processing of pain.
As shown in this review, QST, EEG and (f)MRI can be useful diagnostic instruments to 
analyze central pain processing and help us in finding optimal mechanism-orientated 
treatments for pain in chronic pancreatitis and other chronic visceral pain syndromes. 
Future research should define the presence and pattern of altered pain processing 
for specific chronic pain disorders and compare this with a healthy population using 
diagnostic tools such as QST, EEG and fMRI. Apart from characterization of hyperalgesia 
and descending pain modulation further questions need to be addressed. How does 
hyperalgesia develop over time? How is this influenced by disease progression and our 
treatments? What is the impact of gender and psychological state? Can we predict 
patients who are prone to chronic pain and altered central pain processing? The only 
way to increase our knowledge in this respect is to measure the effect of pain and 
nociception on central pain processing in large-scale clinical studies using QST, EEG or 
fMRI before and after interventions and during disease progression.78 This will help us 
evaluate therapies and guide us to the proper treatment for a specific patient at a specific 
disease stages. Such personalized medicine is the key to improved pain treatment and 
may pave the way to new and more effective therapeutic approaches.
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suMMaRy
The aim of this thesis was to describe the central pain mechanisms underlying chronic 
pain in chronic pancreatitis, and to provide new insights into pain treatment in chronic 
pancreatitis. 
Four aims were formulated and discussed in the presented chapters:
1. To identify changes in central pain processing (central sensitization) in chronic 
pancreatitis
2. To identify prognostic factors for altered central pain processing in chronic 
pancreatitis
3. To evaluate pain management in chronic pancreatitis and its relation to altered 
central pain processing
4. To propose a new, holistic view on pain management in chronic pancreatitis 
based on specific alterations in central pain processing present in the individual 
patient (personalized medicine)
Patients with painful chronic pancreatitis often have altered central pain processing which 
might be associated with abnormal brain morphology. In chapter 2 we described the 
assessment of cortical thickness (a sign of structural reorganization), using a 3T magnetic 
resonance scanner, in brain areas involved in visceral pain processing. Brain morphology 
was analyzed of nineteen patients with painful chronic pancreatitis and compared with 
fifteen healthy individuals. Cortical thickness was assessed by using an automated 
method with surface-based cortical segmentation of the primary (SI) and secondary (SII) 
somatosensory cortex; prefrontal cortex (PFC); frontal cortex (FC); anterior (ACC), mid 
(MCC), and posterior (PCC) cingulate cortex; and insula. The occipital middle sulcus was 
used as a control area. The pain score was determined based on the average amount 
of daily pain for one week. We found that chronic pancreatitis patients, compared with 
controls, had reduced overall cortical thickness (P < 0.01). These results were unaffected 
by confounders like diabetes, alcohol use, or opioid treatment (all P > 0.05). A similar 
decrease in cortical thickness was found for the chronic pancreatitis patients compared 
to controls for the SII (P < 0.01), PFC (P < 0.05), FC (P < 0.001), MCC (P = 0.001) and 
insula (P < 0.01). Brain areas without differences in cortical thickness between both 
groups were the control area, SI, ACC, and PCC (all P > 0.05). Cortical thickness in the 
affected areas correlated with pain score (r = 0.47, P < 0.01). It was concluded that 
chronic pancreatitis patients have reduced cortical thickness in brain areas involved in 
pain processing. These alterations seem to have functional significance and support the 
present literature from basal and clinical science on changes in central pain processing 
and neural remodeling. As a result of long-term, ongoing pain input to the neuromatrix, 
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cortical thickness might serve as a measure for overall pain system dysfunction.
Changes in spinal or supraspinal central nervous system pain processing caused by visceral 
nociceptive input plays an important role in chronic pain. Disease stage and progression 
of chronic pancreatitis were introduced as possible contributors to the extent of these 
changes in central pain processing in chronic pancreatitis in chapter 3. We divided 60 
chronic pancreatitis patients into two subgroups based on the M-ANNHEIM severity 
index of chronic pancreatitis: ’moderate’ and ’severe’. Both groups were compared with 
fifteen healthy controls. We compared all three groups using quantitative sensory testing 
for pressure pain detection and tolerance thresholds, and electric pain detection and 
tolerance thresholds, measured in six selected dermatomes (C5, T4, T10, T10 BACK 
(dorsal), L1 and L4). Also the conditioned pain modulation response to a cold pressor 
task was measured. Firstly, we compared the ‘severe’ with ‘moderate’ chronic pancreatitis 
patients and showed that the ‘severe’ chronic pancreatitis patients had overall lower 
pressure pain detection (P < 0.001), electric pain detection (P < 0.05) and electric pain 
tolerance thresholds (P < 0.05) than ‘moderate’ chronic pancreatitis patients. Secondly, 
we compared the ‘severe’ chronic pancreatitis patients with healthy controls and showed 
that the ‘severe’ chronic pancreatitis patients had lower pressure pain detection (P = 
0.001), electric pain detection (P < 0.01) and electric pain tolerance thresholds (P < 
0.05) results when compared with healthy controls. No significant differences were 
found between groups for the pressure pain tolerance thresholds. Finally, there were 
no significant differences between ‘moderate’ chronic pancreatitis patients and healthy 
controls for all measured thresholds. These results suggest variations in supraspinal central 
sensitization (central pain processing), which is related to disease stage: more severe 
disease exhibits more central sensitization. Descending pain modulation, measured by the 
conditioned pain modulation was much higher (better) in the healthy controls compared 
to all chronic pancreatitis patients (P < 0.0001), suggesting that central pain processing 
is affected not only for ascending mechanisms, but also for descending mechanisms. 
Overall, these results suggest that central sensitization is affected by disease stage in 
chronic pancreatitis and should be taken into account when managing pancreatitis pain.
In chapter 4 we evaluated the relationship between pain processing and pain outcome 
after pancreatic duct decompression or pancreatic resection in patients with chronic 
pancreatitis. Quantitative sensory testing was used to measure electric pain detection 
and electrical pain tolerance thresholds in two dermatomes (C5 and L4) distant from 
the pancreas in 48 chronic pancreatitis patients. Inhibitory descending pain control 
mechanisms were assessed using the conditioned pain modulation paradigm. Chronic 
pancreatitis patients were divided into two subgroups based on their pain outcome 
after surgery: ‘poor pain outcome’ (visual analogue scale (VAS) score greater than 30) 
and ‘good pain outcome’ (VAS score 30 or less). Chronic pancreatitis patients were 
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compared with fifteen healthy controls. Overall, chronic pancreatitis patients had lower 
electric pain detection and tolerance thresholds and a lower CPM response compared 
to healthy controls (P < 0.05). Patients with a poor pain outcome after surgery had 
lower electric pain detection thresholds than patients with a good pain outcome (P < 
0.01). There was a negative correlation between VAS score and electric pain detection 
(rs = −0.45, P < 0.05) and electric pain tolerance thresholds (rs = −0.46, P < 0.05), and 
conditioned pain modulation response (rs  =  −0.43, P < 0.01) in chronic pancreatitis 
patients. Based on these results we concluded that chronic pancreatitis patients exhibit 
altered central pain processing after pain-relieving surgery compared to healthy controls. 
Chronic pancreatitis patients with a poor pain outcome after surgery showed more 
central sensitization and more pronociceptive descending pain modulation compared 
with chronic pancreatitis patients with a good pain outcome after surgery. These results 
suggest that these changes have become relatively independent of peripheral nociceptive 
input. The observed differences should be considered when managing persistent pain 
after pain-relieving surgery for chronic pancreatitis and should be dealt with before a 
new surgical intervention is considered.
As a follow-up to the studies in chapter 3 and 4, altered pain processing in chronic 
pancreatitis was further explored in chapter 5. Independence of central sensitization 
from ongoing peripheral nociceptive input has been suggested to be present in chronic 
pancreatitis patients that remain painful after successful denervation procedures 
of the pancreas. In these cases pain is not driven by nociception from the pancreas 
but is caused by persisting, autonomous changes in the central nervous system. We 
investigated whether bilateral thoracoscopic splanchnicectomy, performed to reduce 
nociceptive input in chronic pancreatitis patients, affects central pain processing. 
Seventeen chronic pancreatitis patients were studied preoperatively and six weeks after 
bilateral thoracoscopic splanchnicectomy. Pressure pain thresholds were measured, using 
quantitative sensory testing, before and after splanchnicectomy in a dermatome distant 
from the pancreas (C5) and a pancreatic dermatome (T10 BACK (dorsal)), reflecting 
supraspinal and spinal central sensitization, respectively. Chronic pancreatitis patients 
were divided into two groups based on their change in thresholds: ‘hypoalgesic’ 
patients had an increase in thresholds after intervention and ‘hyperalgesic’ patients had 
no change or a decrease in thresholds after intervention. This division was made both 
for the pancreatic dermatome (T10) and for the dermatome distant from the pancreas 
(C5). Postoperative scores on the pain numeric rating scale (NRS) were correlated to the 
change in pain thresholds. After splanchnicectomy, ten patients showed C5 pain pressure 
threshold increase (hypoalgesic), seven patients had unaltered or lower pain pressure 
thresholds (hyperalgesic). Preoperative pain NRS was similar between groups (median 4 
vs. 5). After splanchnicectomy, NRS in the hypoalgesic group was lower (median 1 vs. 6, 
Summary
11
189
P < 0.01) and NRS change greater (median -2 vs. 0, P < 0.01). Whole group NRS and C5 
pain pressure thresholds changes showed a significant negative correlation (rs = 0.53, 
P < 0.05). This was not the case for pancreatic pain pressure thresholds. We found that 
an increase in pressure pain thresholds in a dermatome distant from the pancreas (C5), 
reflecting supraspinal sensitization, was associated with a significant reduction in pain 
scores postoperatively after bilateral thoracoscopic splanchnicectomy. This was not the 
case for the pancreatic dermatome (T10), reflecting more segmental spinal processing. 
These results suggest that a subgroup of chronic pancreatitis patients with chronic pain 
has altered pain processing that may be independent of ongoing peripheral nociceptive 
input, resulting in persisting pain despite bilateral thoracoscopic splanchnicectomy. If 
confirmed, these results indicate the importance of sensory testing for indication and 
management of interventional pain treatments. Also, these tests can be of prognostic 
value for the success of an intervention preoperatively and can be used postoperatively 
to measure the effect of an intervention. 
Central sensitization and hyperalgesia, key phenomena in chronic pain, are associated with 
N-methyl-D-aspartate (NMDA) receptor activation. In chapter 6 the effects of S-ketamine 
(NMDA receptor antagonist) and placebo infusion on generalized hyperalgesia and pain 
relief were described in chronic pancreatitis patients. We conducted a blinded crossover 
trial, in which ten chronic pancreatitis pain patients received S-ketamine for three hours 
at 2 mcg/kg/min or placebo infusion at an equivalent rate in randomized order. Clinical 
pain was assessed via visual analog scale (VAS) and short Dutch Language Version McGill 
Pain Questionnaire (sf-MPQ-DLV). Pressure pain thresholds, using quantitative sensory 
testing, were measured in dermatome C5, T4, T10 BACK (dorsal), L1 and L4. The sum of 
pressure pain thresholds was calculated before, at the end of, and one hour after infusion. 
Median pain before infusion was 29 mm at rest and 32 mm during activity (VAS score). 
Patients in the S-ketamine groups showed a significant increase in sum of pressure pain 
thresholds at infusion end compared to pre-infusion values (P < 0.05) and compared to 
the placebo group (P < 0.01). However, this effect was not sustained: the sum of pain 
pressure thresholds one hour after the infusion end were similar to pre-infusion values and 
to values in patients treated with placebo. No significant changes were observed in VAS 
and sf-MPQ-DLV scores during the study. S-ketamine was tolerated well by all patients. 
This study showed that S-ketamine infusion is more effective than placebo in increasing 
pain pressure thresholds in chronic pancreatitis pain patients immediately after infusion. 
These results confirm the acute antihyperalgesic effect of S-ketamine. Despite short-term 
positive effects of S-ketamine, this effect did not outlast the infusion. Still many questions 
remain unsolved regarding the optimal dosage, duration and route of administration to 
describe an optimal treatment schedule with S-ketamine. When these topics are better 
understood, a more prolonged effect of S-ketamine may turn out to be feasible. 
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Agents such as pregabalin (gabapentinoid) can be used to treat patients with neuropathic 
pain. Evidence from basic science and human studies has shown that chronic pancreatitis 
patients have abnormal pain processing that resembles the pain processing in patients 
with neuropathic pain disorders. In chapter 7 we described a randomized controlled trial 
which compared pregabalin and placebo and its effect on pain in chronic pancreatitis 
patients. Sixty-four chronic pancreatitis patients were randomized in this double-blind, 
placebo-controlled trial to evaluate the effects of pregabalin as an adjuvant analgesic. 
Patients were randomly assigned to groups given increasing doses of pregabalin or 
placebo (control) for three consecutive weeks. The primary endpoint was clinical pain 
relief, based on a visual analogue scale documented by a pain diary. Secondary endpoints 
included patients’ global impression of change (PGIC) score, changes in physical and 
functional scales, pain character, quality of life, and tolerability. Pregabalin, compared 
with placebo, resulted in more effective pain relief after three weeks of treatment (36% 
vs. 24%, P < 0.05). The percentage of patients with ‘much’ or ‘very much’ improved 
health status (PGIC score) at the end of the study was higher in the pregabalin than the 
control group (44% vs. 21%, P < 0.05). Changes in physical and functional scales, pain 
character, quality of life, and number of adverse events (mostly mild to moderate) were 
comparable between (the) groups. 61% of patients tolerated the maximum dosage of 
pregabalin and 90% tolerated the maximal placebo dosage. Medication compliance 
was high in both groups (> 90%). This study showed the efficacy and tolerability of 
pregabalin as an adjuvant analgesic for the treatment of pain in chronic pancreatitis. 
A dosage of pregabalin between 150 mg and 300 mg twice daily resulted in clinical 
significant pain reduction. 
In chapter 8 the experimental endpoints of the randomized controlled trial comparing 
pregabalin and placebo in chronic pancreatitis were discussed. The aim of the study was 
to evaluate the effect of pregabalin on pain processing in chronic pancreatitis as assessed 
by quantitative sensory testing. Electric pain thresholds and pressure pain thresholds 
were measured in six body dermatomes (C5, T4, T10, L1, L4 and T10 BACK (dorsal)). 
Descending endogenous pain modulation was quantified using the conditioned pain 
modulation (CPM) paradigm. The main effect parameter was the change in the sum of 
all body pain threshold values after three weeks of study treatment versus baseline values 
between the two treatment groups. All 64 randomized patients were analyzed. Changes 
in sum of pain thresholds were comparable, after three weeks of study treatment, 
between the pregabalin and placebo group. For individual dermatomes the change in 
pre and post treatment thresholds was significantly larger in the pregabalin group for 
electric pain detection thresholds in dermatome C5 (P < 0.01), for electric pain tolerance 
thresholds in dermatomes C5 (P < 0.05) and L1 (P = 0.05), and for pressure pain 
tolerance thresholds in dermatome T4 (P < 0.01). No differences were observed between 
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pregabalin and placebo regarding conditioned pain modulation. These results show 
that the moderate antihyperalgesic effect of pregabalin is mostly seen in dermatomes 
distant from the pancreas and implies a reduction of central sensitization instead of 
segmental sensitization. The effect was strongest for superficial tissues, i.e. skin (electric 
stimulation), and lower for deeper tissues (pressure stimulation). It is suggested that 
quantitative sensory testing can be of clinical use for monitoring pain treatments in the 
context of chronic pain.
A further analysis of the experimental endpoints of the randomized controlled trial 
comparing pregabalin and placebo in chronic pancreatitis were discussed in chapter 9. 
Quantitative sensory testing was used to investigate differences in pain sensitivity and 
modulation in chronic pancreatitis among responders and non-responders to placebo or 
pregabalin treatment. Responders were defined as achieving a > 30% pain reduction after 
three weeks’ treatment. Based on their pain response, chronic pancreatitis patients were 
assigned post-hoc to one of four groups: responders and non-responders to pregabalin 
(N = 16 and N = 15), or to placebo (N = 12 and N = 17 respectively). Quantitative sensory 
testing was used to measure change in pain sensitivity before and after treatment, using 
electric pain detection thresholds in dermatomes C5 (generalized effects) and ventral 
T10 (segmental effects). Descending endogenous pain modulation was quantified via a 
conditioned pain modulation (CPM) paradigm. A per protocol analysis was performed on 
60 patients. The increase in electric pain detection thresholds in dermatome C5 versus 
baseline was significant in pregabalin responders (P < 0.01). The change in electric 
pain detection thresholds in C5 was significantly different for pregabalin responders 
(less hyperalgesia) compared to placebo responders (P < 0.05). Similarly to dermatome 
C5, there was a significant increase in electric pain detection thresholds in dermatome 
T10, compared to baseline, in pregabalin responders (P < 0.01). However, the sizes of 
the changes in electric pain detection thresholds in the T10 dermatome were similar in 
the four groups. Conditioned pain modulation versus baseline increased significantly 
only for pregabalin responders (a more effective response, P < 0.01). In contrast, the 
placebo responders showed a less effective response after three weeks of treatment (P < 
0.05). The changes in conditioned pain modulation were significantly different between 
pregabalin responders and placebo responders (P < 0.001). This study showed a potent 
placebo effect on pain relief in chronic pancreatitis patients, although without anti-
hyperalgesic effects. In contrast to the placebo group, chronic pancreatitis patients with 
pain relief on pregabalin did show anti-hyperalgesic effects and increased endogenous 
inhibitory modulation. These results suggest that the mechanisms underlying analgesic 
response to placebo and pregabalin are different.
Known causes of pain in chronic pancreatitis are increased intrapancreatic pressure, pan-
creatic inflammation and pancreatic or extrapancreatic complications. Despite advances 
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regarding treatments aimed at these causes, chronic pancreatitis pain management 
remains a major clinical challenge. It is increasingly recognized that changes in central 
pain processing are also a cause of ongoing chronic pain in chronic pancreatitis. Findings 
in other visceral pain syndromes (e.g. inflammatory bowel disease and esophagitis) show 
similar changes in pain processing, and suggest that these and chronic pancreatitis 
should be managed in a similar fashion. Based on advances in diagnostics and recent 
improvements in chronic pain management we proposed in chapter 10 a systematic 
mechanism-orientated approach to pain management in chronic pancreatitis based on a 
holistic view of the mechanisms involved. When altered central pain processing is present, 
conventional pain treatment targeting the nociceptive focus, e.g. opioid analgesia or 
surgical/endoscopic intervention often fails, even if technically successful. In these cases 
specific treatment should be instituted, targeting changes in central pain processing 
such as gabapentinoids, ketamine or tricyclic antidepressants, based on appropriate 
diagnostic measures. Altered central pain processing can be visualized by quantitative 
sensory testing, electroencephalography and (functional) magnetic resonance imaging. 
These diagnostic tools to analyze central pain processing can be useful in defining 
optimum pain management for chronic pancreatitis and other visceral pain syndromes. 
Future research should be aimed at a better understanding of changes in central pain 
processing in chronic pancreatitis and how this is influenced by ongoing nociceptive 
input and therapies. Furthermore, diagnostic tools aimed at central pain processing 
should be improved. Such an approach will hopefully help to predict which patients are 
at risk for developing chronic pain, and which ones will respond positively to an available 
(given) therapy. This may serve as the basis for achieving personalized medicine.
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neDeRlanDse saMenVaTTInG 
Het doel van dit proefschrift was om de onderliggende centrale mechanismen van 
chronische pijn bij chronische pancreatitis te beschrijven en nieuwe inzichten te verkrijgen 
in deze mechanismen.
De volgende vier doelen werden geformuleerd en zijn besproken in de verschillende 
hoofdstukken:
1. Het opsporen van veranderingen in de centrale pijnverwerking (centrale 
sensitisatie) bij chronische pancreatitis
2. Het opsporen van prognostische factoren voor een veranderde centrale 
pijnverwerking bij chronische pancreatitis
3. Het evalueren van pijnbehandelingen bij chronische pancreatitis en de relatie 
tussen het succes en veranderde centrale pijnverwerking
4. Het formuleren van een nieuwe, meer holistische benadering van pijn bij 
chronische pancreatitis, die gebaseerd is op specifieke veranderingen in de 
centrale pijnverwerking in de individuele patiënt (personalized medicine)
Chronische pancreatitis patiënten met chronische pijn hebben vaak veranderingen in 
centrale pijnverwerking, die geassocieerd zijn met een abnormale morfologie van het 
brein. In hoofdstuk 2 berekenden wij met behulp van een 3T magnetische resonantie 
scanner de corticale dikte van het brein, een maat voor structurele reorganisatie, in 
hersengebieden die betrokken zijn bij viscerale pijnverwerking. De hersenmorfologie van 
negentien chronische pancreatitis patiënten met pijn werd geanalyseerd en vergeleken 
met die van vijftien gezonde individuen. De corticale dikte van de primaire (SI) en 
secundaire (SII) somatosensorische cortex; prefrontale cortex (PFC); frontale cortex (FC); 
anterieure (ACC), middelste (MCC), en posterieure (PCC) cingulate cortex; en van de 
insula werden beoordeeld met behulp van oppervlakte-gebaseerde corticale segmentatie. 
De occipitale middelste sulcus werd gebruikt als een controle gebied. De pijnscore werd 
bepaald aan de hand van dagelijkse pijn, gedurende een week. Wij vonden een afname 
in totale corticale dikte bij chronische pancreatitis patiënten vergeleken met de gezonde 
individuen (P < 0.01). Deze resultaten werden niet beïnvloed door mogelijke verstorende 
factoren zoals diabetes, alcoholgebruik of behandeling met opioïden (alle P > 0.05). Per 
hersengebied bekeken, was er een significante afname van de corticale dikte in SII (P < 
0.01), PFC (P < 0.05), FC (P < 0.001), MCC (P = 0.001) en insula (P < 0.01), bij chronische 
pancreatitis patiënten vergeleken met de gezonde individuen. Hersengebieden zonder 
significante verschillen in corticale dikte tussen beide groepen waren het controlegebied, 
SI, ACC, en PCC (alle P > 0.05). Corticale dikte in de aangedane gebieden was 
gecorreleerd met de pijnscore (r = 0.47, P < 0.01). Er werd geconcludeerd dat chronische 
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pancreatitis patiënten een afname van corticale dikte hebben in hersengebieden die 
betrokken zijn bij pijnverwerking. Deze veranderingen lijken functionele betekenis te 
hebben en ondersteunen de huidige literatuur uit basaal en klinisch onderzoek over 
veranderingen in de centrale pijnverwerking en neurale remodellering. Als gevolg van 
langdurige, aanhoudende nociceptieve input aan de neuromatrix kan corticale dikte 
mogelijk dienen als een maat voor dysfunctionele pijnverwerking.
Veranderingen in pijnverwerking in het centrale zenuwstelsel op spinaal en/of supraspinaal 
niveau door viscerale nociceptieve input spelen een belangrijke rol bij chronische pijn. 
In hoofdstuk 3 werden ziektestadium en ziekteprogressie van chronische pancreatitis 
geïntroduceerd als mogelijke factoren die de uitgebreidheid van veranderingen in cen-
trale pijnverwerking beïnvloeden. Wij verdeelden 60 chronische pancreatitis patiënten 
op basis van de M-ANNHEIM Severity Index voor chronische pancreatitis in twee 
subgroepen; ‘matig’ en ‘ernstig’ ziektebeloop. Beide groepen werden vergeleken 
met vijftien gezonde controles. We vergeleken alle drie de groepen met behulp van 
kwantitatieve sensorische testen voor de detectie en tolerantie van drukpijn en van 
elektrische pijn, gemeten in zes dermatomen (C5, T4, T10, T10 BACK (dorsaal), L1 
en L4). Ook de geconditioneerde pijnmodulatierespons op koude-intolerantie werd 
gemeten. De resultaten toonden aan dat de chronische pancreatitis patiënten met 
een ‘ernstig’ ziektebeloop een lagere drempel hadden voor de detectie van drukpijn 
(P < 0.001), detectie van elektrische pijn (P < 0.05) en tolerantie van elektrische pijn 
(P < 0.05) vergeleken met chronische pancreatitis patiënten met een ‘matig’ ziekte-
beloop. Ook tussen de ‘ernstige’ subgroep en gezonde controles werden verschillen 
gevonden voor de drempel voor detectie van drukpijn (P < 0.001), detectie van elektrische 
pijn (P < 0.01) en tolerantie van elektrische pijn (P < 0.05) (waarbij de gezonde controles 
steeds hogere waarden hadden). Er werden geen significante verschillen gevonden in 
drempels voor tolerantie van drukpijn tussen alle groepen. Ten slotte waren er geen 
significante verschillen tussen de patiënten met een ‘matig’ ziektebeloop en gezonde 
controles voor alle gemeten kwantitatieve sensorische testen. Deze resultaten duiden op 
variaties in supraspinale centrale sensitisatie ofwel centrale pijnverwerking, die gerelateerd 
is aan ziekte-ernst: ernstiger ziekte vertoont meer centrale sensitisatie. Descenderende 
pijnmodulatie, gemeten door de geconditioneerde pijnmodulatierespons was veel sterker 
(beter) in de gezonde controles vergeleken met alle chronische pancreatitis patiënten (P 
< 0.0001). Dit suggereert dat centrale pijnverwerking niet alleen beïnvloed wordt door 
ascenderende mechanismes, maar ook door descenderende. Samenvattend, centrale 
pijnverwerking lijkt beïnvloed te worden door het ziektestadium van de chronische 
pancreatitis. Hiermee dient rekening gehouden te worden bij de behandeling van pijn bij 
chronische pancreatitis.
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In hoofdstuk 4 evalueerden wij de relatie tussen pijnverwerking en pijn na chirurgische 
decompressie van de ductus pancreaticus en/of partiële pancreasresectie bij chronische 
pancreatitis patiënten. Kwantitatieve sensorische testen werden gebruikt om in 48 
chronische pancreatitis patiënten drempels voor de detectie en tolerantie van elektrische 
pijn te meten in twee dermatomen die op afstand liggen van het pancreas dermatoom 
(C5 en L4). Descenderende pijnmodulatie werd gemeten door de geconditioneerde 
pijnmodulatierespons. Chronische pancreatitis patiënten werden onderverdeeld in twee 
subgroepen op basis van hun pijn na pancreaschirurgie: ‘slechte pijnuitkomst’ (score 
gemeten op een visuele analoge schaal (VAS) van meer dan 30) en ‘goede pijnuitkomst’ 
(VAS score van 30 of minder). Chronische pancreatitis patiënten werden vergeleken met 
vijftien gezonde controles. De gehele groep chronische pancreatitis patiënten had een 
lagere drempel voor de detectie en tolerantie van elektrische pijn, evenals een lagere 
geconditioneerde pijnmodulatierespons in vergelijking met gezonde controles (P < 0.05). 
Patiënten met een ‘slechte pijnuitkomst’ na de ingreep hadden lagere elektrische pijn 
detectie drempels dan patiënten met een ‘goede pijnuitkomst’ (P < 0.01). Er was een 
negatieve correlatie tussen de VAS score en de drempels voor detectie van elektrische 
pijn (rs = -0.45, P < 0.05), tolerantie van elektrische pijn (rs = -0.46, < 0.05) en 
geconditioneerde pijnmodulatierespons (rs = -0.43, P < 0.01) bij chronische pancreatitis 
patiënten. Concluderend vertonen chronische pancreatitis patiënten na pijnverlichtende 
pancreaschirurgie een veranderde pijnverwerking. Chronische pancreatitis patiënten met 
een ‘slechte pijnuitkomst’ na de operatie toonden meer centrale sensitisatie en meer 
pronociceptive descenderende pijnmodulatie dan chronische pancreatitis patiënten met 
een ‘goede pijnuitkomst’ na de operatie. Deze resultaten suggereren dat de gevonden 
veranderingen relatief onafhankelijk van de perifere nociceptieve input zijn geworden. 
De waargenomen verschillen moeten worden meegenomen bij het behandelen van 
aanhoudende pijn na pijnverlichtende pancreaschirurgie bij chronische pancreatitis, en 
moet onder controle zijn voordat een nieuwe chirurgische ingreep wordt overwogen.
In vervolg op de studies uit hoofdstuk 3 en 4 werden in hoofdstuk 5 veranderingen 
in pijnverwerking bij chronische pancreatitis verder onderzocht. Mogelijk is er centrale 
sensitisatie - onafhankelijk van perifere nociceptieve input - aanwezig bij chronische 
pancreatitis patiënten die geen baat hebben gehad van denervatie procedures van 
het pancreas. In deze gevallen is de oorzaak van de pijn niet de nociceptieve input 
vanuit het pancreas, maar een gevolg van aanhoudende autonome veranderingen 
in het centrale zenuwstelsel. Wij onderzochten of bilaterale thoracoscopische 
splanchnicusdenervatie, uitgevoerd om nociceptieve input te verminderen bij chronische 
pancreatitis patiënten, de centrale pijnverwerking beïnvloedt. Zeventien chronische 
pancreatitis patiënten werden preoperatief en zes weken na bilaterale thoracoscopische 
splanchnicusdenervatie onderzocht. Drempels voor drukpijn werden gemeten met 
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behulp van kwantitatieve sensorische testen voor en na splanchnicusdenervatie in een 
dermatoom ver van het pancreas gelegen (C5) en in het pancreas dermatoom (T10), als 
afspiegeling van respectievelijk supraspinale en spinale centrale sensitisatie. Chronische 
pancreatitis patiënten werden verdeeld in twee groepen op basis van hun veranderingen 
in pijndrempels: ‘hypoalgetische’ patiënten hadden een stijging van de drempels na 
interventie en ‘hyperalgetische’ patiënten hadden een afname of geen verandering van 
de drempels na interventie. Deze onderverdeling werd zowel gemaakt voor het pancreas 
dermatoom (dorsaal T10), als voor het dermatoom ver van het pancreas (C5). Postoperatieve 
pijnscores op een numerieke schaal (NRS) werden gecorreleerd aan de veranderingen 
in pijndrempels. Na splanchnicusdenervatie vertoonden tien patiënten een toename in 
drempels voor drukpijn in C5 (hypoalgetisch), zeven patiënten hadden ongewijzigde of 
lagere drempels voor drukpijn (hyperalgetisch). De preoperatieve pijnscore (NRS) was 
vergelijkbaar tussen de groepen (mediaan 4 vs. 5). Na splanchnicusdenervatie was in de 
‘hypoalgetische’ groep de pijnscore lager (mediaan 1 vs. 6, P < 0.01) en de verandering 
in pijnscore groter (mediaan -2 vs. 0, P < 0.01). De pijnscore en drempel voor drukpijn 
in dermatoom C5 lieten een statistisch significante negatieve correlatie zien (rs = 0.53, P 
< 0.05); dit was niet het geval voor drempels voor drukpijn in het pancreasdermatoom. 
We vonden dat een toename van drempels voor drukpijn in een dermatoom ver van 
het pancreas dermatoom gelegen (C5), als afspiegeling van supraspinale sensitisatie, 
was geassocieerd met een significante afname in postoperatieve pijnscore na bilaterale 
thoracoscopische splanchnicusdenervatie. Dit was niet het geval voor het pancreas 
dermatoom (T10), als afspiegeling van meer segmentale spinale pijnverwerking. Deze 
resultaten suggereren dat een subgroep van chronische pancreatitis patiënten met 
chronische pijn veranderingen heeft in pijnverwerking die mogelijk onafhankelijk zijn 
van perifere nociceptieve input. Dit resulteert in persisterende pijn ondanks bilaterale 
thoracoscopische splanchnicusdenervatie. Indien bevestigd in toekomstige studies, geven 
deze resultaten het belang aan van sensorische testen voor de indicatie en toepassing 
van pijnbehandelingen. Daarbij kunnen deze testen preoperatief van prognostische 
waarde zijn voor wie baat heeft bij een interventie en postoperatief voor het meten van 
het effect van de interventie.
Centrale sensitisatie en hyperalgesie, belangrijke processen bij chronische pijn, zijn 
geassocieerd met N-methyl-D-aspartaat (NMDA) receptoractivatie. In hoofdstuk 6 
is het effect van S-ketamine (NMDA receptorantagonist) en placebo beschreven op 
gegeneraliseerde hyperalgesie en pijn bij chronische pancreatitis patiënten. Wij voerden 
een geblindeerde cross-over studie uit, waarin tien chronische pancreatitis patiënten 
gerandomiseerd werden voor ofwel een drie uur durende infusie van S-ketamine (2 
mcg/kg/min) ofwel placebo. Klinische pijn werd beoordeeld middels een VAS score en 
de Nederlandse vertaling van de McGill Pain Questionnaire (sf-MPV-DLV). Drempels 
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voor drukpijn werden gemeten door middel van kwantitatieve sensorische testen in 
de dermatomen C5, T4, T10 BACK (dorsaal), L1 en L4. De som van de drempels voor 
drukpijn werd berekend vóór infusie, direct na het stoppen van de infusie en één uur na 
de infusie. Gedurende de infusie van S-ketamine en placebo rapporteerden patiënten 
weinig bijwerkingen. Wanneer er sprake was van een bijwerking dan was deze mild en 
gaf deze geen reden tot staken van de infusie. De mediane VAS score vóór infusie was 
29 mm in rust en 32 mm tijdens activiteit. Patiënten in de S-ketamine groep vertoonden 
een significante toename van de som van drempels voor drukpijn direct na het stoppen 
van de infusie, vergeleken met waardes vóór infusie (P < 0.05) en vergeleken met de 
placebogroep (P < 0.01). De significante toename van de drempels voor drukpijn in de 
S-ketamine groep was kortdurend, aangezien de som van drempels voor drukpijn één 
uur na infusie vergelijkbaar was met pre-infusie waardes en met die van de placebo 
groep. Er werden geen significante verschillen waargenomen in VAS score en sf-MPV-
DLV score gedurende de studie. Deze studie toonde aan dat bij chronische pancreatitis 
patiënten met pijn, S-ketamine direct na infusie effectiever is dan placebo in het verhogen 
van drempels voor drukpijn. Deze resultaten bevestigen het acute anti-hyperalgetische 
effect van S-ketamine. Ondanks het positieve korte termijn effect van S-ketamine op de 
pijndrempels was het effect na het stoppen van de infusie snel weer verdwenen. Veel is 
nog onbekend over de optimale dosering, duur en route van toediening van S-ketamine, 
wat het definiëren van een optimaal behandelschema moeilijk maakt. Wanneer deze 
onderwerpen beter onderzocht zijn is een langer aanhoudend effect van S-ketamine 
mogelijk te bewerkstelligen.
Medicatie zoals pregabaline wordt gebruikt om patiënten met neuropathische pijn te 
behandelen. Basaal wetenschappelijk onderzoek en humane studies hebben aangetoond 
dat sommige chronische pancreatitis patiënten een abnormale pijnverwerking hebben, 
die gelijkenissen vertoont met die van patiënten met neuropathische pijn. In hoofdstuk 7 
onderzochten we het effect van pregabaline als adjuvante pijnstiller op de pijn bij 
chronische pancreatitis patiënten. Vierenzestig patiënten werden gerandomiseerd in 
deze dubbelblinde, placebo-gecontroleerde studie. Patiënten kregen gedurende drie 
achtereenvolgende weken opklimmende doses van pregabaline of placebo. Het primaire 
eindpunt was klinische pijn, gemeten op basis van de VAS score, gedocumenteerd in een 
pijndagboek. Secundaire eindpunten waren de ‘globale indruk van verandering in pijn’ 
(PGIC score), veranderingen in fysieke en functionele scores, het karakter van de pijn, 
kwaliteit van leven en tolerantie van de studiemedicatie. Pregabaline gaf een effectievere 
pijnreductie dan placebo na drie weken van behandeling (36% vs. 24%, P < 0.05). Het 
percentage patiënten met een sterk tot een zeer sterk verbeterde gezondheidstoestand 
aan het einde van de studie was hoger in de pregabalinegroep dan in de controlegroep 
(PGIC score 44% vs. 21%, P < 0.05). Veranderingen in de fysieke en functionele scores, 
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karakter van de pijn, kwaliteit van leven en het aantal bijwerkingen (meestal mild tot matig) 
waren vergelijkbaar tussen beide groepen. De maximale dosering van studie medicatie 
werd door 61% van de patiënten in de pregabalinegroep verdragen, tegenover 90% 
in de placebogroep. Therapietrouw was hoog in beide groepen (> 90%). Deze studie 
toonde de werkzaamheid en tolerantie van pregabaline aan als adjuvante pijnstiller in de 
behandeling van pijn bij chronische pancreatitis patiënten. Een dosering van pregabaline 
tussen de 150 mg en 300 mg tweemaal daags resulteerde in een klinisch significante 
vermindering van de pijn.
In hoofdstuk 8 werden de experimentele eindpunten beschreven van de in hoofdstuk 
7 beschreven studie. Het doel van de studie was om het effect van pregabaline op 
pijnverwerking te evalueren bij chronische pancreatitis patiënten door middel van 
kwantitatieve sensorische testen. Drempels voor elektrische pijn en drukpijn werden 
gemeten in zes verschillende dermatomen (C5, T4, T10, L1, L4 en T10 BACK (dorsaal)). 
Descenderende pijnmodulatie werd gekwantificeerd door middel van de geconditioneerde 
pijnmodulatierespons. De belangrijkste uitkomstmaat was de verandering in de som 
van alle drempels voor elektrische pijn en drukpijn uit alle dermatomen na drie weken 
behandeling met de studiemedicatie ten opzichte van de baselinewaardes in beide 
studiegroepen. Alle 64 gerandomiseerde patiënten werden geanalyseerd. Veranderingen 
in de som van drempels voor elektrische pijn en drukpijn waren vergelijkbaar tussen de 
pregabaline en de placebogroep na drie weken behandeling met de studiemedicatie. 
Voor de afzonderlijke dermatomen was de toename in pijndrempels (na de behandeling) 
significant groter in de pregabalinegroep dan in de placebogroep voor de volgende 
stimuli: elektrische pijn in dermatoom C5 (P < 0.01), tolerantiedrempel van elektrische pijn 
in dermatomen C5 (P < 0.05) en L1 (P = 0.05), en tolerantie van drukpijn in dermatoom 
T4 (P < 0.01). Er werden geen verschillen waargenomen tussen pregabaline en placebo 
met betrekking tot de geconditioneerde pijnmodulatierespons. Deze resultaten tonen 
een gematigd anti-hyperalgetisch effect van pregabaline, met name in dermatomen 
ver van het pancreas gelegen, en duiden op vermindering van centrale sensitisatie in 
plaats van segmentale sensitisatie. Dit effect was sterker bij oppervlakkige weefsels zoals 
de huid (elektrische stimulatie) dan in dieper gelegen weefsels (drukstimulatie). Deze 
bevindingen suggereren dat kwantitatieve sensorische testen van klinisch nut kunnen 
zijn voor het monitoren van pijnbehandeling in de context van chronische pijn en het 
vinden van prognostische factoren die het klinisch succes beïnvloeden.
Een nadere analyse van de experimentele eindpunten uit de pregabaline studie werd 
besproken in hoofdstuk 9. Kwantitatieve sensorische testen werden gebruikt om ver-
schillen in gevoeligheid voor pijnprikkels en pijnmodulatie tussen responders en non-
responders op een behandeling met placebo of pregabaline bij chronische pancreatitis 
patiënten te onderzoeken. Responders werden gedefinieerd als > 30% pijnreductie na 
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de behandeling van drie weken. Op basis van het verschil in pijn na studiebehandeling 
werden de chronische pancreatitis patiënten verdeeld over vier groepen: responders en 
nonresponders op pregabaline (N = 16 resp. N = 15) en responders en nonresponders 
op placebo (N = 12 resp. N = 17). Kwantitatieve sensorische testen werden gebruikt 
om veranderingen in de gevoeligheid voor pijnprikkels voor en na de behandeling te 
meten, gebruikmakend van drempels voor de detectie van elektrische pijn in dermatoom 
C5 (gegeneraliseerde effecten) en ventrale T10 (segmentale effecten). Descenderende 
endogene pijnmodulatie werd gekwantificeerd door middel van de geconditioneerde 
pijnmodulatierespons. Een per protocol analyse werd uitgevoerd op 60 patiënten. De 
toename van drempels voor de detectie van elektrische pijn in dermatoom C5 ten 
opzichte van de uitgangswaarde was statistisch significant in de pregabalineresponders 
(P < 0.01). De verandering in drempels voor de detectie van elektrische pijn in C5 was 
significant verschillend (minder hyperalgesie) voor pregabalineresponders in vergelijking 
met placeboresponders (P < 0.05). Een statistisch significante toename in drempels 
voor de detectie van elektrische pijn vergeleken met uitgangswaardes werd gevonden 
in pregabalineresponders in dermatoom T10 (P < 0.01) en in dermatoom C5 (P < 
0.01). De grootte van de veranderingen in drempels voor de detectie van elektrische 
pijn in het T10 dermatoom was vergelijkbaar tussen de vier groepen. Geconditioneerde 
pijnmodulatierespons versus uitgangswaardes was alleen statistisch significant hoger in de 
pregabalineresponders (een effectievere respons, P < 0.01). De placeboresponders lieten 
daarentegen een minder effectieve respons na drie weken behandeling zien (P < 0.05). 
De veranderingen in de geconditioneerde pijnmodulatie waren significant verschillend 
tussen pregabalineresponders en placeboresponders (P < 0.001). Deze studie toonde 
een sterk placebo-effect op pijn bij chronische pancreatitis patiënten, echter zonder 
antihyperalgetische effecten. In tegenstelling tot de placebogroep lieten chronische 
pancreatitis patiënten met pijnvermindering op pregabaline antihyperalgetische effecten 
en een versterkte endogene pijnmodulatie zien. Deze resultaten suggereren dat de 
onderliggende mechanismes die een analgetische respons op placebo en op pregabaline 
teweeg brengen, verschillend zijn.
Bekende oorzaken van pijn bij chronische pancreatitis zijn: verhoogde intrapancreatische 
druk, opvlamming van de pancreatitis en (extra)pancreatische complicaties. Ondanks de 
geboekte vooruitgang in de behandeling van deze oorzaken, blijft de behandeling van 
pijn bij chronische pancreatitis een uitdaging. Veranderingen in centrale pijnverwerking 
wordt steeds meer erkend als oorzaak van aanhoudende intense pijn bij chronische 
pancreatitis. Vergelijkbare veranderingen in centrale pijnverwerking worden ook in 
andere viscerale pijn syndromen, zoals inflammatoire darmziekten en oesofagitis, 
gevonden en suggereert dat deze syndromen een vergelijkbare behandeling van 
pijn vergen. In hoofdstuk 10 stelden we op basis van bekende pijnmechanismen en 
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recente ontwikkelingen, met betrekking tot de diagnostiek en behandeling van pijn 
bij chronische pancreatitis, een systematische benadering van pijn voor bij chronische 
pancreatitis. Alvorens behandeling te starten, dient goede diagnostiek verricht te worden 
naar veranderingen in centrale pijnverwerking. Deze veranderingen kunnen worden 
vastgesteld door middel van kwantitatieve sensorische testen, elektro-encefalografie en 
(functionele) beeldvorming door middel van magnetische resonantie. Daarbij kunnen 
deze diagnostische hulpmiddelen nuttig zijn om centrale pijnverwerking te analyseren 
en te helpen bij het bepalen van de optimale pijnbestrijding voor chronische pancreatitis 
en andere viscerale pijnsyndromen. In het geval dat conventionele pijnbehandeling 
(opioïden, chirurgie en/of endoscopie) gericht op de nociceptieve bron faalt, is 
vaak de centrale pijnverwerking veranderd. In deze gevallen dient een specifieke 
behandeling gericht op centrale pijnverwerking te worden ingesteld, bijvoorbeeld met 
gabapentinoïden, ketamine of tricyclische antidepressiva. Toekomstig onderzoek moet 
gericht zijn op een beter begrip van veranderingen in de centrale pijnverwerking en de 
diagnostiek hiervan en hoe deze beïnvloed wordt door onze interventies. Daarbij zal 
de invloed van aanhoudende (chronische) nociceptieve input hierop uitgediept moeten 
worden om tot een betere behandeling te komen. Een dergelijke aanpak zal helpen 
om te voorspellen welke patiënten een verhoogd risico hebben op het ontwikkelen van 
chronische pijn, en welke positief zullen reageren op een bepaalde therapie, zodat een 
individueel behandelplan bereikt kan worden.
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DankwooRD
Bij het totstandkomen van dit proefschrift ben ik bijgestaan door veel mensen. Mijn 
dank gaat uit naar allen die hierbij direct of indirect betrokken zijn geweest. Een aantal 
mensen wil ik graag in het bijzonder bedanken.
Geachte prof. dr. van Goor, beste Harry, als student nam jij mij onder je hoede en startte 
ik met onderzoek naar chronische pancreatitis. Dit onderzoek groeide al snel uit tot 
een promotietraject met een promotiedatum die vakkundig vooruit werd geschoven. 
Veel dank ben ik je verschuldigd, voor de vrijheid die je mij hebt gegeven, voor de 
mogelijkheden die je mij hebt geboden en voor je persoonlijke begeleiding. Samen 
hebben we menig congres bezocht en ik ben blij dat ik hierdoor veel van de wereld heb 
mogen zien. Je deur staat net zoals jaren geleden nog steeds open voor overleg of om 
gewoon bij te kletsen. Hopelijk kunnen we in de toekomst samen blijven werken, of het 
nu in het onderzoek is of in de kliniek. Dank voor de mooie tijd.
Geachte prof. dr. Gooszen, dank voor alle mogelijkheden die u mij heeft geboden om mij 
te ontwikkelen in de wetenschap in binnen- en in buitenland. Het is zichtbaar uw passie 
om jonge onderzoekers te stimuleren en te begeleiden. Zo heeft u mij ook bijgestaan 
met praktische problemen rond het managen van PONCHO, publiceren en promoveren. 
Ondanks uw drukke agenda was er altijd tijd voor een prettig en doelgericht gesprek over 
het onderzoek dan wel gewoon bijpraten over hoe het nu eigenlijk ging. Ik heb genoten 
van het onderzoek wat we samen hebben verricht en ik ben blij dat ik u als promotor heb.
Geachte dr. Wilder-Smith, beste Oliver, jouw kunde als wetenschapper en je methodo-
logische kennis vormen de ruggengraat van ons onderzoek. Geregeld maakte ik de tocht 
naar je werkkamer met het lood in de schoenen, omdat ik vast was gelopen met de data of 
het schrijven. Maar je vond altijd een oplossing, gevolgd door een opbeurend verhaal. Als 
pijnexpert is je reputatie internationaal onbetwist, dank voor het mee laten delen in veel 
van je internationale contacten. Ik heb warme herinneringen aan onze lange gesprekken 
over de wetenschap en het leven en ik hoop nog lang met je samen te mogen werken.
Geachte leden van de manuscriptcommissie en overige opponenten, dank voor uw 
kritische beoordeling van mijn proefschrift. Ik zie uit naar een vruchtbare discussie tijdens 
de verdediging.
Prof. dr. Drewes, dear Asbjørn, the Danish and Dutch collaboration for the pregabalin 
trial has been a success. Several studies from this trial are part of this thesis and we 
wouldn’t have succeeded without your knowledge and energy. On our research mee-
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tings scattered around the globe it has always been a good laugh with you.
Søren Olesen, thank you for the fruitful scientific collaboration. You are a passionate 
researcher and we spent many hours discussing (our) studies, pancreatitis and life. It didn’t 
matter if it were Aalborg, Nijmegen or any conference; visits were always productive and 
fun. I hope we can continue working together on future projects.
Dr. Buscher, beste Hessel, samen met Harry en Oliver legde je de basis voor onze studies 
naar chronische pijn bij chronische pancreatitis. Dank voor je pionierswerk.
Dank aan alle co-auteurs die hebben bijgedragen aan dit proefschrift. Zonder jullie 
bijdrage zou dit proefschrift er niet zijn geweest.
My gratitude goes out to many international colleagues in the field of Pancreatology. 
Thank you for your support of our studies and the productive meetings and discussions.
Leden en onderzoekers van de Pancreatitis Werkgroep Nederland. Naast het onderzoek 
naar chronische pancreatitis ben ik blij dat ik ook de mogelijkheid heb gekregen om voor 
de Werkgroep onderzoek te doen naar acute pancreatitis. Jullie toegewijde steun en de 
wil om kennis en krachten te bundelen, is het ‘geheime’ succes van de Werkgroep. Dank 
voor de leerzame tijd.
Dr. van Ramshorst en dr. Boerma, beste Bert en Djamila. Het St. Antonius Ziekenhuis is 
al jarenlang hofleverancier van het pancreatitis onderzoek en nauw betrokken bij alle 
studies. Dankzij jullie persoonlijke inzet en de steun van jullie afdeling is een groot aantal 
studies een succes geworden. Met veel plezier maakte ik altijd de rit naar Nieuwegein 
voor een onderzoeksoverleg of bespreking. Dank voor de mogelijkheid en het vertrouwen 
om de PONCHO trial mede te mogen opzetten en coördineren.
Marc Besselink, jouw naam is al lang niet meer weg te denken uit de wereld van pancreatitis. 
Met je enthousiasme, kennis en doorzettingsvermogen weet je veel mensen te motiveren 
en inspireren, zo ook mij. Aan je energie die je in je werk stopt lijkt soms geen einde te 
komen, net zo min als aan je nieuwe ideeën. Dank voor je begeleiding en adviezen.
Hjalmar van Santvoort, ik ken weinig mensen die zo gedreven en gepassioneerd zijn voor 
hun vak als jij. Je hebt aandacht voor elk detail en je bent altijd op zoek naar de perfecte 
balans, of het nu gaat om onderzoek, gitaar spelen of je gezin. Dank voor je interesse, 
steun en altijd opbouwende feedback.
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Olaf Bakker, meerdere grote studies pronken ondertussen achter jouw naam. Ondertussen 
heb je je proefschrift met verve verdedigd; het was een absolute kroon op je werk. 
Hopelijk wachten je dezelfde successen in je verdere chirurgische carrière.
Sandra van Brunschot, welk congres hebben we niet samen bezocht? Stad en land 
reisden we af voor presentaties, overleggen, dataverzameling en nog veel meer. Op 
menig congres waren we de jongste vertegenwoordiging van de Werkgroep en struinden 
we ’s avonds de leukste diners en feestjes af. Ik ben je dankbaar voor je continue hulp en 
al het plezier. Het einde van onze samenwerking is nog niet in zicht en ik hoop dat we 
nog lang onderzoek kunnen blijven doen naar het pancreas.
Yama Issa, uren hebben we doorgebracht al pratend en discussiërend over chronische 
pan creatitis en zoveel meer. Je zit in de afrondende fase van veel studies en ook jouw 
pro motie komt steeds dichterbij. Een nieuwe uitdaging staat alweer op je te wachten 
in de kliniek, maar jou kennende komt dit zeker goed. Je bent een goede gangmaker 
en we hebben samen veel lol kunnen trappen. We zien elkaar jammer genoeg niet 
meer zo vaak als we zouden willen, maar het wederzien is altijd mooi. Dank voor de 
samenwerking en mooie tijd.
Mark van Baal, samen maakten we de start als onderzoeker in Nijmegen, om daarna als 
collega’s te werken in het Canisius-Wilhelmina Ziekenhuis. Ondanks onze verschillende 
onderzoeks lijnen - jij experimenteel onderzoek naar pancreatitis en ik klinisch onderzoek 
naar chronische pancreatitis - hebben we elkaar tegenwoordig gevonden in de acute panc-
reatitis. Ik zie uit naar onze verdere samenwerking en hoop dat we elkaar vaak blijven zien. 
En… mochten we ooit nog op congres gaan, liever geen hostel meer met stapelbedden.
Usama Ahmed Ali, de makkelijke weg en snel promoveren gaat bij jou niet op. Naast 
het opzetten van de chronische pancreatitis studies voor de Werkgroep ging je naar 
Oxford en de VS om je onderzoeksvaardigheden uit te breiden. Je epidemiologische 
en methodologische kennis zijn voor veel mensen onmisbaar gebleken, en als kritische 
toehoorder was je altijd van toegevoegde waarde. Dank voor de hulp in het onderzoek 
en voor de prachtige reis naar je geboorteland.
Rian Nijmeijer, inmiddels ben je gepromoveerd en hard aan de weg aan het timmeren als 
MDL-arts in opleiding. Je was de snelste onderzoeker binnen onze club en combineerde 
dit met het opzetten van je eigen tak van onderzoek. Dank voor de goede sfeer en 
succes met het afronden van je opleiding.
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Nicolien Scheepers, rasoptimist met onuitputtelijke energie. Je nam de PONCHO 
coördinatie van mij over en zette de APEC trial ondertussen op. Met verve coördineer 
je de Werkgroep en ben je uitgegroeid tot een kritisch onderzoeker die overloopt van 
ideeën. Succes met het afronden van APEC en met de start van je opleiding tot MDL-arts. 
Ik hoop in de toekomst nog veel van je aanwezigheid te mogen genieten.
David Da Costa, je nam PONCHO van mij over en we hebben ondertussen de studie 
mooi weg kunnen zetten. De studie is in goede handen bij je gekomen en zal zeker 
leiden tot een mooi proefschrift. Onze samenwerking is nog lang niet klaar en ik kijk uit 
naar de vervolgstudies van PONCHO. Succes met je plannen voor na je promotie, ik ben 
ervan overtuigd dat je een goede plek zult vinden.
Janneke van Grinsven, Bob Hollemans, Xavier Smeets, Noortje Hallensleben, jullie 
kwamen als nieuwe arts-onderzoekers bij de Werkgroep toen ik al vertrokken was. Het 
is mooi om te zien dat door jullie enthousiasme nieuwe energie in de groep is gekomen 
en jullie anderen nu op sleeptouw nemen. Succes met jullie studies en ik zie uit naar jullie 
proefschriften.
Vera Zeguers, Hellen van Wezel, Hetty van der Eng en Anneke Roeterdink. Jullie waren 
de drijvende kracht achter het datacentrum en de trials. Geen enkele arts, secretaresse of 
verpleegkundige ontkwam aan jullie vasthoudendheid totdat de patiënt was geïncludeerd 
of de gegevens waren verkregen. Dank voor jullie goede werk, adviezen en gezelligheid.
Marjan de Vries en Tjarda Tromp, het kan geen toeval zijn dat jullie weer een kamer 
delen. Ondertussen zijn jullie onmisbaar binnen de afdeling en kan ik, net zoals jaren 
geleden, nog steeds binnen lopen voor een goed gesprek of een lach. Het is jammer dat 
er geen derde werkplek is op jullie kamer.
Collega promovendi en andere oud kamergenoten. Onderzoek doen kan je overal, maar 
op de oude afdeling was het altijd erg goed toeven. Het was in de winter flink stoken en 
in de zomer soms onhoudbaar, maar de sfeer was altijd goed. Absolute hoogtepunten 
waren het met zijn allen organiseren van de Chirurgencup en de skiweekenden met de 
afdeling. Excuus voor mijn soms drukke aanwezigheid en dank voor de mooie tijd.
Dr. Rosman en dr. Verhoeven, beste Camiel en Bas, jullie hebben mij altijd aangemoedigd 
om mijn opleiding zelf in te vullen en elke keer weer op zoek te gaan naar nieuwe 
uitdagingen. Dank voor het ondersteunen van mijn onderzoek en de persoonlijke 
begeleiding gedurende mijn opleiding.
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Beste chirurgen in het Canisius-Wilhelmina Ziekenhuis. Bij binnenkomst in jullie ziekenhuis 
was ik onervaren en groen als gras. Dankzij jullie vertrouwen en geduld heb ik een goede 
basis in de chirurgie gekregen. Sinds dag één in het CWZ was ik verkocht aan ons vak. 
Sindsdien is mijn enthousiasme hiervoor alleen maar gegroeid en dit is grotendeels jullie 
verdienste. Ik zie ernaar uit om mijn opleiding verder te mogen vervolgen bij jullie. Dank 
voor de leerzame tijd en mooie momenten tijdens en na het werk.
Beste chirurgen in het Radboudumc. Dank voor de warme ontvangst die ik wederom 
mocht krijgen. De sfeer op de afdeling is goed en er heerst een prettig opleidingsklimaat. 
Naast het opereren geven jullie ons assistenten de mogelijkheid om ons ook op andere 
vlakken te ontwikkelen, en het onderzoek bloeit als nooit tevoren. Dank voor de 
belangstelling voor en de ondersteuning van mijn onderzoek.
Collega’s en oud-collega chirurgen in opleiding. Als onderzoeker en AIOS tegelijk heb 
je een soort van gespleten persoonlijkheid. Zonder jullie steun in de kliniek had ik deze 
twee paden niet tegelijk kunnen bewandelen. Samen maken we de sfeer en die is goed. 
Hopelijk blijven we in toekomst genoeg tijd houden voor nog veel leuks op en na het 
werk.
Mannen van de culiclub, als jongste van het gezelschap voel ik mij wel het nakomertje 
tussen de gepromoveerden. De weekenden naar de Elzas of het hoge Noorden hebben 
we inmiddels verruild voor koken dicht bij huis. Ondertussen is er een flinke aanwas en 
komen we niet meer met zijn zessen samen maar met twintig plus. Dank voor de toffe 
weekenden en de mooie tijd samen.
Mannen van de culiclub (op zondag), ik hoop dat we in de toekomst met zo’n diverse 
groep samen kunnen blijven komen in Lent. Dank voor de prettige afwisseling buiten 
het medische vak.
Mannen van Ferus Ebrius, wat hebben we door de jaren heen toch veel samen 
meegemaakt en veel lol gehad. Van studenten in oranje tuinbroek naar, voor sommigen, 
een wit pak met klompen. Hechte vriendschappen heb ik overgehouden aan deze tijd 
en ik kan mij geen betere studententijd voorstellen dan ik samen met jullie heb gehad.
Beste Stijn, Bram, Martijn, Ruben, Jimmie en Theo, we hebben een mooie club met zijn 
allen. Straks is mijn onderzoek geen excuus meer en ik kijk uit naar al het moois wat we 
nog met zijn allen gaan doen.
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Beste paranimfen, wat is het fijn dat jullie mij bij willen staan op dit unieke moment. Stijn, 
straks staan we net zoals vroeger in rokkostuum, alleen nu zonder blackjack tafel en met 
een wit rokhemd. Caesar, we hebben al zo veel samen mogen delen, prachtig dat we dit 
aan het rijtje kunnen toevoegen. 
Beste familie, kennissen en vrienden van thuis. Wat is het soms jammer dat Zeeland toch 
een flink stuk reizen is vanuit Nijmegen. Desalniettemin voelt de rit naar de kust nog 
steeds als thuiskomen. Dank voor alle support in voor- en tegenspoed. Dit proefschrift is 
misschien een Nijmeegse aangelegenheid, maar de basis voor dit alles lag bij jullie.
Schoonfamilie Luijks, sinds ik Hilde leerde kennen staat jullie deur altijd wagenwijd 
open, met daarachter immer gezelligheid. Ondanks dat dit proefschrift en andere ver-
plichtingen geregeld voor mijn afwezigheid zorgden, bleven jullie dit steunen en kwamen 
er opbeurende woorden als dit nodig was. Met trots kijken jullie al uit naar onze beide 
promoties en ik ben blij dat we dat met zijn allen kunnen vieren. Dank voor alles.
Beste opa, u wordt 98 en op uw hoge leeftijd staat u nog steeds positief in het leven, 
met veel interesse in de mensen om u heen. Het is fijn om te zien hoe enthousiast u 
bent als uw geliefde (achter)kleinkinderen u bezoeken. Hopelijk bent u in staat om de 
verdediging bij te wonen en kunnen we de komende tijd van u blijven genieten.
Eveline, Caesar en Jules, wat zijn jullie met zijn drieën een geweldig stel. De 2e telg van 
jullie gezin is op komst en ik kijk erg uit naar zijn komst. We wonen jammer genoeg 
niet bij elkaar om de hoek, maar via facetime kunnen we tegenwoordig goed contact 
houden. Ik ben trots op wat jullie hebben bereikt en soms ook wat jaloers op jullie mooie 
stekkie in Willemstad. Dank voor jullie immer luisterend oor en oprechte interesse.
Pa en ma, jaren geleden hadden we het denk ik nooit verwacht: een promotie in de 
medische wetenschappen. Dank voor alle vrijheid die jullie mij hebben gegeven in het 
maken van eigen keuzes. Of het nu de ad hoc switch van de TU naar de RU, of een verre 
reis ‘voor de studie’ was, jullie steunden me altijd en stonden steeds voor mij klaar. Dit 
proefschrift was er niet geweest zonder jullie adviezen, liefde en zorg.
Lieve Hilde, ik bewonder je om wie je bent en om wat je in mij boven haalt. Zonder 
jouw luisterend oor en peptalks was dit alles er niet geweest. Wat heb je ongekend hard 
gewerkt aan je eigen proefschrift de afgelopen tijd. Met als resultaat dat we nagenoeg 
tegelijk kunnen promoveren en dit samen kunnen gaan vieren. Geweldig! Samen met 
Joost gaan we een mooie tijd tegemoet. Jij bent de liefde van mijn leven!
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